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ABSTRACT.
The research described in this thesis has centered on the development of a non­
radioactive iodine label for use in immunoassays. A protein can be iodinated with non- 
radioactive iodine, used in an immunoassay, and the iodine label detected by a 
chemical method.
A microassay was developed to measure iodine by means of its catalytic effect on the 
oxidation of antimony(III) by cerium(IV). The reaction was monitored both spectro- 
photometrically, by measuring the absorbance of cerium(IV), and fluorimetrically, by 
measuring the fluorescence of cerium(III) or by measuring the fluorescence produced 
by the oxidation of 8-hydroxyquinoline-5-sulphonic acid with cerium(IV). The 
detection of potassium iodide, iodine-containing organic compounds and iodinated 
proteins was possible using the microassay. Iodinated Bolton-Hunter reagent, an 
iodine-containing hapten which is used to iodinate proteins, could also be detected 
using the microassay. The catalytic activity of iodide is greater than that of iodine in 
iodocompounds, therefore, it was not possible to achieve the same sensitivity using 
IBHR as with potassium iodide.
A two-site immunoassay for the measurement of human IgG was set up and the 
effectiveness of non-radioactive iodine as a label in the immunoassay was illustrated 
using several assay formats. Initially, IBHR-labelled antibodies were used and directly 
compared to enzyme-labelled antibodies. The cerium (IV) - antimony(III) reaction was 
successfully used to detect the iodine label. The results obtained were comparable to 
those obtained using an enzyme label, with respect to accuracy and precision of the 
standards and with respect to the results obtained for serum samples. However, the use 
of enzyme-labelled antibodies enabled measurement of lower concentrations of human 
IgG.
In order to improve the detection limit when using the iodine label, the use of the 
avidin-biotin system and of bispecific F(ab’)2 antibodies was investigated. IBHR- 
labelled avidin and IBHR-labelled biotin were prepared, and used in a labelled avidin- 
biotin (LAB) immunoassay and bridged avidin-biotin (BRAB) immunoassay, 
respectively. Bispecific F(ab’)2 antibodies were prepared by a chemical method, and 
were used in an immunoassay as bridging agents between human IgG and iodinated 
BSA. An improvement in the detection limit was achieved using IBHR-labelled avidin 
in the LAB immunoassay.
An immunoassay for the measurement of thyroxine, which eliminates the necessity to 
prepare labelled derivatives of antigen or antibody, was developed. In this assay 
format, anti-thyroxine antibodies were used to capture thyroxine. Thyroxine contains 
four iodine atoms which served as the label, and these were monitored using the 
cerium (IV) - antimony (HI) reaction.
ABBREVIATIONS
Ab Antibody
Ag Antigen
AP Alkaline phosphatase
BCA Bicinchoninic acid
BHR Bolton Hunter reagent
BRAB Bridged avidin-biotin
BSA Bovine serum albumin
CV Coefficient of variation
Da Dalton
Di-IBHR Di-iodinated Bolton Hunter reagent
DMF Dimethylformamide
EDTA Ethylene diamine tetra-acetic acid
EIA Enzyme immunoassay
ELISA Enzyme-linked immunosorbent assay
EMIT Enzyme multiplied immunoassay technique
Fab Antigen binding fragment of antibody
Fc Crystallisable fragment of antibody
FIA Fluoroimmunoassay
HPLC High performance liquid chromatography
HRP Horseradish peroxidase
IBHR Iodinated Bolton Hunter reagent
ICI Iodine monochloride
IgG Immunoglobulin G
IRMA Immunoradiometric assay
LAB Labelled avidin-biotin
ME Mercaptoethanol
NHS N-hydroxysuccinimide
OPDA o-phenylenediamine
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate buffered saline
r Correlation coefficient
RIA Radioimmunoassay
RT Room temperature
SD Standard deviation
SDS Sodium dodecyl sulphate
t 3 3 ’ ,3,5-tri-iodothyronine
t4 3 \5  ’ ,3,5-tetra-iodothyronine
TEMED Tetra-methyl-ethylene diamine
TLC Thin layer chromatography
v /v Volume per volume
w /v Weight per volume
1. INTRODUCTION.
Immunoassays enable the measurement of the concentration of an analyte by means of 
the antibody - antigen reaction. Immunoassays can be divided into unlabelled and 
labelled assays (Porstmann and Kiessig, 1992). Unlabelled assays are based on 
secondary immune reactions, for example, precipitation and agglutination, and are 
monitored by light scattering or particle counting methods. Labelled assays are based 
on the primary immune reaction, and are monitored by attachment of a label to either 
the antibody or antigen. Detection of the label is by physicochemical means, and 
depends on the assessment of the fraction of the labelled reagent that is present in 
either the bound form (i.e. in an antibody - antigen complex) or the free form (i.e. 
uncomplexed) for heterogeneous assays. For homogeneous assays the activity of the 
label must be altered by the immune reaction in such a way as to make separation of 
the bound and free forms unnecessary.
Immunoassays are a valuable and widely used analytical technique for the measurement 
of biological compounds, such as peptide hormones, steroid hormones, serum proteins, 
enzymes and drugs, to femtomole levels (Porstmann and Kiessig, 1992). Their strength 
lies in the combination of versatility, specificity and sensitivity. Immunoassays can, 
in theory, be developed for the measurement of any compound provided an antibody 
specific for the compound is available. The specificity of an antibody for an antigen 
enables analysis of an analyte that is present even in complex sample matrix, such as 
serum, with little or no pretreatment of the sample. The high sensitivity is dependent 
on the affinity of the antibody - antigen binding reaction, and on the detection system 
for measurement of the label.
Several types of label have been employed in immunoassays. The first immunoassays 
introduced in the 1950s and 1960s used radioactive compounds as labels. However, 
problems associated with the use of radioactive materials led to the development in the 
1970s of non-isotopic labels, such as enzymes, fluorescent compounds and luminescent 
compounds. In principle, any material which can be accurately determined at low 
levels and can be attached to the antibody or antigen can be used as a label.
This thesis describes the use of non-radioactive iodine as a label. Using the 
methodology that already exists for radioiodination, a compound can be labelled with 
non-radioactive iodine, used in an immunoassay, and the iodine label detected using 
a chemical method.
1
1.1 Antibodies.
Antibodies belong to a group of proteins known as immunoglobulins. Immuno­
globulins comprise part of the immune system of vertebrates, and bind strongly and 
specifically to foreign molecules (antigens). The antibody - antigen binding reaction 
is reversible and non-covalent. The sites on foreign molecules that are recognised by 
antibodies are called antigenic determinants, and may consist, for example, of a 
sequence of a few amino acids in the structure of a protein. Substances that are not 
immunogenic, but are antigenic, are known as haptens.
The basic structure of immunoglobulins comprises four polypeptide chains; two 
identical light chains and two identical heavy chains (Turner, 1989). The light chain 
is about 212 amino acid residues in length and the heavy chain is about 450 amino acid 
residues in length. The heavy chains are linked by disulphide bonds. The light chains 
are also attached to the heavy chains by disulphide bonds, so that one light chain 
associates with one heavy chain. There are two types of light chain, K and X. There 
five types of heavy chain, y, p, a, 8 and e, that result in five classes of 
immunoglobulins, IgG, IgM, IgA, IgD and IgE. These differ in molecular weight, 
number of units, available antigen binding sites and distribution in the blood (Turner, 
1989). Subclasses of immunoglobulins also exist. For example, there are four human 
IgG subclasses: IgGl, IgG2, IgG3 and IgG4, which have heavy chains yv  y2, y3 and y4. 
The differences between subclasses are less than the differences between different 
classes, i.e., IgGl is more closely related to IgG2, IgG3 or IgG4 than to IgM, IgA, IgD 
or IgE.
IgG is the major type of immunoglobulin in normal human serum. The structure of 
IgG is illustrated in Fig 1.1, and will be discussed here.
The light and heavy chains of IgG are divided into domains of approximately 110 
amino acid residues. These domains are constant or variable between different IgG 
molecules. The light chain is made up of one amino-terminal variable domain (VL) and 
one carboxy-terminal constant domain (CL). The heavy chain is made up of one 
amino-terminal variable domain (VH) and three constant domains (CH1, CH2, CH3). 
Regardless of the subclass, IgG molecules always have carbohydrate moieties attached 
to the domains.
The variable domains are not uniformly variable throughout their length; there are three 
hypervariable regions or complementarity determining regions (CDR1, CDR2, CDR3) 
that show much more variability than the rest of the chain. These regions vary in size 
and in sequence between different immunoglobulins and are the regions that determine
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the specificity of the antibody - antigen interaction. The remaining parts of the 
variable domain are known as framework regions (FR1, FR2, FR3, FR4). The function 
of these regions is to place the hypervariable regions into the right position for contact 
with antigen, and to bring stability to the three dimensional structure of the variable
domains.
The region between the Chi and CH2 of the heavy chain is called the hinge region. The 
two predominant amino acids in this region are cysteine and proline. The cysteine 
residues form the disulphide bonds that link the heavy chains. The number of 
interchain disulphide bonds in the hinge region varies, for example, human IgGl has 
two, while IgG3 has fifteen. Proline residues are frequently found in flexible regions 
of proteins. Flexibility is important for the function of immunoglobulins as it 
contributes to the ability to bind antigen.
Treatment of IgG with the proteolytic enzymes papain or pepsin cleaves the molecule 
into fragments, as illustrated in Fig 1.2. Papain cleaves the heavy chains at the hinge 
region above the disulphide bonds, to yield two identical Fab (or antigen binding) 
fragments and one Fc (or crystallisable) fragment. The Fab fragment comprises a light 
chain, linked by disulphide bonds to a fragment of the heavy chain consisting of the 
VH and O n  domains. The Fc fragment comprises the Q12 and Ch3 domains from both 
heavy chains, linked by disulphide bonds. Treatment with pepsin cleaves IgG below 
the disulphide bonds of the hinge region, to yield an F(ab’)2 fragment, some low 
molecular weight peptides and a portion of the Fc fragment, a pFc’ fragment. The 
F(ab’)2 fragment consists of the two Fab fragments linked by the hinge region. The 
pFc’ fragment comprises the regions from both heavy chains.
IgG is the immunoglobulin exploited for use in immunoassays. Properties of 
antibodies, such as affinity, specificity and titre, are important as the sensitivity and 
specificity of immunoassays depends on the characteristics of the antibody. Polyclonal 
antiserum is serum from an immunised animal, and contains a heterogeneous 
population of antibodies that differ in their properties. Monoclonal antibodies are 
derived from the fusion of antibody-producing cells with myeloma cells to produce a 
hybridoma, a technique which was developed by Kohler and Milstein (1975). The 
myeloma cells confer immortality to the hybridoma, and it secretes monoclonal 
antibodies that are homogeneous in affinity and titre, and are specific to a single 
antigenic determinant of the immunogen. Monoclonal antibodies can also be produced 
by genetic engineering (Owens and Young, 1994). A comparison of the properties of 
polyclonal antiserum and monoclonal antibodies is shown in Table 1.1.
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Antibody affinity is a thermodynamic measurement of the energy of the interaction 
between a single binding site of the antibody and its corresponding antigenic 
determinant. Avidity is a term used to express the ability of antiserum to bind 
antigens, and depends on the affinity and the number of binding sites (Tijssen, 1985). 
Polyclonal antiserum generally contains antibodies to all the determinants of an antigen, 
which contributes to the avidity. This is not obtained with monoclonal antibodies 
which react with one antigenic determinant. Mixing monoclonal antibodies which react 
with two or more different determinants on an antigen may result in an "affinity bonus" 
(Tijssen, 1985).
Non-specificity of an immunoassay can occur due to cross-reactivity (Tijssen, 1985). 
An antibody binding site is specific for a particular antigenic determinant, but cross- 
reactivity can sometimes occur with antigens of similar molecular structure. Cross­
reactivity can also occur with different antigens that share the same epitope (shared 
reactivity). For monoclonal antibodies, problems due to shared reactivity can generally 
be avoided by selection during cloning against the appropriate antigenic determinant. 
Production of monoclonal antibodies is expensive and time-consuming, but the major 
advantage compared with polyclonal antiserum is that the very specific properties of 
monoclonal antibodies allows standardisation of immunoassays with respect to 
sensitivity and specificity.
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Figure 1.1 The structure of IgG.
The light chains are made up of a variable domain (V J and a constant domain (CL). 
The heavy chains are made up of a variable domain (VH) and three constant domains 
(CH1, CH2 and CH3). The variable domains are divided into three complementarity 
determining regions (CDR1, CDR2, CDR3) and four framework regions (FRI, FR2, 
FR3, FR4). The antigen binding sites are located at the end of the variable regions. 
Disulphide bonds link the four chains.
Fc
Low MW 
peptides
pFc'
F(ab’) 2
Figure 1.2 Treatment of IgG with proteolytic enzymes.
Papain cleaves the molecule yielding two Fab fragments and a Fc fragment. Pepsin 
cleaves the molecule yielding a F(ab’)2 fragment and a pFc’ fragment.
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Polyclonal antiserum Monoclonal antibodies
Antigenic determinant Several Single
Specificity Variable Standard
Affinity Variable May be selected during 
cloning
Yield of useful antibody Up to 1 mg/ml Up to 100pg/ml in tissue 
culture.
Up to 20mg/ml in ascitic 
fluid.
Relative cost Low High
Table 1.1 Comparison of polyclonal antiserum and monoclonal antibodies. (Data taken 
from Campbell, 1984).
1.2 Labels used in immunoassays.
The label in immunoassays is employed to assist in the observation of the distribution 
of antibody or antigen in the bound or free fractions. The label used in an 
immunoassay is often the most distinguishing feature, and is the basis of a system of 
classification. Thus, radioimmunoassay (RIA) represents an immunoassay using 
radiolabelled antigen, and immunoradiometric assay (IRMA) represents an 
immunoassay using radiolabelled antibody. Similarly, enzyme immunoassay (EIA), 
immunoenzymometric assay (IEMA), fluoroimmunoassay (FIA), immunofluorometric 
assay (IFMA), etc. are terms which represent immunoassays using alternative labels. 
Radiolabels are robust, and the disintegrations are unaffected by physical or chemical 
factors. In contrast, the majority of non-isotopic labels are vulnerable to the effects of 
pH, ionic strength and temperature, or the presence of inhibitors or quenchers. As a 
result, immunoassays using radiolabels are always heterogeneous and require separation 
of antibody-bound and free fractions. The separation technique must effectively 
remove the free fraction without disruption of the antibody - antigen complexes. It 
must be simple to perform, applicable to a wide range of analytes and be readily 
automated (Porstmann and Kiessig, 1992). The use of non-isotopic labels provides the 
potential for the development of homogeneous immunoassays, which do not require a 
separation step.
1.2.1 Radiolabels.
The main isotopes used as radioactive labels for immunoassays are 14C, 3H, 125I and 131I. 
Some properties of these isotopes are listed in Table 1.2. There are two types of 
labelled reagent preparation: intrinsic and extrinsic labelling. With intrinsic labelling, 
the radiolabel replaces a non-radioactive element which is present in the molecule. 
Usually 14C or 3H are used to intrinsically label a compound by substitution of a carbon 
or hydrogen, although radioactive iodine can be substituted for non-radioactive iodine 
in the thyroid hormones. With extrinsic labelling the radiolabel is introduced into an 
already complete molecule of the compound.
The sensitivity of immunoassays depends, among other factors, on the specific activity 
of the tracer. Labelling with 14C and 3H provides tracers which have a long shelf-life, 
but which have lower specific activities than tracers obtained using 125I and 131I. With 
a radioactive label of low specific activity, relatively high concentrations are required 
to obtain a practical level of radioactivity in the assay (Parker, 1976). 125I and 131I can 
be counted by scintillation crystals using well type gamma counters, and transfer of
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samples from the test tubes before counting is not necessary. Counting by scintillation 
crystals is, therefore, simpler and faster than liquid scintillation counting. Also, 
iodination can be carried out using simple chemical methods. Thus, iodination is the 
more widely used labelling technique, although the short half-life of 131I makes 125I the 
isotope of choice.
Yalow and Berson (1959) first described the use of RIA for the assay of human insulin. 
RIA is based on the reaction of radiolabelled antigen with its specific antibody, in the 
presence of unlabelled antigen. Concentrations of labelled antigen (tracer) and antibody 
are constant, and the concentrations are such that the tracer is in excess. In the absence 
of unlabelled antigen, the tracer binds quantitatively to the antibody. On addition of 
unlabelled antigen, competition occurs between labelled and unlabelled antigen for the 
available binding sites, and the binding of tracer to antibody is decreased. Thus, the 
ratio of antibody-bound to free tracer decreases with increasing concentration of 
unlabelled antigen. After an incubation period, free tracer is separated from antibody- 
bound tracer, and the radioactivity in the free or bound fraction is measured. A 
schematic representation of RIA is illustrated in Fig 1.3.
The use of IRMA was first described by Miles and Hales (1968). They used radio­
labelled antibody, rather than antigen, in a two-step non-competitive assay for 
measurement of insulin. Unknown antigen, in standards or samples, was first reacted 
with labelled antibody, in excess. Antigen attached to a solid phase matrix was then 
added. Any unreacted antibody bound to this, and was subsequently removed from the 
reaction. This is illustrated in Fig 1.4. The radioactivity of the antibody-unknown 
antigen complexes provides a direct measure of the amount of unknown antigen. This 
immunoassay scheme overcomes problems that may be encountered with the labelling 
of antigen, for example, some antigens may be susceptible to damage due to labelling 
or may lack residues that can be labelled. Antibodies, on the other hand, contain 
numerous residues for labelling.
Alternative formats for IRMA are two-site assays and assays using indirect labelling 
(Hales and Woodhead, 1980). Two-site assays are suitable for compounds with more 
than one antigenic determinant. Antigen is reacted with antibody attached to a solid 
phase matrix (antibody-solid phase). A second labelled antibody is then added; this 
antibody binds to a second antigenic determinant on the antigen. After a separation 
step, the radioactivity of the binding complex (labelled antibody:antigen:antibody-solid 
phase) can be measured, and is directly related to the antigen concentration. This 
binding complex is illustrated in Fig 1.5a. For assays using indirect labelling, the
antibody used for measuring the antigen (primary antibody) is not labelled, instead a 
labelled second antibody, which is generally an anti-immunoglobulin antibody, is used. 
The primary antibody acts as the antigen for the labelled second antibody. Indirect 
labelling can be used in different IRMA formats; its use in a two-site assay is 
illustrated in Fig 1.5b. The two-site assay is carried out as outlined, but the primary 
antibody is not labelled. Labelled second antibody is added, and binds to the primary 
antibody. After a separation step, the radioactivity of the binding complex is again a 
direct measure of the concentration of the antigen. An important requirement for this 
assay format is that the antibody attached to the solid phase matrix must be from a 
different animal species to the primary antibody, to avoid binding of the labelled 
second antibody to it. The advantage of indirect labelling is that one labelled antibody 
can be used for IRMA procedures for many different antigens.
The use of radioactive labels in immunoassays has several advantages. Radioactivity 
can be detected with great sensitivity, and the signal is unaffected by environmental 
factors. Radiolabels are small so they do not normally affect the kinetics of the 
antibody - antigen reaction, and radiolabelling procedures are relatively simple and well 
characterised. However, there are certain disadvantages to the use of radiolabels. As 
the signal produced is unaffected by environmental factors and is unaltered on 
incorporation of the labelled reagent into the antibody - antigen complex, these assays 
are always heterogeneous and are difficult and expensive to automate. Radioiodinated 
reagents only have a short shelf-life due to the short half-life of the isotopes. 125I has 
a half-life of just 60 days, therefore, labelled reagents must be regularly prepared for 
routine assays. There are hazards associated with the handling of radioisotopes due to 
the exposure to ionising radiation, especially in the use of raw isotopes for the 
preparation of tracer. These hazards have resulted in restrictive laws for the use and 
disposal of radioisotopes. The ionising radiation can cause damage to protein 
molecules during labelling and storage. The signal must be detected against a 
background signal due to external radiation sources, which limits the sensitivity of an 
immunoassay. Detection is impractical when the signal approaches the background 
level. These disadvantages led to the development of non-isotopic labels as an 
alternative to radiolabels.
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Isotope Half-Life (#) Specific Activity (#) 
(Ci/mmol)
Counting method
14c 5730yr 0.07 Liquid scintillation
3h 12.3yr 33 Liquid scintillation
125I 60d 2560 Scintillation crystal
131I 8d 19250 Scintillation crystal
(#) Taken from Parker (1976)
Table 1.2 Properties of the main isotopes used for radiolabelling.
(a)
A A A
Ab
A A A
Afl‘
(b)
A A A
Ab Ag*
A  A
A
AQ
Figure 1.3 Schematic diagram of RIA.
(a) Reaction in the absence of unlabelled antigen: labelled antigen (Ag*) binds to 
antibody (Ab).
(b) Reaction in the presence of unlabelled antigen: competition occurs between labelled 
antigen (Ag*) and unlabelled antigen (Ag) for binding to antibody (Ab).
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AO-SP
Figure 1.4 Schematic diagram of IRMA.
Labelled antibody (Ab*) binds to antigen (Ag). Free antibody is removed on addition 
of antigen attached to a solid phase matrix (Ag-SP).
♦13
(a)
Ab* Ag Ab-SP
cb)
Ab* Ab AO Ab-SP
Figure 1.5
(a) Schematic diagram of two-site IRMA.
Antigen (Ag) binds to antibody attached to a solid phase matrix (Ab-SP). Labelled 
antibody (Ab‘) is added, and binds to a second antigenic determinant on the antigen 
(Ag).
(b) Schematic diagram of the use of indirect labelling in a two-site IRMA.
Antigen (Ag) binds to antibody attached to a solid phase matrix (Ab-SP). Primary 
antibody (Ab) is added, and binds to a second antigenic determinant on the antigen 
(Ag). Labelled second antibody (Ab‘) is then added, and binds to primary antibody.
1.2.2 Enzyme labels.
The use of alkaline phosphatase as a label in an immunoassay for IgG was described 
by Engvall and Perlmann (1971). Since then, enzymes have found widespread use in 
immunoassays. The enzyme label is detected by addition of the appropriate substrate, 
and detection of the resulting product by spectrophotometry, fluorimetry, luminescence 
or electrochemical techniques. Detection by spectrophotometry is most frequently used. 
Enzymes are sensitive labels because they are very efficient catalysts; they act 
repeatedly on a substrate to produce an amplified response. The sensitivity depends 
on their efficiency as catalysts, and on the detection of the product with high 
sensitivity.
Since enzymes are affected by environmental factors, heterogeneous and homogeneous 
EIAs can be developed (Engvall, 1980). Heterogeneous EIAs are based on the same 
principles as RIA and IRMA, and separation of the bound and free fractions is required 
before detection of the enzyme label. Enzyme-linked immunosorbent assay (ELISA) 
is an example of heterogenous EIA, with immobilisation of antibody or antigen onto 
a solid phase. Enzyme multiplied immunoassay technique (EMIT) is a homogeneous 
EIA system, in which no separation step is required. Homogeneous assays are rapid 
and simple; there is one incubation and no separation step. The enzyme label used in 
EMIT shows a change in catalytic activity on incorporation of the labelled reagent into 
the immune complex. However, EMIT is generally only applicable to the assay of low 
molecular weight haptens.
The enzymes commonly used as labels are shown in Table 1.3. The choice of enzyme 
is governed by several factors, such as sensitivity, practicality, availability, shelf-life 
and cost (Porstmann and Kiessig, 1992). The enzyme should have a high specific 
activity, and the resulting product should be detectable with high sensitivity. The 
enzyme chosen, or its substrate, should not be present in test samples, and samples 
should not contain substances that could interfere with the activity of the enzyme, for 
example, activators or inhibitors. This is important in heterogeneous assays where 
there may be an incubation of enzyme-labelled compound with sample, and is of prime 
importance in homogeneous assays where there is no separation of reactants from 
sample before measurement of enzyme activity. The enzyme must be stable in the free 
and conjugated form, and possess reactive groups for covalent linkage to antibody or 
antigen. Pure enzyme must be available at low cost, and the substrate must also be 
inexpensive, stable and non-toxic.
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The choice of enzyme in EMIT is restricted to a small group of enzymes whose 
activity is altered after interaction with antibody. Lysozyme acts on a high molecular 
weight substrate, and its activity can be sterically hindered by binding of antibody. 
With glucose-6-phosphate dehydrogenase and malate dehydrogenase, when residues in 
the enzyme molecule are substituted with hapten the enzyme becomes susceptible to 
conformational changes on binding of hapten to antibody, which leads to inhibition of 
enzyme activity (Engvall, 1980). Homogeneous assays have also been developed using 
enzyme co-factors, substrates and inhibitors as labels (Blake and Gould, 1984). In 
these assays the enzyme is not labelled as in EMIT. The binding of antibody to 
hapten-labelled compound causes steric hindrance and alters the enzyme activity by 
alteration of the natural function of the compound with the enzyme.
The use of enzyme labels offers several advantages. Enzyme-labelled compounds have 
a shelf-life of one year or longer. The equipment for detection of the reaction product 
can be inexpensive and is generally available, especially when detection is by 
spectrophotometry. Rapid measurement can be made, and the reaction can be stopped, 
for example, by addition of acid, resulting in a stable product. The time required to 
carry out homogeneous assays is very short, and these assays can be easily automated. 
However, there are disadvantages also, the major one being the possible presence in 
the sample of substances that interfere with the enzyme activity. This is most 
important for homogeneous assays which have, at present, limited sensitivity and are 
generally only applicable to measurement of haptens. Environmental factors must be 
carefully controlled as these affect the enzyme activity. The enzyme label is bulky, 
and labelling with a macromolecule can alter the antibody - antigen binding reaction 
kinetics. An additional incubation step with a substrate is required, and if the product 
is determined spectrophotometrically the dynamic range of the EIA is limited due to 
the narrow dynamic range of spectrophotometric measurement.
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Assay type Enzyme Source Specific activity* 
(U/mg at 37°C)
Heterogeneous Alkaline phosphatase Calf intestine 1000
ß-galactosidase E. coli 600
Peroxidase Horseradish 4500
Urease Jack beans 10000
Glucose oxidase A. niger 200
Homogeneous Glucose-6-phosphate
dehydrogenase
L. mesenteroides 400
Lysozyme Egg white -
Malate
dehydrogenase
Pig heart 1000
* Taken from  Porstmann and K iessig  (1992)
Table 1.3 Enzymes commonly used as labels in EIA.
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1.23 Fluorescent labels.
Luminescent molecules are capable of absorbing energy and emitting it as photons. 
The absorbed energy excites electrons of the molecule from the ground singlet state to 
a higher electronic state. With photoluminescence, excitation is effected by infra-red, 
visible or ultra-violet radiation. Fluorescence and phosphorescence are types of 
photoluminescence. The excitation energy can be lost by non-radiative conversion, for 
example, as heat, or by radiative transition to the ground state (fluorescence) or through 
a semistable triplet state (phosphorescence). The principle of fluorescence and 
phosphorescence is illustrated in Fig 1.6.
Fluorescent molecules were used to label antibodies for qualitative staining techniques 
as early as the 1940s. However, it was not until the 1970s that fluorescent labels were 
used for quantitative immunoassays.
Fluorescent molecules can be characterised by the absorption and emission spectra, the 
Stokes shift, the quantum yield and the fluorescent life-time (decay time). The 
emission wavelength is always longer than the excitation wavelength because of energy 
losses prior to emission. This difference between the wavelengths is known as the 
Stokes shift The ratio between the absorbed and emitted light is defined as the 
quantum yield. The ideal quantum yield is one, but this is rarely attained due to the 
energy losses before emission. The properties of some compounds used as fluorescent 
labels in FIA are listed in Table 1.4. There are several requirements of compounds 
used as fluorescent labels (Wood, 1991). Ideally, the compound should have long 
excitation and emission wavelengths far from the background due to, for example, 
serum. The excitation wavelength should be greater than 360nm, and the emission 
wavelength should be greater than 500nm. The compound should also have a high 
quantum yield and a large Stokes shift of greater than 50nm.
Fluorescein and rhodamine are widely used as fluorescent labels. Fluorescein 
derivatives, for example, fluorescein isothiocyanate (FÏTC), have a high fluorescence 
intensity and a good quantum yield approaching unity. The fluorescence intensity of 
fluorescein is sensitive to pH and is reduced in acidic solutions, unlike the fluorescence 
intensity of rhodamines. Rhodamine B isothiocyanate, tetramethyl rhodamine 
isothiocyanate and lissamine rhodamine B sulphonyl chloride are rhodamine derivatives 
used for labelling of antibodies. Rhodamines have longer excitation and emission 
wavelengths than fluorescein, but the quantum yield is lower. Both fluorescein and 
rhodamine have narrow Stokes shifts of only 28nm and 35nm, respectively. 
Umbelliferone, a 7-hydroxycoumarin, and aminomethyl coumarin acetic acid have the
I
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advantage of large Stokes shifts. However, they also have short emission wavelengths 
which overlap with the serum background.
In principle, fluorescent measurement is very sensitive. Fluorescent molecules can be 
excited many times within one measuring period, and the resulting emission integrated 
with a sensitivity of a few photons. In practice, however, the sensitivity is limited due 
to scattering, background fluorescence and quenching (Hemmila, 1985). Light 
scattering can arise as a result of dissolved molecules or particles in the matrix or the 
solid-phase material. It results in high background values in solutions containing a 
high concentration of protein or small colloidal particles as found in serum. 
Background fluorescence can occur due to the solid phase, the presence of fluorescent 
compounds in the sample or the presence of impurities in the reagents. Serum has a 
very high background fluorescence, which extends over a wide range of wavelengths. 
Quenching occurs due to the sensitivity of fluorescent compounds to environmental 
factors. The close proximity of two fluorescent molecules on a labelled compound can 
cause self-quenching, which precludes the use of multiple labelling to increase the 
sensitivity.
These limitations to the sensitivity mean that conventional FIA methods are not as 
sensitive as RIA, and so have not found widespread use. However, the development 
of new fluorescent labels and new instrumentation has reduced the background and has 
resulted in FIAs which have a sensitivity comparable to RIA and IRMA. The new 
labels are lanthanide ions, for example, europium and terbium, which form highly 
fluorescent chelates with suitable organic ligands (Wood, 1991). These can be detected 
using time-resolved fluorescence (Diamandis and Christopoulos, 1990). This technique 
exploits the difference between the fluorescent life-time of the specific signal and the 
non-specific background. The specific signal of europium and terbium chelates has a 
decay time longer than the average background decay, so that measurements can be 
taken after the background signal has decayed. The specific signal can, therefore, be 
measured with very high sensitivity.
As fluorescence intensity is dependent on environmental factors the development of 
homogeneous FIAs is possible. Homogeneous FIAs are, in general, competitive assays 
and depend on the antibody binding causing some change in the fluorescence properties 
of the label. Homogeneous FIAs are based on the exploitation of, for example, 
polarisation, enhancement of fluorescence, quenching of fluorescence, or excitation 
transfer, i.e. energy transfer from an excited fluorescent dye to an acceptor dye 
molecule (Price and Newman, 1991a). These assays are rapid and simple. However,
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the sensitivity is limited by interferences. Samples, especially serum samples, cause 
high background and a high signal-to-noise ratio. The means by which fluorescence 
is modulated on antibody - antigen binding may only lead to a small degree of 
fluorescent change, and involves close reactant proximity or large changes in molecular 
mass which means that homogeneous assays are applicable only to the quantitation of 
haptens. Careful engineering of labelled molecules must be carried out in order to 
produce modulation on antibody - antigen binding.
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Figure 1.6 The principle of fluorescence and phosphorescence.
Electrons are excited from the ground state singlet (So) to excited singlets (SI, S2). 
The excitation energy can be emitted by non-radiative energy transfer (broken line) or 
radiative transition (solid line) to the ground state or through semi-stable triplet states 
(Tl, T2).
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Compound Excitation 
max (nm)
Emission 
max (nm)
Quantum
yield*
Decay 
time (ns)*
Fluorescein
isothiocyanate
492 520 0.85 4.5
Rhodamine B
isothiocyanate
550 585 0.7 3.0
Umbelliferone 380 450 - -
Aminomethyl coumarin 
acetic acid
350 440-460 • -
Anilino-naphthalene 
sulphonic acid
385 471 0.8 16.0
Eu-(ß-naphthoyltri-
fluoroacetone)3
340 590,613 - 500,000
Tb-EDTA-sulpho-
salicyclic acid
300 490,545 “ -150,000
* Taken from Hemm ila (1985)
Table 1.4 Properties of some compounds used as fluorescent labels.
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1.2.4 Luminescent labels.
Chemiluminescence is light emission that arises due to excitation of a luminescent 
molecule with the exciting energy provided by a chemical reaction, usually an 
irreversible oxidation reaction. In contrast to fluorescence no external excitation light 
source is required. Bioluminescence is a type of chemiluminescence found in 
biological systems, in which an enzyme increases the efficiency of the 
chemiluminescent reaction. Components of both chemiluminescent and bioluminescent 
reactions have been used as labels in immunoassays.
The first chemiluminescent immunoassays were introduced in the mid-1970s, and were 
based on the use of luminol, its isomer, isoluminol, or its substituted derivatives 
(Kricka et al., 1991). These compounds emit blue light, at a wavelength of 425nm, 
when oxidised. The light emission from luminol and its derivatives is relatively slow; 
emission may last more than 25 seconds after initiation of the chemiluminescent 
reaction. The quantum efficiency of these compounds is low, and the quantum yield 
of luminol decreases on covalent coupling to proteins or steroid hormones. Other 
organic compounds which are chemiluminescent on oxidation have also been used as 
labels, for examples, acridinium esters, oxalate esters and dioxetanes. Acridinium 
esters produce light emission in a very rapid flash; the maximum intensity is reached 
0.4 seconds after initiation. Fully automatic luminometers, with automated pipetting 
devices and integration of the light emission from each tube, are therefore required. 
Acridinium esters are unaffected by covalent coupling, but they are difficult to use as 
labels as synthesis of these molecules is complex and there are no commercial sources 
of labelled compounds. Oxalates are efficient labels as they have high quantum yields. 
The compounds themselves are not chemiluminescent, therefore, addition of a 
fluorescent molecule is required and the energy of the reaction is transferred to this. 
Dioxetanes are small molecules, which makes them ideal as labels. However, most 
dioxetanes are thermally unstable, and decompose on emission of light. Recently, 
stable 1,2-dioxetane derivatives have been designed which can generate light with high 
quantum yield (Beck and Koster, 1990).
Chemiluminescent labels are very sensitive. As no external light source is required, 
all the light reaching the detector is due to the chemical reaction and there is no 
background signal due to scattered excitation radiation. The labels are chemically 
stable and have high specific activity. However, there are limitations to the use of 
chemiluminescent labels. Light emission can be of very low intensity, and can decay 
rapidly. In most cases, emission is over in less than 30 seconds. Signal measurement
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must, therefore, be rapid and be carried out in a fully automatic luminometer. 
Reactions are usually performed on one sample at a time. There is no second chance 
of recording signals, as once the reagents are mixed the label is consumed.
An alternative approach to improve the performance of chemiluminescent reactions is 
to use an enzyme, such as horseradish peroxidase (HRP), xanthine oxidase or alkaline 
phosphatase (AP) as the label (Jansen, 1993). HRP catalyses the oxidation of luminol 
as follows:
HRP + Luminol + o x id a n t  IE l e c t r o n i c a l l y  e x c i t e d  in te r m e d ia teA
-» L ig h t  4 2 5 nmAAminophth a la  t e
Hydrogen peroxide is generally used as oxidant, although its replacement with another 
oxidant, for example, urea peroxide, is possible. Luminol can be replaced by one of 
its derivatives. Enhancement of this reaction is possible using appropriate compounds, 
for example, substituted phenols and naphthols which increase the chemiluminescent 
signal by a factor of 100. The half-life time of the signal is one hour. Xanthine 
oxidase can be used in conjunction with luminol and hypoxanthine. This label system 
is superior to almost all existing chemiluminescent labels as the detection limit is 
extremely low and the signal has a half-life time of 30 hours. AP is used with 1,2- 
dioxetanes as substrate. Light emission occurs at 470nm, and the half-life time of the 
signal is approximately 5 hours. Macromolecules, such as bovine serum albumin 
(BSA), can be used to enhance the signal.
The light emission from these reactions is intense and decays slowly. Batches of 
reactions can, therefore, be started and measurements made some minutes later using 
relatively simple instrumentation. Immunoassays using enzymes as labels are 
widespread, and can be easily modified for enhanced chemiluminescent detection. The 
use of an enzyme label provides the advantage of an amplified signal, however, the 
disadvantages associated with the use of enzyme labels in EIAs will also apply to these 
assays.
Bioluminescence occurs in biological systems. Bioluminescent systems consist of an 
enzyme, luciferase, a substrate, luciferin, and co-factors, for example, ATP or NADH 
(Barnard and Collins, 1987). The most extensively studied bioluminescent system is 
that of the firefly, although bioluminescence is also observed in marine bacteria.
Immunoassays using firefly or bacterial luciferase as a label, or using the co-factor as 
a label, have been developed. As the substrate is unstable, and complex chemistry 
would be required for the preparation of substrate-labelled reagents, it has not been 
exploited as a label. Bioluminescent reagents have high quantum yields and stable 
emission of light which eliminates the necessity for automated luminometers. 
Homogeneous immunoassays using luminescent labels are not widespread. Most of the 
assays are based on the alteration of the total light emission or the kinetics of the light 
emission from the reaction on binding of the labelled analyte to antibody. These 
effects have been used to develop homogeneous assays for biotin and some steroids 
hormones (Kricka et al., 1991). However, as with other homogeneous assays, the 
fundamental problem is the susceptibility to interference from biological samples.
1.2.5 Other labels.
Many other labels have been used for immunoassays, including particle labels, metal 
atoms, free radicals, and bacteriophages.
Particle labels are solid particles, for example, sols, latexes and red cells. Red cells can 
be used as particle labels in qualitative and semi-quantitative assays (Coombs, 1987). 
Their detection is based on haemagglutination on formation of the immune complex. 
The red cells are randomly distributed in the test sample in the unagglutinated state. 
Once agglutination occurs large aggregates form due to lattice formation. Treatment 
of the cells with enzyme increases the agglutinability and, therefore, the sensitivity of 
these labels. The main drawback is that the haemagglutination signal is read 
microscopically or by eye, which is not suitable for quantitating small concentration 
differences, as is possible with the precise linear recording of signals from other labels 
which allows construction of a standard curve.
Fully quantitative immunoassays using particle labels can be developed by using light 
scattering for detection of the label (Price and Newman, 1991b). Detection depends 
on changes in light scattering on formation of the antibody - antigen complex. 
Quantitation is performed using turbidimetry, nephelometry, particle counting or photon 
correlation spectroscopy. There are three styles of assay using particle labels. 
Antibody can be coupled to the particle, and addition of antigen results in formation 
of the immune complexes. Standard antigen can be coupled to the particle, and 
addition of antibody results in formation of the immune complexes. Detection of 
unknown antigen in samples is by observation of inhibition of the immune complex 
formation. Both antibody and standard antigen can be independently coupled to
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particles, and detection of unknown antigen is by inhibition of immune complex 
formation. This third approach yields highly scattering immune complexes and results 
in greater sensitivity.
Metal sols, for example, gold, silver, silver iodide and barium sulphate sols, have all 
been used as labels. Gold has superior optical properties and, therefore, is the most 
popular metal sol.
Latex particles can be synthesised using one of three techniques: emulsion 
polymerisation, suspension polymerisation or swollen emulsion polymerisation (Price 
and Newman, 1991b). Emulsion polymerisation is the most suitable technique for 
production of small particles (40-1000nm). The particle size can be determined using 
electron microscopy or photon correlation spectroscopy. Properties of the particle, such 
as density, refractive index and surface charge are important. The particle density 
should, ideally, be equal to that of the suspension buffer as this eliminates the need for 
regular agitation of reagents during the assay. The refractive index of the particle 
influences the light scatter, and the surface charge influences the non-specific 
aggregation of the particles. The use of an appropriate monomer for the polymerisation 
reaction enables introduction of active groups to the particle surface. For example, 
carboxyl groups can be introduced by the use of acrylic acid and amino groups can be 
introduced by the use of acrylamide. Antibody or antigen can thus be coated onto the 
particle using simple coupling chemistry, and the coated particles used to produce 
rapid, simple and inexpensive assays.
The use of metal atoms as labels for immunoassays was first reported by Cais et al. 
(1977). The label can be detected using a suitable analytical method, such as emission, 
absorption or fluorescence spectroscopy, electrochemistry or neutron activation. Metals 
that have been used as labels include iron, mercury, chromium, copper, gold, 
manganese, platinum and cobalt (Schall and Tenoso, 1981). However, the use of metal 
atoms is not widespread as the measuring equipment is expensive and is not generally 
available.
The use of free radicals, or spin labels, has also been reported (Schall and Tenoso, 
1981). Electrons possess a rotational property called spin. When held in a magnetic 
field of appropriate intensity and excited by radiowaves of the right frequency, unpaired 
electrons absorb and scatter energy by resonance. The resonant absorption is altered 
by changes in environment, such as the binding of antibody to antigen, thus enabling 
development of homogeneous assays. Detection is by electron spin resonance (ESR) 
spectroscopy. Assays using spin-labelled compounds are generally only suitable for
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haptens present in m icromolar concentrations. Also, the labels are rather insoluble, and 
the ESR spectrometer is expensive.
Bacteriophages, viruses which cause the lysis and death o f bacterial cells, can be used 
as labels (Schall and Tenoso, 1981). Bacteria grown on culture medium in a petri dish 
form  a dense carpet. In a culture infected w ith bacteriophages, plaques appear where 
the bacteria have been k illed . The number o f plaques is proportional to the severity 
o f the infection by bacteriophages. Bacteriophages can be neutralised by chemically 
coupling a molecule to their surface and reacting the resulting product w ith an antibody 
specific fo r the coupled molecule. The number o f plaques obtained on infection o f a 
bacterial culture by bacteriophages is altered in the presence o f antibody that can 
neutralise the bacteriophages. Concentrations o f haptens can be measured by 
competitive neutralisation o f bacteriophage-hapten conjugates w ith antibodies to hapten. 
Non-radioactive iodine can also be used as a label in immunoassays. Using the 
methodology that already exists fo r radioiodination, a substance can be labelled with 
non-radioactive iodine. The label can be detected using a chemical method, for 
example, a kinetic reaction catalysed by iodine which can be monitored 
spectrophotometrically.
1.3 Non-radioactive iodine as a label.
O’Kennedy and Keating (1991) firs t reported the use o f non-radioactive iodine as a 
label in an immunoassay. The assay was based on the use o f iodinated Bolton Hunter 
reagent (IBHR), an iodine-containing hapten, to label antibodies and detection o f the 
iodine label using the Sandell-Kolthoff reaction, a kinetic reaction between cerium(IV) 
and arsenic(III) which is catalysed by iodine (Section 1.3.2.1). Mouse IgG was 
detected in both a two-site assay and a direct assay using IBHR-labelled anti-mouse 
IgG antibodies. The two-site immunoassay was used to measure mouse IgG in serum, 
ascitic flu id  and cell culture supernatants. The results obtained using IBHR-labelled 
antibodies compared favourably w ith those obtained using a conventional ELISA with 
HRP-labelled antibodies. Non-radioactive iodine was also used as a label in a two-site 
immunoassay fo r detection o f human IgG in standards and human serum samples 
(O ’Kennedy and Keating, 1993).
The use o f the non-radioactive iodine label has several advantages. Iodination o f 
compounds w ith non-radioactive iodine can be easily achieved using one o f the well 
established iodination techniques available fo r radioiodination. The label can be 
detected using a chemical reaction catalysed by iodine, which provides an amplified
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response. The Sandell-Kolthoff reaction was used by O’Kennedy and Keating (1991), 
but there are many other kinetic catalytic reactions that can also be used for the 
detection o f iodine (Section 1.3.2.2).
1.3.1 Iodination techniques.
There are a variety o f techniques available fo r the iodination o f proteins which can be 
divided into substitution techniques and conjugation techniques. Several techniques for 
the direct substitution o f iodine into proteins are available. In itia lly , iodine 
monochloride was used as a direct iodination reagent. Subsequent methods have 
involved the oxidation, at alkaline pH, o f sodium iodide to form  cationic iodine (I+). 
Oxidising agents, such as chloramine T, iodogen, iodo-beads and peroxidases have been 
used. Cationic iodine reacts w ith aromatic moieties present in the protein. In a study 
by Knight and Welch (1978), proteins were labelled using chloramine T, 
lactoperoxidase or chloroperoxidase w ith variation o f the reaction pH in the range 2.2 
to 9.3. The proteins were degraded enzymatically, and the labelled amino acids were 
analysed by chromatography. The pH o f the labelling reaction determined the site o f 
labelling. A t pH 7, predominantly tyrosine was labelled. A t pH 4.5 to 6, predominantly 
cysteine was labelled, although iodination at cysteine residues is unstable and iodide 
was released on enzymatic degradation. Yields o f iodinated histidine and o f di- 
iodinated tyrosine were low  at the pH range tested. Bolton (1986) reported that 
labelling o f histidine is favoured using conditions o f greater alkalinity.
Iodination using substitution techniques is straightforward. The oxidising agent is 
added to the protein, and the iodination reaction is subsequently stopped by addition 
o f a reducing agent. Purification o f the labelled protein is carried out immediately in 
order to remove any unconjugated oxidation products, free iodine and reducing agent. 
Purification can be achieved by gel filtra tion , ion exchange or dialysis. Direct 
iodination methods result in high yields o f incorporation o f iodine into a protein, 
producing a tracer w ith high specific activity. The main drawback o f these methods 
is the exposure o f the protein to 125I, oxidising and reducing solutions which may 
damage the protein.
In conjugation techniques a reactive precursor is labelled by one o f the substitution 
methods, and the labelled product is reacted w ith the protein. This is more gentle than 
direct iodination techniques as the protein never comes into contact w ith the 125I, 
oxidising or reducing solutions. The firs t such method to be described used the Bolton 
Hunter reagent for iodination o f protein (Bolton and Hunter, 1973). This reagent reacts
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with free amino groups in the protein to form amides. In the study by Knight and 
Welch (1978), protein conjugated to IBHR had predominantly lysine residues labelled, 
although labelled histidine and tyrosine were also present. Conjugation techniques can, 
therefore, be used to label different residues to those labelled using substitution 
techniques. This is valuable fo r iodination o f proteins that do not contain tyrosine 
residues, or where iodination o f tyrosine residues renders a protein unsuitable for use 
in RIA. However, conjugation techniques tend to yie ld tracers o f lower specific 
activity than direct iodination as two reaction steps are involved resulting in lower yield 
o f iodine incorporated into the protein (Bolton, 1986).
Iodination o f a protein may result in alteration o f its biological or immunological 
reactivity compared to that observed in its native form. Dénaturation can occur due 
to radiation damage and chemical damage caused by reagents used in the iodination 
reaction, manipulation o f the protein in dilute solutions during iodination and 
purification, and introduction o f iodine into the protein. (These effects are discussed 
in detail in  Section 4.2.2.1). Any loss in immunological reactivity w ill result in a loss 
o f a ffin ity  in  antibody-antigen binding, and a subsequent loss o f sensitivity in the 
immunoassay. The susceptibility o f individual proteins to damage during an iodination 
may vary. One method may damage the protein, while another method may cause no 
damage.
There are many examples in the literature o f comparison o f iodination techniques. 
McCarthy and Markowitz (1983) compared the immunoprécipitation, in the presence 
o f excess antibody, o f prostatic acid phosphatase labelled by the chloramine T, 
lactoperoxidase and Bolton Hunter reagent methods. The Bolton Hunter reagent 
produced a tracer w ith optimal precipitation characteristics suitable fo r use in RIA, 
while the tracer produced using chloramine T and lactoperoxidase produced tracers 
with suboptimal precipitation characteristics. A  comparison o f the chloramine T and 
Iodo-Bead methods fo r iodination o f human a-fetoprotein (hAFP) was performed by 
Lee and G riffiths (1984). The chloramine T method yielded a tracer o f higher specific 
activity than that obtained using Iodo-Beads, but the Iodo-Bead method was a more 
controllable, m ilder method and the tracer produced by this method was more stable 
on storage at -20°C. Thean (1990) iodinated human a-lactalbumin using the 
chloramine T, lactoperoxidase and Iodogen methods. Iodination w ith Iodogen resulted 
in a tracer w ith the highest specific activity and immunoreactivity. A  comparison o f 
the iodination o f epidermal growth factor (EGF) using chloramine T, Iodogen, Iodo- 
Beads, IC I and lactoperoxidase-glucose oxidase-coupled beads (Enzymobeads) was
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carried out by Kienhuis et al. (1992). Iodination using chloramine T, Iodogen and 
Iodo-Beads caused oxidation o f amino acid residues o f EGF, and the resulting tracer 
had a decreased receptor binding a ffin ity compared w ith native EGF. Iodination using 
IC1 and Enzymobeads caused insignificant oxidation, and did not affect the ligand- 
receptor interaction.
The most suitable iodination technique must be assessed fo r the particular protein. The 
choice o f iodination procedure w ill depend on several factors. The stability o f the 
protein during a particular labelling procedure, the desired specific activity o f the 
labelled product and its performance in the system fo r which it is required, and the 
sim plicity and cost o f the labelling procedure are factors which must be considered.
1.3.1.1 Iodine monochloride.
The use o f iodine monochloride (IC1) to iodinate proteins was first introduced by 
McFarlane (1958). Radioactive iodine in  the form o f iodide ions is mixed with a 
solution o f the protein to be iodinated, buffered to a pH o f approximately 8. IQ  is 
added, and two reactions take place. Radioactive iodine is converted to radioactive IC1 
by isotope exchange w ith nonradioactive ICL, and iodination o f tyrosine residues o f the 
protein occurs as a result o f conversion o f IC1 to hypoiodite. The iodination reaction 
can be represented as follows:
I d  + NaOH - HOI + N a d  
HOI + tyrosine residue - iodinated protein + H20
(Angeles Contreras et al., 1983).
The reaction is very rapid, so after just one minute a protective protein can be added, 
and the iodinated protein isolated from the reaction mixture. The only oxidising agent 
present during the iodination is IC1, so no damage can occur to the protein that may 
occur w ith other oxidising agents.
It is also possible to carry out an oxidative IC1 iodination technique which can be used 
to label to high specific activity, and has the advantage that m ild oxidation conditions 
associated w ith the original technique are maintained (Helmkamp et al., 1960). In this 
technique radioiodine is direcdy oxidised to radioactive IC1, as follows:
2KI + KI03 + 6HC1 - 3IC1 + 3KCl + 3HzO
Iodination o f the protein then occurs, without the need fo r an isotope exchange 
reaction.
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1.3.1.2 Chloratnine T.
Hunter and Greenwood (1962) firs t showed that low concentrations o f chloramine T 
promoted incorporation o f inorganic iodide into protein. Chloramine T, the N-chloro- 
derivative o f p-methylbenzenesulphonamide, is an oxidising agent. The structure is 
shown in Fig 1.7.
The iodination reaction is initiated on addition o f chloramine T  to a mixture o f protein 
and sodium iodide, and is allowed to proceed for approximately one minute. The 
reaction is stopped by addition o f sodium metabisulphite, which reduces any unreacted 
chloramine T. Sodium metabisulphite can cause protein denaturation, so addition o f 
tyrosine may be preferable. The level o f protein iodination is affected by the 
concentration and duration o f exposure to chloramine T; both should be kept to a 
minimum to avoid non-specific chloramine T damage to the protein.
The chloramine T method is rapid, and does not require the use o f organic solvents or 
extremes o f pH that might denature the protein. However, chloramine T is a powerful 
oxidising agent which may cause denaturation and optimal reaction conditions need to 
be established fo r each protein, as parameters such as tyrosine reactivity and 
susceptibility to iodination and chloramine T damage have to be assessed.
1.3.1.3 Iodogen.
The use o f Iodogen (l,3,4,6-tetrachloro-3a,6a-diphenylglycouril) as an iodination 
reagent was firs t described by Fraker and Speck (1978). The structure o f Iodogen is 
shown in  Fig 1.7. The reagent is water-insoluble, but soluble in organic solvents such 
as chloroform and dichloromethane. It can be used as a solid phase oxidising agent 
fo r iodination by plating aliquots in  a thin film  on the walls o f the reaction vessel. On 
addition o f sodium iodide and an aqueous solution o f protein the iodination reaction 
proceeds rapidly, and is stopped by decanting the reaction solution away from the 
Iodogen reagent Thus, no reducing agent is required. However, the method requires 
evaporation o f organic solvent fo r plating o f Iodogen on the reaction vessel which is 
tedious and hazardous.
1.3.1.4 Iodo-Beads.
M arkwell (1982) firs t reported the use o f Iodo-Beads fo r protein iodination. Iodo- 
Beads consist o f N-chlorobenzenesulphonamide immobilised on non-porous polystyrene 
beads (Fig 1.7). The iodination procedure is simple. Iodo-Beads are added to a 
solution o f sodium iodide and protein, and iodination is allowed to proceed for 15
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minutes. The reaction is stopped by removal o f the Iodo-Beads with a tweezers or by 
removal o f the reaction solution using a pipette. As w ith Iodogen, the need to use a 
reducing agent is eliminated.
1.3.1.5 Lactoperoxidase.
Lactoperoxidase is an oxidising enzyme that can be used fo r enzymatic iodination o f 
a protein (Marchalonis, 1969). Iodination is carried out in the presence o f low  
concentrations o f hydrogen peroxide; the quantity o f peroxide can be used to control 
the level o f iodination. The iodination reaction is stopped by the addition o f a reducing 
agent, such as mercaptoethanol. Lactoperoxidase iodination is a gentle method and is 
important fo r proteins that are subject to damage using chemical methods. The 
lactoperoxidase method avoids exposure o f the protein to excessive quantities o f strong 
oxidising agents, and fo r some proteins the method is superior in maintaining the 
structural integrity o f the protein.
The reaction conditions for iodination using lactoperoxidase should be carefully 
controlled. Lactoperoxidase is sensitive to inhibition by sodium azide and high salt 
concentrations. The use o f too high a concentration o f peroxide, or partially inactive 
peroxide or enzyme, can cause problems.
Other peroxidases can be used for enzymatic iodination, fo r example, HRP, thyroid 
peroxidase and chloroperoxidase, but these have a lower iodination efficiency than 
lactoperoxidase. Marchalonis (1969) reported that HRP was at least an order o f 
magnitude less effective than lactoperoxidase fo r iodination o f proteins.
1.3.1.6 Bolton Hunter reagent
The firs t conjugation reagent to be used fo r iodination o f proteins was 3-(4- 
hydroxyphenyl) propionic acid N-hydroxysuccinimide ester, which is known as Bolton 
Hunter reagent (Bolton and Hunter, 1973). Bolton Hunter reagent (BHR) is iodinated 
by the chloramine T method, and the iodinated product is extracted into benzene and 
evaporated to dryness. Mono- or di-iodinated BHR can be produced, depending on the 
reaction conditions used. The reaction should be carried out as rapidly as possible due 
to the susceptibility o f the N-hydroxysuccinimide ester to hydrolysis in aqueous 
solution. In order to iodinate proteins, the iodinated reagent is reacted with protein in 
borate buffer, pH 8.5. The reaction scheme is shown in F ig 1.8. Since IBHR was first 
introduced it has been used to label a wide variety o f compounds, such as proteins and 
peptides, antibodies, haptens, drugs, viruses and cell lysates (Langone, 1980).
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The use o f other conjugation reagents has also been reported. Aniline can be iodinated 
by the chloramine T  method, diazotized and reacted w ith the protein under basic 
conditions (Hayes and Goldstein, 1975). This method is suitable fo r proteins that have 
reactive th io l groups. The reagent is presumed to react w ith the phenol moiety o f 
tyrosine residues, producing an iodinated protein that is analogous to that obtained by 
direct iodination (Langone, 1980). The use o f the iodinated derivative o f methyl p- 
hydroxybenzimidate HCL (MPHBIM ) was reported by Wood et al. (1975). MPHBIM  
was iodinated using chloramine T, and the iodinated product was isolated by acid 
precipitation. This reagent reacts w ith amino groups o f the protein. However, the 
positive charge o f the amino groups may be preserved w ith this reagent whereas the 
positive charge is probably lost on reaction w ith IBHR. Garg et al. (1989) used 
iodinated N-succinim idyl (tri-n-butylstannyl) benzoate (ATE) fo r labelling o f 
antibodies. They reported that the labelling efficiency using ATE was twice that 
observed using IBHR. This was possibly due to the inertness to hydrolysis o f the N- 
succinim idyl group o f ATE, due to a lack o f a methylene spacer between this group 
and the aromatic ring.
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Figure 1.7 The structures o f some oxidising agents used fo r iodination o f protein, 
(a) Chloramine T  (b) Iodogen (c) Iodo-beads
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1.3.2 Kinetic catalytic methods for determination of iodine.
The use o f non-radioactive iodine as a label in immunoassays depends on the 
availability o f a suitable detection method fo r iodine. K inetic catalytic methods are 
suitable fo r the sensitive determination o f iodine. Iodide ion is one o f the most 
effective inorganic catalysts (Fritz and Schenk, 1966); it  can be determined at ultratrace 
level in  the presence o f many other ions.
For kinetic catalytic reactions, the presence o f the catalyst increases the rate o f reaction. 
The rate is, therefore, directly proportional to the concentration o f catalyst. Catalytic 
reactions have low  lim its o f detection. They can be used fo r the determination o f 
reactants, catalysts and substances reacting w ith catalysts (activators, inhibitors). 
Several experimental methods can be applied to the measurement o f the rate o f a 
reaction. To determine the rate, the change w ith time o f the concentration o f at least 
one o f the reactants or products must be studied using a suitable method o f analysis. 
Methods that measure the change o f some physical property o f the system, proportional 
to the concentration, as a function o f time are suitable. Spectrophotometric methods 
are most w idely used. Electrochemical methods, polarimetry, fluorescence, and 
luminescence are also used. Determination o f the catalyst concentration can be made 
by plotting the rate o f the reaction against the concentration o f the catalyst. 
Alternatively, the absorbance o f a reactant or product after a fixed time, or the time 
required to reach a fixed absorbance, can be plotted against the concentration o f the 
catalyst.
Spectrophotometric methods are of interest fo r the detection of the non-radioactive 
iodine label in immunoassays, therefore, only kinetic catalytic reactions that can be 
monitored spectrophotometrically w ill be discussed here. Many kinetic catalytic 
reactions have been recommended fo r the determination of iodine (Zak, 1978; 
W illiams, 1979). The most frequently used method is the Sandell-Kolthoff reaction.
1.3.2.1 The Sandell-Kolthoff reaction.
The determination o f iodide by measurement o f its catalytic action on the reaction 
between cerium (IV) and arsenic(III), in acidic solution, was firs t described by Sandell 
and K o ltho ff (1934). The reaction proceeds as follows:
2 Ce4+ + A s 3* -  2 C e 3* + A s 5'
(Y ellow ) (Colourless)
In the absence o f catalyst the reaction requires many hours to go to completion. In the
presence o f catalyst the reaction rate increases, the rate being proportional to the
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catalyst concentration. The reaction was orig ina lly monitored chronometrically which 
involved waiting until the yellow colour due to cerium (IV) ions had disappeared, and 
noting the time. This was too time-consuming fo r routine determinations. Therefore, 
methods based on the employment o f an empirical absorbance-concentration standard 
curve under controlled conditions o f time, temperature, acidity, and concentration and 
order o f reagent addition were developed (Zak, 1978).
The Sandell-Kolthoff reaction is catalysed not only by inorganic iodide, but also by 
iodine-containing organic compounds (Bowden et al., 1955). It is routinely used in a 
large number o f laboratories fo r the determination o f iodine in many types o f samples 
and o f iodine-containing proteins, hormones and drugs. The measurement o f iodine in  
biological samples and foods is o f interest, as absence o f iodide in the diet produces 
several diseases. Iodine deficiency is a major health problem in Asia, A frica and South 
America, and can result in  goitre, irreversible mental retardation and decreased survival 
among children (Dunn et al., 1993). U rinary iodine excretion is used to assess iodine 
deficiency in  communities in these countries. In the developed world studies have 
indicated that the intake o f iodine is several times greater than the Recommended 
Nutrient Intake (RN I) (Fischer et al., 1986). There are regulations that govern the 
amount o f iodine in  certain foods, fo r example, infant formula and table salt, and in 
order to enforce these regulations the iodine content o f foods must be determined. 
Determination o f thyroid hormones is also o f major importance. The primary action 
o f thyroid hormones is to increase the basal metabolic rate in  many tissues. 
Hypothyroidism , a deficiency in  thyroxine (T4) is characteristic o f the disease 
myxoedema. Hyperthyroidism , excessive secretion o f T4, is responsible fo r Graves’ 
disease or exophthalmic goitre.
Many authors have reported the use o f the Sandell-Kolthoff reaction fo r the 
measurement o f iodine in  biological samples. Soon after the introduction o f the 
reaction, Chaney (1940) used it  fo r the determination o f iodine in blood. Samples were 
subjected to chromic acid oxidation followed by d istilla tion o f the iodine. The iodine 
content o f the distilla te was determined by reading the percentage transmittance o f the 
reaction solution exactly 5 minutes after the addition o f eerie sulphate. Percentage 
transmittance was also used by Mougey and Mason (1963) in the determination o f 
inorganic iodide, iodotyrosines and thyroid hormones in serum or plasma, follow ing  
separation by gel filtra tion . Knapp and Leopold (1974) separated the thyroid hormones 
3’ ,3,5-tri-iodothyronine (T3) and T4 by ion-exchange chromatography, and determined 
the hormone concentration by measurement o f the absorbance o f the Sandell-Kolthoff
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reaction at 365nm. Nachtmann et al. (1978) separated the thyroid hormones by HPLC, 
and used the reaction fo r post-column detection as UV  detection was not sufficiendy 
sensitive. Iodide, iodotyrosine, T3 and T4 were also determined by Palumbo et al. 
(1982) by monitoring the absorbance at 410nm. Their method was modified by 
Saboori et al. (1993), and used fo r the determination o f iodine in thyroglobulin. 
Plasma inorganic iodine (P II) was determined by Aumont and Tressol (1987) after 
separation o f iodide from  organically bound iodine by ion-exchange chromatography. 
Follow ing alkaline ashing, iodide was determined by the Sandell-Kolthoff reaction. 
The reaction was arrested by the addition o f brucine, which causes the reduction o f the 
remaining cerium (IV) to colourless cerium (III), w ith oxidation o f brucine to an orange- 
coloured product. The absorbance o f the orange-coloured product was measured. 
Mezzetti et al. (1988) determined T4 and iodine-containing drugs in  plasma follow ing  
separation by ion-exchange chromatography. The Sandell-Kolthoff reaction was 
arrested by addition o f mercuric ions, which inh ib it the catalytic action o f iodide.
The iodine content o f many other biological samples has also been determined using 
the Sandell-Kolthoff reaction. Fischer et al. (1986) determined iodine in  samples o f 
dairy products, meat, eggs, fish, cereal and potatoes after acid digestion o f the organic 
material. Iodine in urine and m ilk  was determined by Aumont and Tressol (1986) after 
alkaline ashing. They used brucine to arrest the reaction. A lkaline ashing, and 
measurement o f the absorbance o f the Sandell-Kolthoff reaction at 410nm or 365nm, 
was used by Ayiannidis and Voulgaropoulos (1988) and Gutierrez et al. (1989) to 
measure iodine in samples such as blood, m ilk , water, salt and alfalfa meal. Urinary 
iodine was measured after alkaline ashing by May et al. (1990) and after acid digestion 
by Dunn et al. (1993). The detection lim it achieved by some o f these authors is shown 
in Table 1.5, and illustrates that the Sandell-Kolthoff reaction is a sensitive method for 
measurement o f iodide and iodine-containing compounds at nanogramme levels in 
biological samples.
A  microassay system based on the Sandell-Kolthoff reaction was developed by 
O’Kennedy et al. (1989). The Sandell-Kolthoff reaction was modified fo r use with 
m icrotitre plates, and the absorbance was monitored using a microplate reader. The 
use o f a microassay system has several advantages. The microassay has good 
sensitivity and reproducibility, small quantities o f reagents are required and many 
samples can be tested simultaneously. O ’Kennedy et al. (1989) used the microassay 
system to measure iodide at nanogramme levels, and to monitor the conjugation o f 
IBHR to ovalbumin and human serum albumin. Their system thus eliminated the need
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to use radioactivity to monitor iodination. The microassay was applied to the detection 
o f non-radioactive iodine-labelled antibodies in immunoassays (Section 1.3). Iodine- 
labelled antibodies were prepared using the IB  HR iodination technique, but w ithout the 
need to use hazardous radioactive materials, and the iodine label was detected using 
the Sandell-Kolthoff microassay. This immunoassay system showed favourable 
comparison w ith ELISA. The main drawback o f the system is that as it is based on 
the use o f the Sandell-Kolthoff reaction it requires the use o f arsenic, a known 
carcinogen. Therefore, the replacement o f the Sandell-Kolthoff reaction w ith another 
kinetic catalytic reaction fo r detection o f the iodine label would be favourable.
1.3.2.2 Other kinetic catalytic reactions.
There are many alternative kinetic catalytic reactions which have detection lim its  
equivalent to that achieved using the Sandell-Kolthoff reaction. The detection lim its  
fo r iodide obtained using some o f these reactions are reported in Table 1.6 and Table
Several o f these reactions involve the use o f hydrogen peroxide as oxidising agent. 
Fuchs et al. (1964) used p-aminophenol and hydrogen peroxide fo r catalytic 
determination o f iodide. Iodide is oxidised by hydrogen peroxide to iodate, which in 
turn oxidises p-aminophenol to a blue indamine dye. The absorbance o f the blue dye 
was measured at 540nm. The oxidation o f benzidine and o-tolidine by hydrogen 
peroxide was used by Yasinskene and Umbrazhyunaite (1975a). The oxidation occurs 
in  two stages: during the firs t stage the absorbance increases due to the formation o f 
a coloured reaction product, while during the second stage the absorbance decreases 
due to decolouration o f the product. Iodide catalyses both stages, but the firs t stage 
o f the reaction was monitored as this was the more sensitive.
Yasinskene and Umbrazhyunaite (1973) also investigated the oxidation o f the organic 
dyes pyrogallol red, bromopyrogallol red and stilbazo by hydrogen peroxide. The 
reactions were based on the decolouration o f the dyes, and the absorbance was 
monitored at 440nm. The use o f bromate, iodate and periodate as alternative oxidising 
agents was examined, but these gave reduced sensitivity. The measurement o f iodide 
using the oxidation o f pyrocatechol vio let by hydrogen peroxide was also investigated 
by Yasinskene and Umbrazhyunaite (1973), a reaction which was used by Yonehara 
et al. (1989) fo r the simultaneous determination o f iodide and bromide. The catalytic 
effect o f bromide is relevant only in the early stages o f the reaction, and ceases after 
less than a minute. Iodide acts as a catalyst throughout the reaction, thus enabling the
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ions to be determined simultaneously. Kreingold et al. (1978) studied the oxidation 
o f o-phenylenediamine (OPDA), diphenylcarbazide and variamine blue by hydrogen 
peroxide. These reactions involve the oxidation o f colourless organic reagents to 
intensely coloured products. The OPDA-hydrogen peroxide reaction was the most 
sensitive o f these reactions.
Other reactions invo lving oxidation by hydrogen peroxide are the reaction o f 3,3’ - 
dimethylnaphthidine w ith hydrogen peroxide (Bognar and Nagy, 1969), and the 
reaction o f sodium 2-thiosemicarbazone-1,2-naphthoquinone-4-sulphonate (TNHS) with 
hydrogen peroxide (Igov et al., 1979).
The reaction o f iron thiocyanate w ith n itrite ions is the most frequently used reaction, 
after the Sandell-Kolthoff reaction, fo r the determination o f iodide. Iodide catalyses 
the oxidation o f thiocyanate by nitrite, and the decrease in the orange colour o f the 
iro n (III) thiocyanate can be used to fo llow  the reaction. The reaction can be 
represented by:
NO2 + 2SCN~ + 4H + - 2NO + {SCN) 2 + 2HzO 
(W illiams, 1979).
The method was firs t proposed fo r the determination o f iodide by Iwasaki et al. (1953). 
However, Ottaway et al. (1969) reported that w ith  this method two w idely different 
iodide concentrations can lead to the same value o f the measured parameter. The 
method can be used i f  i t  is known that the iodide concentration in a sample w ill fa ll 
w ith in lng /m l to lOpg/m l, as accurate results are obtained w ithin these lim its. The 
reaction has been used fo r the determination o f iodine in foods (Moxon and Dixon, 
1980), o f total and free iodide in water samples (Moxon, 1984), and o f inorganic iodine 
in  rain (Foum ier-Bidoz et al., 1992). Iodide and n itrite have been determined 
simultaneously using this reaction (Zhu and Gu, 1993). The reaction is characterised 
by an induction period. The length o f the induction period depends on the concentration 
o f n itrite , and is independent o f iodide. The rate o f the reaction depends on the 
concentration o f iodide, and is independent o f n itrite. Therefore, n itrite and iodide can 
be determined simultaneously by measurement o f the induction period and the reaction 
rate.
Oxidations involving chloramine T or chloramine B also provide sensitive methods o f 
iodide determination. The use o f the reaction between chloramine T and N ,N ’- 
tetramethyl-diaminodiphenylmethane (tetrabase acetate) was reported by Jungreis and 
Gedalia (1960). Tetrabase acetate is oxidised to an unstable blue quinoidal product,
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which decomposes w ith in  a few minutes to produce a yellow-green product. The 
reaction was monitored by measurement o f the absorbance o f the blue compound at 
600nm, as the absorbance o f the fina l product was low. Oxidation o f organic dyes by 
chloramine B was used by Bunikene and Ramanauskas (1968) and Yasinskene and 
Umbrazhyunaite (1975b). The oxidation o f 11 triphenylmethane dyes was studied by 
Bunikene and Ramanauskas (1968). The most sensitive dyes fo r iodide determination 
were b rillian t green, acid green G and acid bright blue. Yasinskene and 
Umbrazhyunaite (1975b) examined the oxidation o f pyrocatechol violet and 
bromopyrogallol red by chloramine B. The use o f chloramine B as an oxidising agent 
fo r bromopyrogallol red proved to be more sensitive than the use o f hydrogen peroxide. 
The determination o f iodide using the oxidation o f chlorpromazine, a tranquillizing 
drug, by bromate was reported by Vinas et al. (1987). The reaction was followed by 
measuring the increase in  absorbance at 525nm due to the formation o f a red 
semiquinone product. The use o f this reaction, w ith hydrogen peroxide as oxidising 
agent, was reported by Liang et al. (1993) fo r the determination o f iodide and by 
Tomiyasu et al. (1994) fo r the differential determination o f iodate and iodide.
The use o f several other kinetic catalytic reactions has also been reported. Bognar and 
Sarosi (1965) used the reaction between cerium(IV) and antimony(III) fo r the 
determination o f traces o f iodine. The reaction was monitored chronometrically using 
ferroin as indicator fo r determination o f the end po in t The catalytic effect o f iodide 
on the reaction between iodate and arsenic(III) was used by Weisz and Rothmaier 
(1974). The reaction scheme is as follows:
3AsO^ + JO3'  -  3AsOi + I~
The oxidation o f arsenic(HI) by hexacyanoferrate(III) was used by Sriramam et al. 
(1987). The reaction was monitored by measurement o f the absorbance o f unreacted 
hexacyanoferrate at 415nm.
Many o f these reactions have low lim its o f detection for iodide, and would be suitable 
fo r the development o f an alternative to the Sandell-Kolthoff microassay described by 
O’Kennedy et al. (1989). The aim o f this project is to develop a microassay for 
measurement o f iodine using one o f these reactions, and to apply this to the detection 
o f the non-radioactive iodine label in immunoassays.
This thesis describes the development and optimisation o f an alternative microassay, 
based on the reaction between cerium(IV) and antimony(III) (Bognar and Sarosi, 1965). 
The use o f the cerium (IV ) - antimony(III) reaction allows the replacement o f
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arsenic(III) w ith antimony (H I), which is advantageous for safety reasons, while 
allowing the continued use o f cerium(IV). Cerium(IV) oxidises iodine-containing 
organic compounds liberating iodine; the bound iodine must be liberated for the 
detection o f these compounds by a catalytic reaction (Section 3.2.3). The catalytic 
activity o f iodide and iodine-containing organic compounds on this new microassay is 
studied, and compared w ith the catalytic activity on the Sandell-Kolthoff microassay. 
The feasibility o f using the new microassay for the detection o f the non-radioactive 
iodine label in an immunoassay using labelled antibodies is assessed by comparison 
with an immunoassay using the Sandell-Kolthoff microassay fo r detection o f the iodine 
label, and comparison w ith an ELISA. The model system used is an immunoassay for 
the measurement o f human IgG. As human IgG has more than one antigenic 
determinant it is suitable fo r use as an analyte in a two-site immunoassay using 
iodinated antibodies fo r detection o f the analyte. The results fo r the model system can 
therefore be extrapolated to illustrate how iodinated antibodies would perform in  
immunoassays for the detection o f other antigens. Alternative immunoassays using 
non-radioactive iodine-labelled reagents in conjunction w ith the avidin-biotin system 
or bispecific antibodies are reported. An immunoassay for T4, which uses the four 
iodine atoms present on T4 as the label, is also evaluated.
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Compound Detection limit 
(ng/ml)
Reference
t 3 0.2 Knapp and Leopold, 1974
t 4 2
Iodide 0.1 Fischer et al., 1986
3 Aumont and Tressol, 1987
<10 Mezzetti et al., 1988
1 Gutierrez et al., 1989
1 O ’Kennedy et al., 1989
10 Dunn et al., 1993
Table 1.5 The detection lim it fo r thyroid hormones or iodide obtained using the 
Sandell-Kolthoff reaction.
Reaction Detection
limit
Reference
p-Aminophenol - H20 2 2.5pg/ml Fuchs et al., 1964
Pyrogallol red - H 20 2 l.lp g /m l Yasinskene and 
Umbrazhyunaite, 1973Bromopyrogallol red - H 2Oz lln g /m l
Stilbazo - H20 2 55ng/ml
Pyrocatechol v io le t - H20 2 2ng/ml
5ng/ml Yonehara et al., 1989
Benzidine - H20 2 4ng/ml Yasinskene and 
Umbrazhyunaite, 1975ao-Tolidine - H 20 2 2ng/ml
OPDA - H20 2 2ng/ml Kreingold et al., 1978
Diphenylcarbazide - H20 2 lln g /m l
Variamine blue - H20 2 20ng/ml
3,3’-dimethylnaphthidine - H20 2 2ng/ml Bognar and Nagy, 1969
TNHS - H20 2 0.5pg/ml Igov et al., 1979
Table 1.6 The detection lim it fo r iodide obtained using several kinetic catalytic 
reactions w ith hydrogen peroxide as oxidising agent.
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Reaction Detection
limit
Reference
Iron thiocyanate - 
nitrite ions
lng /m l Iwasaki et al., 1953
0.4ng/ml Foumier-Bidoz et al., 1992
5pg/ml Zhu and Gu, 1993
Tetrabase acetate - 
chloramine T
1.8ng/ml Jungreis and Gedalia, 1960
B rillia n t green - 
chloramine B
0.6ng/ml Bunikene and Ramanauskas, 1968
Acid green G - 
chloramine B
2. lng /m l
Acid bright blue - 
chloramine B
2.9ng/ml
Pyrocatechol vio let - 
chloramine B
1.3ng/ml Yasinskene and Umbrazhyunaite, 1975b
Bromopyrogallol red - 
chloramine B
1.3ng/ml
Chlorpromazine - 
bromate
5ng/ml Vinas et al., 1987
Cerium (IV) - 
antim ony(III)
lng /m l Bognar and Sarosi, 1965
Iodate - arsenic(III) O .lpg/m l Weisz and Rothmaier, 1974
Table 1.7 The detection lim it fo r iodide obtained using several kinetic catalytic 
reactions.
2. MATERIALS AND METHODS.
2.1 MATERIALS.
A ll chemicals used in  the experimental work were analytical grade, and were purchased 
from Sigma Chemical Co. (St. Louis, Mo., USA) except fo r the follow ing: 
3-(4-hydroxyphenyl) propionic acid N-hydroxysuccinimide ester, 3-iodophenol, and 
benzene were obtained from Aldrich Chemical Co. Ltd. (Dorset, England).
L(+)-tartaric acid, antimony potassium oxide(+)tartrate 0.5-hydrate, potassium iodide, 
sodium periodate, boric acid, di-sodium tetraborate, acetic acid and nitric acid were 
obtained from BDH  Chemicals Ltd. (Poole, England).
L-thyroxine, ethanol, 2-iodophenol and silica gel 60 for column chromatography were 
obtained from Merck Chemical Co. Ltd. (Darmstadt, Germany).
Ammonium persulphate, Tween 20, sulphuric acid, hydrochloric acid, toluene, glycerol, 
bromophenol blue, 2-merc aptoethanol and TLC plates (10 x 20cm; silica gel 60; 0.2mm 
layer thickness) were obtained from Riedel-de Haen (Hannover, Germany).
Ethyl acetate and methanol were obtained from LabScan Analytical Sciences (Dublin). 
Avidin (from  hen egg white), biotin-LC-hydrazide, N-succinim idyl (4-iodoacetyl) 
aminobenzoate (S IAB ) and BCA reagents were obtained from Pierce Chemical Co. 
(Rockford, II., USA).
BioRad dye reagent concentrate was obtained from BioRad Laboratories (München, 
Germany).
Sephadex G-25 (medium) was obtained from Pharmacia LKB  (Uppsala, Sweden). 
Ethanolamine-HCl, N-hydroxysuccinimide - coupling solution and N-ethyl-N ’- 
(dimethylamino-propyl)carbodiim ide - coupling solution were obtained from Pharmacia 
Biosensor Ltd. (Uppsala, Sweden).
PBS tablets were obtained from Oxoid (Hampshire, England).
8-Hydroxyquinoline-5-sulphonic acid monohydrate was obtained from  MTM  Research 
Chemicals Ltd. (Lancashire, England).
M icrotitre plates (Maxisorb, 96-well, flat-bottomed) were obtained from Nunc (Roskilde, 
Denmark).
Dynatech M icroF luor plates (white) were obtained from Dynatech (West Sussex, UK). 
Human serum samples were obtained from S t James’ Hospital (Dublin).
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The antibodies used, and the companies from which they were obtained, were as follows: 
Human IgG, goat anti-human IgG antibodies, rabbit anti-BSA antibodies, HRP-labelled 
rabbit anti-goat IgG antibodies, HRP-labelled goat anti-rabbit IgG antibodies and rabbit 
anti-thyroxine serum were obtained from Sigma Chemical Co. (St. Louis, Mo., USA). 
Sheep anti-thyroxine serum was obtained from Scottish Antibody Production Unit 
(Lanarkshire, Scotland).
Rabbit anti-thyroxine antibodies were obtained from Dako (Glostrup, Denmark).
The fo llow ing instrumentation was used:
Titertek Twinreader plus (Flow Laboratories, Lugano, Switzerland).
Perkin Elmer LS50 Luminescence Spectrophotometer (Perkin Elmer L td , 
Buckinghamshire, England).
Shimadzu UV 160A recording spectrophotometer (Shimadzu Corporation, Tokyo, Japan). 
BIAcore (Pharmacia Biosensor, Uppsala, Sweden).
A tto m ini-gel electrophoresis unit (A tto Corporation, Tokyo, Japan).
2.2 Microassays for the measurement of iodine.
2.2.1 Cerium(IV)- Antimony (HI) spectrophotometric microassay.
Ceric ammonium sulphate (0.02M) was prepared in 6M  H2S04. Concentrated H2S04 
(334ml) was added slow ly to 500ml o f ultrapure water, followed by 12.65g o f ceric 
ammonium sulphate. The solution was stirred until the ceric ammonium sulphate had 
dissolved, cooled to room temperature and made up to 1 litre  w ith ultrapure water. 
Antimony potassium tartrate (0.03M) was prepared in 1% (w /v) tartaric acid.
Standards, or samples, (lOOpl) were added to the wells o f a m icrotitre plate. Antimony 
potassium tartrate (50pl) was added using an eight-channel multipipette, followed by 50pl 
o f ceric ammonium sulphate. The reactants were mixed thoroughly, and after incubation 
at room temperature fo r lh r the absorbance was measured at 380nm using the Titertek 
plate reader.
2.2.2 Cerium(III) fluorimetric microassay.
The procedure was carried out as fo r the cerium (rV)-antimony(III) spectrophotometric
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microassay, except antimony potassium tartrate was used at a concentration o f 0.04M. 
A fte r incubation at room temperature fo r 1 hr the fluorescence was measured at excitation 
and emission wavelengths o f 260nm and 360nm, respectively.
2.2.3 Cerium(IV) - 8-hydroxyquinoIine-5-suIphonic acid fluorimetric microassay. 
The procedure was identical to the cerium (IV)-antimony(III) spectrophotometric 
microassay, except that after incubation at room temperature fo r lh r, 50pl o f 1.5mM 8- 
hydroxyquinoline-5-sulphonic acid was added to the wells. The fluorescence was 
measured at excitation and emission wavelengths o f 370nm and 480nm, respectively.
2.2.4 Sandell-Kolthoff microassay.
The microassay was carried out as reported by O ’Kennedy and Keating (1991). Ceric 
ammonium sulphate (0.1M ) was prepared in  2.5M HjSO^ using the method outlined in 
Section 2.2.1. This solution was diluted to a working concentration o f 0.028M in 10% 
(v/v) H2S04. Arsenious acid (0.075M) was prepared by dissolving 14.84g o f arsenious 
trioxide in 700ml o f ultrapure water containing 28ml o f concentrated H2S04. (Care should 
be taken in  the preparation o f this reagent, as arsenious trioxide is a carcinogen.) The 
solution was heated to near-boiling, stirring constandy, until the arsenious trioxide had 
dissolved. Some precipitation o f arsenious trioxide may occur. A fte r reaching room 
temperature, the solution was made up to 1 litre  w ith ultrapure water.
Standards, or samples, (lOOpl) were added to the wells o f a m icrotitre plate. Arsenious 
acid (60pl) was added using an eight-channel multipipette, followed by 25pi o f ceric 
ammonium sulphate. The plate was mixed well, and after incubation at room temperature 
fo r 5min the absorbance was measured at 414nm using the Titertek plate reader.
2.3 Preparation of iodinated Bolton Hunter reagent.
2.3.1 Preparation of mono-iodinated Bolton Hunter reagent (IBHR).
IBHR was prepared as reported by O’Kennedy et al. (1989). A  0.1M solution o f 3-(4- 
hydroxyphenyl)propionic acid N-hydroxysuccinimide ester (Bolton Hunter reagent) and a 
2M solution o f iodine monochloride (IC1) were prepared in ethyl acetate. IC1 was added 
to Bolton Hunter reagent at a 2:1 molar ratio. The reaction was allowed to proceed at 4°C 
overnight. IBHR, which forms as a white precipitate, was recovered by centrifugation at
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400g fo r 10 m in. The precipitate was washed several times in ice-cold ethyl acetate. The 
precipitate was dried under nitrogen, and stored at -20°C.
The purity was tested by TLC on silica gel plates w ith a fluorescent indicator, and a 
solvent system o f ethyl acetate : toluene (1:1, v/v). EBHR had an R f value o f 0.50.
2.3.2 Preparation of di-iodinated Bolton Hunter reagent (di-IBHR).
This was carried out according to the method o f Bolton and Hunter (1973). Bolton Hunter 
reagent (O .lmg) was reacted w ith 0.68mg o f Nal and 25mg o f chloramine-T in 5ml of 
0.25M phosphate buffer, pH 7.5 (iodide : Bolton Hunter reagent molar ratio o f 10:1). 
After approximately 30 seconds the reaction was stopped by the addition o f 60mg o f 
sodium metabisulphite in  5ml o f 0.05M phosphate buffer, pH 7.5. DMF (1ml) was 
immediately added, and the iodinated products were extracted in to benzene and evaporated 
to dryness under nitrogen. The products were identified by TLC on silica gel plates with 
a fluorescent indicator, and a solvent system o f ethyl acetate : toluene (1:1, v/v). Di-IBHR  
had an R f value o f 0.68.
D i-IBHR was purified  by chromatography on a silica column w ith a solvent system of 
ethyl acetate : toluene (1:2, v/v). The reaction products were dissolved in ethyl acetate : 
toluene (1:2, v/v), and applied to the top o f a silica column (particle size 0.063mm) in a 
75ml separation funnel (12 x 3cm). Fractions (0.5ml) were collected, and the purity o f 
each fraction was tested by TLC. Fractions found to contain d i-IBHR  were pooled, and 
evaporated to dryness under nitrogen.
2.4 Preparation of IBHR-labelled antibodies.
The method was carried out as reported by O ’Kennedy et al. (1989). IBHR was dissolved 
at a concentration o f 4mg/m l in benzene, containing 4% (v/v) DMF. One milligramme 
was dried under nitrogen, and reconstituted w ith 200pl o f DMF. Antibody (lm g in 1ml 
o f 0.1M borate buffer, pH 8.5) was added. The reaction was allowed to proceed for 2hr 
at 4°C. The reaction mixture was centrifuged at 400g fo r 10 min, to remove any 
precipitate that may have formed during the reaction. Any unreacted IBHR was removed 
by dialysis at 4°C fo r 24hr against 0.03M phosphate buffer, pH 7.3.
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2.5 Preparation and assessment of horseradish peroxidase (HRP) - labelled antibodies.
2.5.1 Preparation of HRP-labelled antibodies.
The procedure was carried out using a modification o f the method described by Tijssen 
and Kurstak (1984). There are three steps involved: (i) activation o f HRP (ii) conjugation 
o f HRP to antibodies ( iii)  purification o f the conjugate.
(i) Activation o f HRP.
HRP (0.5mg) was weighed into an eppendorf tube, and was dissolved in 0.05ml o f freshly- 
prepared 0.1M sodium bicarbonate. Following addition o f 0.05ml o f 8mM NaI04, the 
eppendorf was sealed, and stored in  the dark fo r 2hr at room temperature.
(ii) Conjugation o f HRP to antibodies.
Antibody (lm g ) was dissolved in  0.2ml o f 0.1M sodium carbonate, pH 9.2. This was 
added to the activated HRP, followed by dry Sephadex G-25 (approximately O.lg). The 
eppendorf tube was sealed and stored in the dark fo r 3hr at room temperature. The 
reaction m ixture was eluted from  the Sephadex by centrifugation at 8000g for 15min, and 
1/20 volume o f freshly-prepared NaBH4 (5mg/ml in O.lmM NaOH) was added. A fter 
incubation fo r 30min at room temperature, 3/20 volume o f another freshly-prepared NaBH, 
solution was added. This was incubated for lh r  at room temperature.
( iii)  Purification o f the conjugate.
An equal volume o f saturated ammonium sulphate was added gradually to the reaction 
mixture to precipitate the free and conjugated antibody, and incubated fo r lh r at 4°C. After 
centrifugation at 8000g fo r 15min, the precipitate was washed w ith 50% (w/v) ammonium 
sulphate, and recentrifuged. The precipitate was resuspended in a minimum volume o f 
0.1M PBS, pH 7.3, and dialysed against 0.1M PBS, pH 7.3, fo r 24hr at 4°C.
2.5.2 Measurement of the enzyme activity of HRP-labelled antibodies.
The enzyme activity was measured using the method described by Catty and Raykundalia 
(1989). The conjugate was diluted to a concentration o f 1 jig/m l IgG in 0.1M PBS, pH 7.3; 
20pl was added to 3ml o f freshly-prepared substrate solution (lOmg o f OPDA in 25ml of 
0.15M citrate-phosphate buffer, pH 5.0, with 5pl o f 30% (w/v) H jO j). The tube was 
wrapped in  fo il, and incubated at room temperature. Aliquots (200pl) were removed at 0, 
5, 10, 15, 20, 25 and 30 m in intervals, and transferred to the wells o f a m icrotitre plate. 
The reaction was stopped by the addition o f 25pl o f 2.5M HC1. The absorbance was read
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at 492nm using the Titertek plate reader.
2.6 Immunoassay for the measurement of human IgG using labelled antibodies.
2.6.1 Immunoassay for the measurement of human IgG.
M icrotitre plates were coated w ith lOOpl o f anti-human IgG antibodies (lOpg/ml) diluted 
in 0.03M phosphate buffer, pH 7.3, fo r 2hr at 37°C. They were washed (5 times) in 0.03M 
phosphate buffer, pH 7.3, containing 0.05% (v/v) Tween 20, and once in  phosphate buffer 
alone. The plates were blocked by incubation w ith 0.5% (w /v) gelatin in 0.03M phosphate 
buffer, pH 7.3, (200pl) fo r lh r at 37°C. The plates were washed as before. Human IgG 
standards (range 0 - 2pg/m l) were prepared in blocking solution; lOOpl o f each standard 
or diluted human serum sample was added to the appropriate wells, and incubated for lh r  
at 37°C. The plates were washed as before. D ilutions o f IBHR-labelled anti-human IgG 
antibodies (1/20) and HRP-labelled anti-human IgG antibodies (1/160) were prepared in 
blocking solution. The labelled antibodies (lOOpl) were added to the wells, and incubated 
fo r 30 m in at 37°C. The plates were washed as before. Appropriate substrates were 
added, and the absorbance measured using the Titertek plate reader.
2.6.2 Detection of IBHR-labelled antibodies.
For the detection o f IBHR-labelled antibodies by the cerium (IV)-antimony(III) reaction, 
50 pi o f 0.03M antimony potassium tartrate in 1% (w /v) tartaric acid was added to the 
plate, followed by 50pl o f 0.02M eerie ammonium sulphate in 6M  H2S04. The plate was 
mixed well, and the absorbance measured at 380nm.
For detection by the Sandell-Kolthoff reaction, 60pl o f 0.075M arsenious acid was added 
to the plate, followed by 25pl o f 0.028M eerie ammonium sulphate in 10% H2S04. The 
plate was mixed well, and the absorbance measured at 414nm.
2.6.3 Detection of HRP-labelled antibodies.
For the detection o f HRP-labelled antibodies, lOOpl o f substrate solution (Section 2.5.2) 
was added to the plate. The absorbance was measured at 405nm.
2.6.4 Immunoassay for determination of optimum dilution of labelled antibodies.
M icrotitre plates were coated, washed and blocked as described in Section 2.6.1. Human
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IgG standards (range 0 - 1  pg/ml) were prepared in blocking solution; lOOpl o f each 
standard was added to the appropriate wells, and incubated fo r lh r at 37°C. The plates 
were washed as before. A  range o f dilutions o f IBHR-labelled or HRP-labelled anti­
human IgG antibodies, diluted in blocking solution (lOOpl) were added to the wells, and 
incubated fo r 30 min at 37°C. The plates were washed as before. Appropriate substrates 
were added, and the absorbance measured using the Titertek plate reader.
2.7 Preparation and use of labelled avidin.
2.7.1 Preparation of IBHR-labelled avidin.
IBHR was dissolved at a concentration o f 4mg/ml in benzene, containing 4% (v/v) DMF; 
0.15mg was dried under nitrogen, and reconstituted w ith 50pl o f DMF. Avid in (lm g in 
lm l o f 0.1M borate buffer, pH 8.5) was added The reaction was carried out as described 
in Section 2.4.
2.7.2 Preparation of biotinylated antibodies.
N-hydroxysuccinim idobiotin (0.4mg) was dissolved in 200pl o f DMF. Antibody (lm g in 
lm l o f 0.1M borate buffer, pH 8.5) was added. The reaction was carried out as described 
in Section 2.4.
2.7.3 Immunoassay for the measurement of human IgG using IBHR-labelled avidin.
Microtitre plates were coated and washed as described in Section 2.6.1. The plates were 
blocked by incubation w ith 1.5% (w/v) BSA in 0.03M phosphate buffer, pH 7.3, (200pl) 
fo r lh r at 37°C. The plates were washed as before. Human IgG standards (range 0 - 
0.5pg/ml) were prepared in blocking solution; lOOpl o f each standard or diluted human 
serum sample was added to the appropriate wells, and incubated fo r lh r at 37°C. The 
plates were washed as before. Biotinylated anti-human IgG antibodies, diluted 1/200 in 
blocking solution, (lOOpl) were added to the wells, and incubated fo r lh r at 37°C. The 
plates were washed as before. IBHR-labelled avidin, diluted 1/16 in blocking solution, 
(lOOpl) was added, and incubated fo r 20min at room temperature. A fte r washing, 
appropriate substrates were added, and the absorbance measured using the Titertek plate 
reader.
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2.7.4 Immunoassay for determination of optimum dilution of biotinylated antibodies.
M icrotitre plates were coated, washed and blocked, and human IgG standards were added, 
as described in Section 2.7.3. A range o f dilutions o f biotinylated anti-human IgG 
antibodies, diluted in blocking solution, (lOOpl) were added to the appropriate wells, and 
incubated fo r lh r at 37°C. IBHR-labelled avidin, diluted in blocking solution, (lOOpl) was 
added, and incubated fo r 20min at room temperature. A fter washing, appropriate 
substrates were added, and the absorbance measured using the Titertek plate reader.
2.7.5 Immunoassay for determination of optimum dilution of IBHR-labelled avidin.
M icrotitre plates were coated, washed and blocked, and human IgG standards and 
biotinylated anti-human IgG antibodies were added, as described in Section 2.7.3. A range 
o f dilutions o f IBHR-labelled avidin, diluted in blocking solution, (lOOpl) were added to 
the appropriate wells, and incubated fo r 20min at room temperature. A fte r washing, 
appropriate substrates were added, and the absorbance measured using the Titertek plate 
reader.
2.8 Preparation and use of labelled biotin.
2.8.1 Preparation of IBHR-labelled biotin.
IBHR was dissolved at a concentration o f 4mg/ml in benzene, containing 4% (v/v) DMF. 
One milligramme was dried under nitrogen, and reconstituted w ith lOOpl o f DMF. Biotin 
hydrazide was dissolved at a concentration o f 1.5mg/ml in 0.1M borate buffer, pH 8.5. 
A 0.25ml aliquot o f biotin hydrazide was added to the IBHR. The reaction was carried 
out as described in Section 2.4.
The reaction o f biotin-LC-hydrazide w ith IBHR was carried out as above, except that 
0.36ml o f a 1.5mg/ml solution o f biotin-LC-hydrazide was added to the IBHR. 
IBHR-labelled biotin was purified using the TLC method described by Evangelatos et al. 
(1991). TLC was carried out on silica gel plates (0.2mm layer thickness) with a 
fluorescent indicator, and a solvent system o f butanol: 2M ammonia : ethanol (3:1:1, v/v). 
IBHR-containing spots were visualised under a UV lamp. B iotin hydrazide or biotin-LC- 
hydrazide-containing spots were visualised as reported by McCormick and Roth (1970), 
using a spray reagent consisting o f equal volumes o f 2% (v/v) H2S04 in ethanol and 0.2% 
(w /v) p-dimethylaminocinnamaldehyde in ethanol. The reaction products had the follow ing
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R f values: IBHR, 0.24; biotin hydrazide, 0.46; biotin-LC-hydrazide, 0.50; IBHR-labelled 
biotin hydrazide, 0.81; and IBHR-labelled biotin-LC-hydrazide, 0.84. The IBHR-labelled 
biotin was recovered by scraping o ff the appropriate spot area, and eluting w ith 50%(v/v) 
ethanol. The solution was centrifuged at 400g fo r lOmin to remove the silica gel; the 
supernatant was evaporated to lOOpl under nitrogen, and made up to 1ml with 0.03M  
phosphate buffer, pH 7.3.
2.8.2 Use of avidin coated plates to detect IBHR-labelled biotin.
M icrotitre plates were coated w ith lOOpl o f avidin (lOpg/m l) diluted in 0.03M phosphate 
buffer, pH 7.3, fo r 2hr at 37°C. The plates were washed and blocked as described in 
Section 2.7.3. Samples (lOOpl) diluted in 0.03M phosphate buffer, pH 7.3, were added to 
the appropriate wells, and incubated fo r 20min at room temperature. The plates were 
washed as before. Appropriate substrates were added, and the absorbance measured using 
the Titertek plate reader.
2.8.3 Colorimetric assay for biotin.
The colorimetric assay was carried out using a modification o f the method described by 
McCormick and Roth (1970). Standards were prepared by dissolving biotin hydrazide or 
biotin-LC-hydrazide in 0.03M phosphate buffer, pH 7.3. Appropriate aliquots were taken, 
dried under nitrogen, and reconstituted with 1ml o f 2% (v/v) H2S04 in ethanol. IBHR- 
labelled biotin (lOOpl) was dried under nitrogen and reconstituted w ith 1ml o f 2% (v/v) 
H2S04 in ethanol. To the standards and samples was added 1ml o f 0.2% (w/v) p- 
dimethylaminocinnamaldehyde in ethanol. The tubes were mixed, and the absorbance was 
measured at 533nm after lh r.
2.8.4 Immunoassay for the measurement of human IgG using IBHR-labelled biotin 
or biotinylated HRP.
The immunoassay was carried out as outlined in Section 2.7.3, except that after incubation 
with biotinylated anti-human IgG antibodies, the plates were washed, and lOOpl o f avidin 
(diluted in blocking solution) was added. A fter incubation fo r 20min at room temperature, 
the plates were washed as before. IBHR-labelled biotin or biotinylated HRP, diluted in 
blocking solution, (lOOpl) was added, and incubated fo r 20min at room temperature. A fter
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washing, appropriate substrates were added, and the absorbance measured using the 
Titertek plate reader.
2.8.5 Immunoassay for determination of optimum dilution of avidin.
M icrotitre plates were coated, washed and blocked, and human IgG standards and 
biotinylated anti-human IgG antibodies were added, as described in  Section 2.7.3. A  range 
o f dilutions o f avidin, diluted in blocking solution, (lOOpl) were added to the appropriate 
wells, and incubated fo r 20min at room temperature. A fter washing, biotinylated HRP, 
diluted in blocking solution, (lOOpl) was added, and incubated fo r 20min at room 
temperature. The plates were washed, appropriate substrates were added, and the 
absorbance measured using the T itertek plate reader.
2.9 Preparation and use of bispeciftc Ffab’^ antibodies.
2.9.1 Preparation of bispecific F(ab’)2 antibodies.
A ffin ity-purified  antibodies were used fo r the production o f bispecific antibodies. The 
preparation was carried out using a modification of the method of Glennie et al. (1987). 
Goat anti-human IgG antibodies and rabbit anti-BSA antibodies were subjected to pepsin 
degradation to yie ld F(ab’)2 fragments. Antibodies (5mg/ml in 0.1M sodium acetate, pH 
4.2) were incubated at 37°C fo r 18hr w ith O.lmg/ml pepsin. The samples were dialysed 
at 4°C fo r 24hr, against 0.2M Tris-HC l, pH 8.0, containing lOmM EDTA. Fab’^  
fragments were produced by reduction o f the F(ab’)2 fragments w ith 2-mercaptoethanol 
(2ME) at 30°C fo r 30min. The Fab’SH fragments were cooled to 4°C. This temperature 
was maintained throughout the remainder of the preparation procedure. They were passed 
through a Sephadex G-25 column equilibrated w ith 50mM sodium acetate, pH 5.3, 
containing 0.5mM EDTA. A  ha lf volume o f 12mM o-phenylenedimaleimide, dissolved 
in chilled DMF, was added to the rabbit Fab’SH component and incubated for 30min. The 
maleimidated Fab’ (Fab’^ ^  were passed through a Sephadex G-25 column equilibrated 
with 50mM sodium acetate, pH 5.3, containing 0.5mM EDTA. The Fab’ were mixed, and 
incubated fo r 18hr. A fte r incubation, the pH was adjusted to 8.0 using 1M Tris-HCl, pH 
8.0, and the solution treated fo r 30min at 30°C w ith 20mM 2ME and 25mM iodoacetamide 
to remove unwanted products. Excess reagents were removed by dialysis at 4°C for 24hr 
against 0.1M PBS, pH 7.3, and the bispecific F(ab’)2 was purified by a ffin ity
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chromatography.
2.9.2 Immunoassay for the detection of goat and rabbit Fab’ fragments of the 
bispeciflc F(ab’)2 antibodies.
M icrotitre plates were coated w ith lOOpl o f human IgG or BSA (lOpg/m l) diluted in 
0.03M phosphate buffer, pH 7.3, fo r 2hr at 37°C. The plates were washed and blocked 
as described in Section 2.6.1. D ilutions o f bispecific F(ab’)2, anti-human IgG antibodies 
and anti-BSA antibodies were prepared in 0.03M phospate buffer, pH 7.3, and lOOpl o f 
each were added to the appropriate wells. The plates were incubated fo r 1 hr at 37°C, and 
washed as before. HRP-labelled anti-rabbit IgG antibodies or anti-goat IgG antibodies 
(lOOpl) were added to the appropriate wells, and incubated fo r 30min at 37°C. The plates 
were washed as before, substrates were added, and the absorbance measured using the 
Titertek plate reader.
2.9.3 Immunoassay for the measurement of human IgG using bispecific F(ab’)j 
antibodies.
M icrotitre plates were coated, blocked, and washed as described in Section 2.6.1. Human 
IgG standards (range 0 - 2pg/m l) were prepared in blocking solution; lOOpl was added to 
the appropriate wells and incubated fo r lh r at 37°C. The plates were washed as before. 
Bispecific F(ab’)2 antibodies diluted in blocking solution were added to the wells (lOOpl) 
and incubated for lh r at 37°C. The plates were washed as before. Iodinated BSA or 
HRP-labelled BSA (lOOpl) were added to the appropriate wells, and incubated fo r 30min 
at 37°C. The plates were washed as before, substrates added, and the absorbance measured 
using the Titertek plate reader.
2.9.4 Preparation of BSA, iodinated by the IBHR and chloramine T  iodination 
methods.
IBHR-labelled BSA was prepared as oudined in Section 2.4. To 1ml o f IBHR-labelled 
BSA (3mg/ml) was added 0.25m l o f sodium iodide (15mM in 0.05M phosphate buffer, pH 
7.5) and 0.1ml o f chloramine T  (2mg/m l in 0.05M phosphate buffer, pH 7.5). A fter lm in  
at room temperature the reaction was stopped by the addition o f 0.35ml o f sodium 
metabisulphite (2mg/ml in 0.05M  phosphate buffer, pH 7.5). Excess reagents were
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removed by dialysis at 4°C for 24hr against 0.03M phosphate buffer, pH 7.3.
2.10 Immunoassay for the measurement of thyroxine.
M icrotitre plates were coated w ith lOOpl o f anti-thyroxine (T4) antibodies (10pg/ml) diluted 
in 0.03M phosphate buffer, pH 7.3, fo r 2hr at 37°C. They were washed and blocked as 
outlined in Section 2.6.1. A  50pM stock solution was prepared by dissolving T4 in 0.1M  
NaOH; standards (0 - 300nM) were prepared from this by dilution in 0.03M phosphate 
buffer, pH 7.3. Standards (lOOpl) were added to the appropriate wells and incubated for 
lh r at 37°C. The plates were washed as before. Appropriate substrates were added, and 
the absorbance measured using the Titertek plate reader.
2.11 Protein assays.
2.11.1 BioRad assay.
Standards, in the range 0 - 25pg/ml, were prepared. To 0.8ml o f standards or samples was 
added 0.2ml o f BioRad dye reagent concentrate. The tubes were mixed gently, and the 
absorbance measured at 595nm after a period from 5 min to lh r.
2.11.2 Bicinchoninic acid (BCA) assay.
The reagents fo r this assay were purchased in k it form, and consisted o f two reagents: 
Reagent A : sodium carbonate, sodium bicarbonate, BCA detection reagent and sodium 
tartrate in 0.2M sodium hydroxide.
Reagent B: 4% (w /v) copper sulphate solution.
The working reagent was prepared by combining 50 parts reagent A  with 1 part reagent 
B. Standards, in the range 0 - lm g/m l, were prepared. Standards or samples (lOpl) were 
added to the wells o f a m icrotitre plate, and 200pl o f working reagent was added. The 
plate was incubated at 37°C fo r 30min, and the absorbance measured at 560nm.
2.12 Antibody purification.
2.12.1 Ammonium sulphate precipitation.
Serum was cooled to 4°C, and an equal volume o f saturated ammonium sulphate was 
added drop wise. The solution was incubated fo r lh r at 4°C w ith gentle stirring, and then 
centrifuged at 400g fo r 30min. The precipitated antibody was washed w ith 50% (v/v)
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ammonium sulphate, and centrifuged as before. The pellet was resuspended in a minimum 
volume o f 0.1M PBS, pH 7.3, and dialysed at 4°C fo r 24hr against 0.1M PBS, pH 7.3.
2.12.2 Affinity chromatography.
(i) Preparation o f a ffin ity  columns.
CNBr-activated Sepharose (0.4g) was suspended in 3ml o f 0.001M HC1, and transferred 
to a sintered glass funnel, where it was washed over 15min w ith 80ml o f 0.001M HC1, 
followed by 2ml o f coupling buffer (0.1M NaHC03 containing 0.5M NaCl, pH 8.3). 
Antigen (6mg in 2.8ml o f coupling buffer) was added to the washed gel and mixed in a 
shaking waterbath fo r 3hr at room temperature. The gel was returned to the funnel and 
washed w ith 5ml o f coupling buffer. The gel was transferred to a flask containing 3ml 
o f blocking buffer (0.2M glycine in coupling buffer, pH 8.3) and incubated fo r lh r at room 
temperature. To remove non-covalently bound protein, the gel was washed with 3 cycles 
o f alternating pH, each cycle consisting o f 5ml each o f 0.1 M  sodium acetate containing 
0.5M NaCl, pH 4.5, and 0.1M Tris-HC l containing 0.5M NaCl, pH 8.5. The gel was 
suspended in 0.1 M  PBS, pH 7.3, and used to pour a 1ml column.
(ii) A ffin ity  purification.
The column was washed w ith 0.1M PBS, pH 7.3, to remove any protein that may have 
leaked from the gel during storage. The ammonium sulphate-purified antibody sample was 
applied slow ly to the column, followed by washing with 0.1M PBS, pH 7.3. Fractions 
( lm l) were collected, and the presence o f protein was detected by measurement o f the 
absorbance at 280nm. When no more protein could be detected, dissociating buffer (0.1M  
glycine/HCl, pH 2.5) was added, the column was clamped o ff and le ft fo r 5min before 
elution o f the specific antibody. To lm l o f antibody-containing fractions was added lOOjil 
o f 1M Tris, pH 10.5; these fractions were pooled and dialysed at 4°C for 24hr against 
0.1M PBS, pH 7.3.
The column was regenerated by washing w ith 5ml each o f 0.1M Tris-HC l containing 0.5M 
NaCl, pH 8.5; 0.1M sodium acetate containing 0.5M NaCl, pH 4.5; and PBS. The column 
was stored at 4°C in 0.1M PBS, pH 7.3, containing 0.02% (w /v) sodium azide.
2.13 SDS-polyacrylamide gel electrophoresis.
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was earned out using a modification
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o f the procedure described by Laemmli (1970). Proteins were separated on a resolving gel 
containing 10% (w/v) acrylamide, 0.26% (w /v) bisaciylamide, 0.1% (w/v) SDS, 0.03% 
(w /v) ammonium persulphate, 0.1% (v/v) TEMED and 0.375M Tris-HCl, pH 8.8. A  
stacking gel containing 3% (w /v) acrylamide, 0.08% (w/v) bisacrylamide, 0.1% (w /v) SDS, 
0.075% (w/v) ammonium persulphate, 0.1% (v/v) TEMED and 0.125M Tris-HCl, pH 6.8, 
was used. Protein samples (lm g /m l) were diluted 1:1 in solubilisation buffer consisting 
o f 2% (w /v) SDS, 10% (w /v) glycerol, 0.05% (w /v) bromophenol blue and 0.08M Tris, 
pH 6.8, and were incubated fo r 2min at 100°C. The samples (20pl) were applied to the 
gel. The gels were run at 18mA/gel in electrode buffer containing 0.1% (w /v) SDS, 
0.192M glycine and 0.025M Tris, pH 8.3. Proteins were visualised by staining the gels 
fo r 15min in 0.5% (w /v) Coomassie brillian t blue in acetic acid:water:methanol (1:10:8 
v/v/v), and destaining in  the same solvent system.
2.14 Extraction procedure for the measurement of iodine.
The iodine-containing compound was dissolved in  200pl DMF. One m illilitre  o f eerie 
ammonium sulphate (0.02M in  6M  H2S04) was added, and the solution mixed thoroughly 
fo r 10min. The liberated iodine was extracted into 3x lm l volumes o f toluene. The 
aqueous and organic layers were separated by centrifugation for 5min at 400g, and the 
toluene layer was removed; the toluene extracts were combined and the volume made up 
to 3ml. The absorbance was read at 497nm.
2.15 Real-time biospecific interaction analysis (BIAcore).
Analyses on the BIAcore were carried out by M r. Gary Keating, Biology Department,
D.C.U.
2.15.1 Procedure for studying the relative binding pattern of iodinated antibodies.
The carboxymethylated dextran surface o f the sensor chip was activated by derivatisation 
with a 1:1 mixture o f N-hydroxysuccinim ide (NHS)-coupling solution and N-ethyl-N ’- 
(dimethylamino-propyl)carbodiim ide (EDC)-coupling solution (35pl at a flow  rate o f 
5pl/m in) forming reactive NHS-ester groups. Human IgG (200pg/ml in lOmM sodium 
acetate, pH 5.5) was immobilised onto the chip (35pl at 5pl/m in). Any remaining NHS- 
ester groups on the chip were deactivated w ith 1M ethanolamine, pH 8.5 (35pl at 5pl/m in). 
Anti-human IgG antibodies, labelled w ith various amounts o f IBHR, (100pg/ml in 0.03M
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phosphate buffer, pH 7.3) were passed over the chip (50pl at 2pl/m in). The human IgG 
surface on the chip was regenerated between runs with 6pl pulses o f lOmM HC1.
2.15.2 Procedure for studying the binding of iodinated avidin to biotinylated 
antibodies.
The dextran surface was activated as in Section 2.15.1. Protein A (lOOpg/ml in lOmM  
sodium acetate, pH 4.0) was immobilised onto the chip (40pl at 2pl/m in). Any remaining 
NHS-ester groups were deactivated as in Section 2.15.1. Biotinylated anti-human IgG  
antibodies (0.25mg/ml in PBS) were passed over the chip (20pl at lOpl/m in), followed by 
avidin or IBHR-labelled avidin (lOOpg/ml in 0.03M phosphate buffer, pH 7.3). The 
protein A  surface was regenerated between runs w ith 6pl pulses o f 50mM HC1.
2.15.3 Procedure for studying the binding of iodinated BSA to anti-BSA antibodies.
The dextran surface was activated as in Section 2.15.1. Anti-BSA antibodies (lOOpg/ml 
in lOmM sodium acetate, pH 5.0) were immobilised onto the sensor chip (40pl at 2pl/m in). 
Any remaining NHS-ester groups were deactivated as in Section 2.15.1. BSA samples 
(lOOpg/ml in 0.03M phosphate buffer, pH 7.3) were passed over the chip (20pl at 5pl/m in). 
The antibody surface was regenerated between runs with 6pl pulses o f 20mM HC1.
2.15.4 Procedure for studying the binding of anti-T4 antibodies to T4.
The dextran surface was activated as in Section 2.15.1. T4 (500pg/ml in ethanoklOmM  
sodium acetate, pH 5.0 ( l: l,v /v ) )  was immobilised onto the sensor chip (50pl at lOpl/min). 
Any remaining NHS-ester groups were deactivated as in Section 2.15.1. Anti-T4  
antibodies (lOOpg/ml in 0.03M phosphate buffer, pH 7.3) were passed over the chip (25pl 
at 5pl/m in). The T4 surface was regenerated between runs w ith 6pl pulses o f 20mM HC1.
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3. DETERMINATION OF IODINE USING THE CERIUM(IV) - ANTIMONY (HD 
REACTION.
3.1 Introduction.
Bognar and Sarosi (1965) determined iodine concentrations by measuring its catalytic 
action on the reaction between cerium (IV ) and antimony (HI):
2Ce* + Sb* — 2Ce^ + Sb5*
(yellow) (colourless)
The reaction conditions were as follows: to 0.01ml o f potassium iodide solution was added 
lm l o f 0.05M antimony potassium tartrate in 1% (w /v) tartaric acid, 1ml o f 7M HjSO^ 
and lm l o f 0.001M ferroin. The volume was adjusted to 4ml w ith H20 , and the reaction 
was started by the addition o f lm l o f 0.01M eerie ammonium sulphate in 0.5M HjSO^ 
The time, t, fo r formation o f a red colour due to the reduction o f the ferroin indicator, was 
recorded, and a graph o f 1/t plotted against iodide concentration was prepared The 
reaction was used to measure iodide concentrations o f lng/m l.
This chapter describes major modifications to the assay conditions reported by Bognar and 
Sarosi (1965). The assay was adapted for use in a microassay format, and was monitored 
spectrophotometrically by measuring the absorbance o f the yellow cerium(TV) solution. 
The microassay was optimised w ith respect to reagent concentration and temperature, and 
was evaluated as an alternative to the Sandell-Kolthoff microassay (O ’Kennedy et al., 
1989). Several compounds have been reported to interfere in  the Sandell-Kolthoff reaction 
(Sandell and K o ltho ff, 1937), and the effect o f three compounds (chloride, bromide and 
azide) on the cerium (IV ) - antimonyfTQ) microassay was studied.
The Sandell-Kolthoff reaction is catalysed by iodide and by iodine-containing organic 
compounds; the catalytic activity o f iodide is greater than that o f iodine in iodo-compounds 
(Bowden et al., 1955). The catalytic activity o f some iodo-compounds was determined in  
the cerium(IV) - antimony(UI) microassay, and compared to the catalytic activity in the 
Sandell-Kolthoff reaction.
The use o f fluorim etric monitoring o f the cerium(IV) - antimony(IH) microassay, by 
fluorimetric detection o f cerium (III) or cerium(IV), was investigated. The measurement 
o f the fluorescence o f cerium(HI) produced by the reduction o f cerium(TV) with 
arsenic(III) was firs t reported by K irkbright et al. (1966), while the measurement o f the
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fluorescence produced by the oxidation o f 8-hydroxyquinoline-5-sulphonic acid with 
cerium(IV) was reported by Pal et al. (1977). The reaction conditions for the fluorimetric 
microassays were optimised, and the methods were evaluated as alternatives to 
spectrophotometric detection o f the cerium (IV) - antimony(III) microassay.
3.2 Results and discussion.
3.2.1 Optimisation of reaction variables for the spectrophotometric microassay.
The cerium (IV ) - antimony (III) microassay was optimised w ith respect to concentration 
o f eerie ammonium sulphate, H2S04 and antimony potassium tartrate, and incubation 
temperature. The assay was optim ised fo r the measurement o f potassium iodide standards, 
in  the range 2 to lOng/ml, by altering each reaction variable in  turn, while keeping the 
others constant. The optimum conditions chosen were those that yielded good linearity 
(correlation coefficient, r) and a large difference in absorbance values over the range o f 
standards tested (slope) fo r graphs o f absorbance plotted against potassium iodide 
concentration. The results shown are the mean o f at least four determinations. Error bars 
have not been plotted in the graphs as this was beyond the capacity o f the computer 
system available; standard deviation values have been included in the text.
The microassay was monitored by measuring the absorbance o f eerie ammonium sulphate; 
its absorbance spectrum in  6M  H2S04 is illustrated in Fig 3.1. The absorbance maximum 
fo r cerium(TV) is 320nm; the molar absorptivity at this wavelength is 5.6 x 103, while it  
is only one-sixth o f this at 400nm (Marczenko, 1976). The Sandell-Kolthoff microassay 
was monitored at 414nm (O ’Kennedy et al., 1989), as filters fo r this wavelength are 
widely available on microplate readers since it is used to monitor ELISA. O ’Kennedy and 
Keating (1993) reported the use o f 340nm to monitor the Sandell-Kolthoff microassay. 
Potassium iodide levels o f lng /m l could be detected using 3.5 x 10'3M  eerie ammonium 
sulphate in 10% (vAO H2S04, and an incubation period o f 30min. However, monitoring 
at 340nm may produce absorbance readings that are not reliable, as many plate readers 
lack a proper filte r fo r this wavelength, or there may be background absorbance due to the 
plate material. It was decided, therefore, to monitor the absorbance o f cerium(IV) for the 
cerium(IV) - antimony(III) microassay at 380nm.
The effect o f increasing the eerie ammonium sulphate concentration from 0.008M to 
0.03M were studied in the microassay (Fig 3.2). As the cerium (IV) concentration was
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increased, there was an increase in the slope from a value o f 0.021 (±0.002) using 0.008M 
cerium(IV) to 0.059(±0.005) using 0.03M cerium(IV). The correlation coefficient obtained 
using 0.02M cerium (IV) (r=0.994) was better than those obtained using 0.025M or 0.03M 
cerium(IV) (r=0.988 and 0.989, respectively). A  eerie ammonium sulphate concentration 
o f 0.02M was chosen as the optimum concentration.
The sulphuric acid concentration was varied from 4M  to 8M, as shown in Fig 3.3. The 
slope o f the calibration graph increased slightly from a value o f 0.043(±0.006) using 4M  
to a value o f 0.045(±0.002) using 6M  HjSO,,, and then decreased slightly fo r higher 
concentrations o f H2S04. A ll concentrations o f H2S04 tested gave correlation coefficients 
o f 0.99. A concentration o f 6M  H2S04 was chosen as the optimum. The reaction was also 
studied in two other acids: HC104 and HN 03. Solutions o f cerium(IV) in HC104 and 
HNOj are much stronger oxidising agents than in H2S04 (Ko lthoff et al., 1969). Fukasawa 
et al. (1973) reported that the sensitivity o f the Sandell-Kolthoff reaction was better in 
HC104 - HC1 medium than in  H 2S04. A  twenty-fold increase in the catalytic activity o f 
iodine measured in the Sandell-Kolthoff reaction was reported by Knapp and Leopold 
(1974) when H N 03 was used instead o f H2S04, and O ’Kennedy et al. (1989) reported a 
ten-fold improvement in the sensitivity o f the Sandell-Kolthoff microassay using 10% (v/v) 
H N 03 instead o f H2S04. The use o f HC104 and H N 03 in the cerium(IV) - antimony(HI) 
microassay resulted in  a very rapid reaction and did not lead to any improvement in 
sensitivity. Mishra and Gupta (1968) studied the chloride catalysed cerium (IV) - 
antimony(III) reaction and reported that on addition o f HC104 the rate increased, due to 
the increase in hydrogen ion concentration. On addition o f H2S04, the rate decreased as 
the increase in hydrogen ion concentration led to a corresponding increase in the 
concentration o f sulphate ion, which decreases the rate in cerium(IV) oxidations.
The concentration o f antimony potassium tartrate was varied from 0.02M to 0.05M (Fig 
3.4). For the antim ony(III) concentrations tested, the slope o f the calibration graph 
decreased w ith increasing concentration, from a value o f 0.054(±0.007) using 0.02M  
antimony(III) to a value o f 0.046(±0.002) using 0.05M antimony (III). The correlation 
coefficient obtained using 0.02M antimony(III) was 0.983, for all other antimony(IH) 
concentrations tested the correlation coefficient was 0.99. An antimony(III) concentration 
o f 0.03M was chosen as the optimum.
The microassay was studied at incubation temperatures o f room temperature (20°C), 25°C,
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30°C and 37°C (Fig 3.5). The slope o f the calibration graph increased w ith increasing 
temperature. A  value o f 0.051(±0.004) was obtained for the slope at 20°C, while a value 
o f 0.068(±0.005) was obtained at 37°C. However, a correlation coefficient o f 0.995 was 
obtained at 20°C, compared w ith 0.988 at 37°C. Incubation at 20°C was chosen as the 
optimum. The sensitivity o f the Sandell-Kolthoff reaction is reported to increase as the 
temperature is increased (Knapp and Leopold, 1974), but this was not observed under the 
conditions used here for the cerium (IV ) - antimony(III) microassay.
Potassium iodide standards were measured in the optimised microassay and a graph o f 
absorbance plotted against concentration was prepared (Fig 3.6). The assay shows 
excellent linearity (r=0.995) fo r potassium iodide standards in the range 2 to lOng/ml. The 
intra-assay accuracy and precision (Table 3.1) and inter-assay accuracy and precision 
(Table 3.2) were calculated fo r the standards. The accuracy o f the assay is determined by 
the closeness o f the mean o f the analytical result to the true value; the mean value should 
fa ll w ithin 90 to 110% o f the true value. The intra- and inter-assay mean values fo r the 
potassium iodide standards were w ith in  96 to 107% o f the true values. The precision o f 
the assay is determined by the percentage coefficient o f variation (%CV), which should 
be less than 10%. The intra- and inter-assay %CV values fo r the potassium iodide 
standards were less than 10%. The detection o f potassium iodide levels o f 2ng/ml in the 
cerium(IV) - antim ony(III) microassay compares well w ith the levels detected in the 
Sandell-Kolthoff microassay. O ’Kennedy et al. (1989) detected 0.01 to 0.1pg/ml K I using 
0.075M arsenious acid, 0.028M eerie ammonium sulphate diluted in 10% (v/v) HjSO,, and 
an incubation period o f 5min. Potassium iodide levels o f lng /m l could be detected using 
0.014M eerie ammonium sulphate diluted in 10% (v/v) H N 03, and an incubation period 
o f 15 min. O ’Kennedy and Keating (1993) detected lng /m l potassium iodide by 
monitoring the absorbance at 340nm.
The optimised microassay was used fo r the measurement o f IBHR standards. A graph o f 
absorbance plotted against concentration fo r IBHR standards is shown in Fig 3.7. The 
linear range is 0.02 to O .lpg/m l (r=0.991). Intra-assay accuracy and precision results are 
shown in Table 3.3; inter-assay accuracy and precision results are shown in Table 3.4. 
The intra- and inter-assay mean values fo r the standards were w ithin 95 to 110% o f the 
true value, and the %CV values were less than 10%, with the exception o f the intra-assay 
%CV for 0.02jig/m l which was 10.1%.
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F igure 3.1 Absorbance spectrum o f eerie ammonium sulphate in  6M  H2S04.
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Figure 3.2 E ffect o f cerium (IV ) concentration on the slope and correlation coefficient (r) 
o f the graph o f absorbance plotted against concentration fo r potassium iodide standards 
assayed in  the cerium (IV) - antimony(IH) spectrophotometric microassay.
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Figure 3.3 Effect o f sulphuric acid concentration on the slope and correlation coefficient 
(r) o f the graph o f absorbance plotted against concentration fo r potassium iodide standards 
assayed in  the cerium (IV) - antim ony(III) spectrophotometric microassay.
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Figure 3.4 Effect o f antim ony(III) concentration on the slope and correlation coefficient 
(r) o f the graph o f absorbance plotted against concentration fo r potassium iodide standards 
assayed in the cerium (IV ) - antim ony(III) spectrophotometric microassay.
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Figure 3.5 E ffect o f temperature on the slope and correlation coefficient (r) o f the graph 
o f absorbance plotted against concentration fo r potassium iodide standards assayed in  the 
cerium (IV) - anümony(III) spectrophotometric microassay.
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Figure 3.6 Graph o f absorbance at 380nm plotted against concentration o f potassium 
iodide standards (0 to 10ng/ml) assayed in the optimised cerium(IV) - antimony(III) 
spectrophotometric microassay.
The insert displays the graph o f absorbance at 380nm plotted against concentration of 
potassium iodide standards in the range 20 to 100ng/ml.
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K I conc. (ng/m l) Mean ± SD %CV
2 1.95 ± 0.19 9.9
4 4.03 ± 0.31 7.8
6 5.88 ± 0.55 9.4
8 8.59 ± 0.62 7.2
10 9.57 ± 0.88 9.2
Table 3.1 Intra-assay accuracy and precision results fo r potassium iodide standards 
assayed in the cerium (IV) - antimony(III) spectrophotometric microassay (n=8).
K I conc. (ng/m l) Mean ± SD %CV
2 2.08 ± 0.15 7.3
4 4.18 ± 0.37 8.9
6 6.05 ± 0.45 7.4
8 7.87 ± 0.34 4.3
10 9.89 ± 0.27 2.7
Table 3.2 Inter-assay accuracy and precision results fo r potassium iodide standards 
assayed in the cerium (IV) - antimony(III) spectrophotometric microassay (n=7).
o00
CO
w
<
I B H R  conc. (ug/ml)
Figure 3.7 Graph o f absorbance at 380nm plotted against concentration o f IBHR standards 
assayed in the optimised cerium (IV) - antimony(III) spectrophotometric microassay.
The insert displays the graph o f absorbance at 380nm plotted against concentration o f 
IBHR standards in the range 0.2 to lug/m l.
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IBHR conc. (]ug/ml) Mean ± SD % c v
0.02 0.022 ± 0.002 10.1
0.04 0.044 ± 0.003 6.9
0.06 0.062 ± 0.003 5.4
0.08 0.081 ± 0.004 4.8
0.1 0.095 ± 0.004 3.8
Table 3.3 Intra-assay accuracy and precision results fo r IBHR standards assayed in the 
cerium (IV) - antim ony(III) spectrophotometric microassay (n=8).
IBHR conc. (jig/ml) Mean ± SD % c v
0.02 0.021 ± 0.002 9.9
0.04 0.044 ± 0.003 7.1
0.06 0.061 ± 0.004 6.1
0.08 0.078 + 0.004 4.5
0.1 0.099 ± 0.004 4.0
Table 3.4 Inter-assay accuracy and precision results fo r IBHR standards assayed in the 
cerium (IV) - antim ony(III) spectrophotometric microassay (n=8).
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3.2.2 In terferent species.
The effect o f chloride, bromide and azide in the cerium(IV) - antimony(in) and Sandell- 
K o ltho ff microassays was studied; the results are shown in Tables 3.5 and 3.6. The 
interferent species were measured in the microassays, and the absorbance o f wells to which 
the interferent species was added was compared to the absorbance o f control wells.
The addition o f chloride led to only a slight enhancement o f the Sandell-Kolthoff 
microassay. A chloride concentration o f 2mg/ml resulted in absorbance values that were 
94% o f the control, in the absence o f iodide, and 92% o f the control in the presence o f 
lOng/ml iodide. Small amounts o f chloride are reported to enhance the Sandell-Kolthoff 
reaction, and the addition o f NaCl can be used to obtain linear calibration graphs (Sandell 
and Kolthoff, 1937). The addition o f chloride led to a much greater enhancement o f the 
reaction in the cerium (IV) - antim ony(III) microassay. The absorbance values on addition 
o f 2mg/ml chloride were just 42% o f the control, in the absence o f iodide, and 51% o f the 
control, in the presence o f lOng/ml iodide. Chloride acts as a catalyst fo r the cerium(IV) - 
antimony(III) reaction, although M ishra and Gupta (1968) reported that the catalytic action 
o f iodide in the reaction was greater than chloride. They obtained a rate constant o f 10 
in the presence o f 248pg/ml chloride, and a rate constant o f 12 in the presence o f only 
0.127pg/ml iodide. Bognar and Sarosi (1965) reported that, in the absence o f iodide, the 
addition o f 20pg/ml chloride enhanced the cerium(IV) - antimony(III) reaction, while in 
the presence o f O.lpg/m l iodide the addition o f 200)ig/ml chloride had no effect on the rate 
o f the reaction. The addition o f 0 .1M PBS, which contains 0.14M NaCl and 0.003M KC1, 
'•'was found to interfere in the cerium (IV) - antimony(III) microassay. In the absence o f 
iodide, the addition o f PBS gave absorbance values that were only 19% o f the control, and 
values that were 24% o f the control in the presence o f lOng/ml iodide. PBS is widely 
used as a diluent fo r proteins, and as a buffer in the washing steps o f immunoassays, but 
its use to dilute iodinated proteins to be assayed in the cerium(TV) - antimony(III) 
microassay or as a washing buffer fo r an immunoassay using iodinated antibodies would 
lead to inaccurate results. I t was, therefore, decided to use 0.03M phosphate buffer, pH 
7.3, as an alternative to PBS. On addition o f higher molar phosphate buffers (0.04M, 
0.05M, 0.1M tested) to the microassay the cerium(IV) solution became cloudy.
Bromide is reported to enhance the Sandell-Kolthoff reaction to a greater extent than 
chloride (Sandell and K o ltho ff, 1937). In the Sandell-Kolthoff microassay, lOpg/ml
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bromide caused greater enhancement o f the reaction, giving an absorbance value 73% o f 
the control, in  the absence o f iodide, than 2mg/ml chloride, which gave an absorbance 
value 94% o f the control. This was also observed fo r the cerium(IV) - antimony(III) 
microassay, but to a smaller extent. In the absence o f iodide, the addition o f lOpg/ml 
bromide gave an absorbance value 39% o f the control, while the addition o f 2mg/ml 
chloride gave an absorbance value 42% o f the control. M ishra and Gupta (1968) reported 
a rate constant o f 12 fo r the cerium (IV) - antimony(III) reaction in the presence o f 32pg/ml 
bromide, and a rate constant o f 10 in  the presence o f 248pg/ml chloride. In the presence 
o f iodide, the microassay was enhanced to a smaller extent by bromide; lOpg/ml bromide 
gave an absorbance value only 39% o f the control, in the absence o f iodide, but an 
absorbance 70% o f the control in the presence o f lOng/ml iodide. A  sim ilar trend was 
observed by Bognar and Sarosi (1965), who reported enhancement o f the cerium(IV) - 
antim ony(III) reaction by lOpg/ml bromide, in the absence o f iodide, while in the presence 
o f O .lpg/m l iodide the addition o f 0.2pg/ml bromide inhibited the reaction.
The interference o f azide in  the Sandell-Kolthoff microassay was reported by O’Kennedy 
et al. (1989). Azide, a reducing agent, caused decolouration o f eerie ammonium sulphate, 
independent o f the presence o f iodine or arsenic(III). They reported a 35% decrease in the 
absorbance o f eerie ammonium sulphate at 414nm in the presence o f 0.02% (w/v) azide, 
and a 95% decrease in  the absorbance in the presence o f 0.2% (w/v) azide. When tested 
here in the Sandell-Kolthoff microassay, 0.02% (w /v) azide gave an absorbance value that 
was 16% o f the control, in the absence o f iodide, and a 7% o f the control in  the presence 
o f lOng/ml iodide; 0.2% (w /v) azide gave absorbance values 4% o f the control in both the 
absence and presence o f iodide. The observations fo r the cerium (IV) - antimony(III) 
microassay were sim ilar; 0.02% (w /v) azide gave an absorbance value 19% o f the control, 
in the absence o f iodide, and 23% o f the control, in the presence o f iodide; 0.2% (w/v) 
azide gave an absorbance value 4% o f the control, in the absence o f iodide, and 3% o f the 
control, in the presence o f iodide. Samples stored in buffer containing 0.02% (w/v) 
sodium azide, which is w idely used as a preservative fo r protein solutions, cannot be 
assayed in the microassay w ithout taking this interference into account.
Other ions that have been reported to interfere in the cerium (IV) - antimony(HI) reaction 
include vanadium, tungtsen, selenium, tellurium , osmium, manganese, silver, mercury and 
fluoride (Bognar and Sarosi, 1965). In addition, Zak (1978) reported interference in the
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Sandell-Kolthoff reaction by cyanide, thiocyanate and citrate. Oxidising or reducing agents 
(fo r example, bromate, n itrite or ferrous ion) that react w ith antimony (III) or cerium(IV) 
w ill also cause interference.
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Interferent species Abs (380nm) expressed as a% of the control wells
No iodide lOng/ml iodide
20pg/ml chloride 66 70
2mg/ml chloride 42 51
PBS 19 24
lOpg/ml bromide 39 70
1 mg/ml bromide 4 11
0.02% (w /v) azide 19 23
0.2% (w/v) azide 4 3
Table 3.5 E ffect o f three interferent species in the cerium (IV ) - antimony (III) 
spectrophotometric microassay.
Interferent species Abs (414nm) expressed as a % of the control wells
No iodide lOng/ml iodide
20pg/ml chloride 92 86
2mg/ml chloride 94 92
PBS 93 93
lOpg/ml bromide 73 81
1 mg/m l bromide 78 80
0.02% (w /v) azide 16 7
0.2% (w /v) azide 4 4
Table 3.6 E ffect o f three interferent species in the Sandell-Kolthoff microassay.
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3.2.3 Catalytic activity of iodine in iodine-containing organic compounds.
It has been reported that the catalytic activity o f iodine in organic compounds is inferior 
to that o f inorganic iodide (Bowden et al., 1955; Pantel and Weisz, 1977). In order to 
compare the catalytic activity o f iodo-compounds to that o f iodide, Pantel (1982) 
introduced a "relative molar coefficient o f catalytic activ ity", F:
where Q  is the molar concentration o f iodide and C0 is the molar concentration o f organic 
compound that have exactly the same catalytic activity. Coefficient F is suitable fo r iodo- 
compounds containing one iodine atom, but fo r compounds containing more than one 
iodine Timotheou-Potamia (1988) introduced coefficient K , the "catalytic activity per 
iodine atom o f the compound". Coefficient K  is calculated as follows:
A > 1 0 0 - ^ -
mC0
Where Ct and C0 are defined as fo r coefficient F, and m is the number o f iodine atoms per 
mole o f organic compound.
Several iodine-containing organic compounds were assayed in the cerium(IV) - 
antim ony(III) microassay along w ith  potassium iodide. The catalytic activity was directly 
compared to that o f potassium iodide in  order to calculate the K  values. The K  values 
obtained are reported in Table 3.7; also reported are the number o f moles o f organic 
compound that are required to give the same catalytic activity as one mole o f iodide. The 
structures o f some iodine-containing compounds are illustrated in F ig 3.8 and 3.9.
The K  value for IBHR was calculated as 33.7%, while fo r di-IBHR K  was calculated as 
25.5%. O ’Kennedy et al. (1989) reported a K  value o f 33.1% fo r IBHR assayed in the 
Sandell-Kolthoff microassay, which is sim ilar to the value obtained in the cerium(IY) - 
antim ony(III) microassay.
The K  values calculated fo r T3 and T4 were 37.0% and 47.0%, respectively. Higher K  
values have been reported fo r these compounds assayed using the Sandell-Kolthoff 
reaction. Values o f 42% and 57% were obtained fo r T3 and T4, respectively, by 
Timotheou-Potamia (1988), and a value o f 62% was obtained fo r T4 by O ’Kennedy et al.
78
The K  values obtained fo r the iodophenol compounds were 13.0% fo r 2-iodophenol, 1.3% 
fo r 3-iodophenol and 50.0% fo r 4-iodophenol. Pantel (1982) reported F values o f 0.09 for 
2-iodophenol, 0.0015 fo r 3-iodophenol and 0.42 fo r 4-iodophenol in the Sandell-Kolthoff 
reaction using a potentiometric stat-method (an F value o f 1 is equivalent to a K  value o f 
100 fo r iodo-compounds containing one iodine atom). The K  values obtained in  the 
cerium (IV) - antimony(III) microassay were slightly higher than those obtained by Pantel 
(1982), but the same pattern o f catalytic activity was observed, i.e. 4-iodophenol > 2- 
iodophenol > 3-iodophenol. O’Kennedy et al. (1989) reported a K  value o f 40.0% fo r 4- 
iodophenol.
N-succinim idyl (4-iodoacetyl) aminobenzoate (SIAB) was tested in  the cerium(IV) - 
antim ony(III) microassay, in  order to compare the catalytic activity o f aliphatic iodine- 
containing compounds w ith aromatic iodine-containing compounds. The K  value o f SIAB 
was calculated as 7.5%; 13.3 moles o f SIAB are required to give the same catalytic 
activity as one mole o f iodide in  the cerium (IV) - antimony(III) microassay. A ll o f the 
aromatic iodine-containing compounds, w ith the exception o f 3-iodophenol, displayed 
higher catalytic activities than SIAB. Bowden et al. (1955) reported that the Sandell- 
K o ltho ff reaction was relatively insensitive to aliphatic iodine-containing compounds. 
The catalytic activity o f iodine in  iodo-compounds is complex, and has been investigated 
by several authors. Bowden et al. (1955) determined the amount o f iodine liberated from  
iodo-compounds fo llow ing treatment w ith excess cerium(IV). The iodine-containing 
compound was mixed thoroughly w ith  a eerie sulphate solution; the liberated iodine was 
extracted w ith  benzene, which was in  turn extracted w ith sodium thiosulphate, followed 
by back titra tion w ith I2. They found that there was a correlation between the percentage 
o f iodine liberated, and the amount o f iodo-compound detectable on paper chromatography 
using a cerium (IV) - arsenic(III) reagent fo r detection. One o f their conclusions was that 
the detection o f iodine-containing compounds depends on the liberation o f iodine by 
oxidation w ith cerium (IV). Cerium (IV) has wide application in the oxidation o f organic 
compounds (Ho, 1986). Oxidations utilising cerium (IV) are very rapid, as it is a very 
powerful oxidising agent which removes one electron at a time from the substrate. The 
lim itations to its use are the fact that acidic conditions must be used, and large amounts 
o f cerium (IV) are required as it  is a one equivalent oxidant.
(1989).
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An experiment was carried out to study the liberation o f iodine from  iodo-compounds by 
cerium (IV). IBHR, T3, T4 and SLAB were treated w ith eerie ammonium sulphate, and the 
liberated iodine was extracted into toluene. Iodine forms a violet-coloured solution in 
organic solvents, and this can be used fo r its colorimetric determination (Marczenko, 
1976). Potassium iodide was used to prepare a standard curve (Fig 3.10); the 
milligrammes o f iodine liberated from  the iodo-compound was determined from the 
standard curve, and from  this the percentage o f the total iodine liberated was calculated. 
The results obtained are reported in Table 3.8. The percentage o f total iodine liberated 
from  T3 and T4 was calculated as 32.8% and 23.2%, respectively. Bowden et al. (1955) 
reported that 10.9% o f the iodine in  T3 and 7.9% o f the iodine in  T4 was liberated, which 
is considerably lower than the results obtained here. For IBHR, 15.5% o f the total iodine 
was liberated. I t  is not possible to achieve the same sensitivity in  the cerium(IV) - 
antim ony(III) microassay using IBHR standards as w ith potassium iodide standards 
(Section 3.2.1). The sensitivity is lim ited by the fact that only a percentage o f the iodine 
in IBHR is liberated to catalyse the reaction. Di-iodinated BHR, which has a higher 
catalytic activ ity than IBHR (Table 3.7), was tested in  the microassay to see i f  any 
improvement in  sensitivity could be obtained. F ig 3.11 shows the graph o f absorbance 
plotted against concentration that was obtained fo r both compounds. The same range o f 
standards (0.052 to 0.258jaM) could be assayed fo r both compounds, thus the use o f di- 
IBHR offered no advantage w ith respect to the sensitivity.
From their experiments, Bowden et al. (1955) also concluded that the catalytic activity o f 
iodine in  an iodobenzene ring is strongly dependent on the nature and position o f the 
second substituent o f the ring. O f the compounds they tested, an electron-donating group, 
fo r example, a hydroxyl or amino group, in  a position ortho to the iodine atom was 
necessary fo r liberation o f significant amounts o f iodine. There was no liberation o f iodine 
when, fo r example, a methyl ether group was in  a position ortho to the iodine. Similar 
observations were made by Morreale de Escobar and Rios (1958) and by Barker (1964). 
Morreale de Escobar and Rios (1958) studied the catalytic activity in the Sandell-Kolthoff 
reaction o f 3,5-di-iodotyrosine, 3,5-di-iodothyronine, T3 and T4. They found that the 
catalytic activ ity o f the compounds depended not only on the number o f iodine atoms but 
on their position in  the molecule. Iodine atoms on the outer ring, w ith a hydroxyl group 
ortho to the iodine, showed greater catalytic activity than iodine atoms on the inner ring,
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with an ether oxygen ortho to the iodine. Barker (1964) studied the deiodination o f 
thyroxine analogues by measuring the decolouration o f cerium(IV) - arsenic(III) reagents 
on paper chromatography; 3,5-di-iodothyronine was used as the reference compound. 
Removal o f the 4 ’-hydroxyl group o f 3,5-di-iodothyronine resulted in a complete loss o f 
reactivity; replacement w ith a 4 ’-amino group caused a return o f reactivity, while 
replacement w ith a 4 ’-methyl ether yielded a compound w ith low reactivity. Pantel (1982) 
reported that 2-, 3-, and 4-iodoaniline showed sim ilar catalytic activity in the Sandell- 
K o ltho ff reaction to 2-, 3-, and 4-iodophenol, while substitution in the 4- position w ith 
alkyl or methyl ether groups resulted in iodobenzene compounds that had significantly 
lower catalytic activ ity than 4-iodophenol or 4-iodoaniline.
Bowden et al. (1955) suggested that the aniline side chain o f 3,5-di-iodotyrosine and 3,5- 
di-iodothyronine may be partly responsible fo r liberation o f iodine, as replacement o f the 
aniline side chain o f 3,5-di-iodotyrosine w ith, fo r example, a carboxyl or nitro group 
yielded compounds which liberated less iodine, and replacement o f the aniline side chain 
o f 3,5-di-iodothyronine w ith a cyano group yielded a compound which did not liberate 
iodine. Barker (1964), however, found that alterations to the aniline side chain o f 3,5-di- 
iodothyronine did not alter the reactivity. As removal o f the ether oxygen to yield 4 ’- 
hydroxy-diphenyl analogues resulted in  compounds that did not liberate iodine, Barker 
(1964) suggested that liberation o f the iodine from  3,5-di-iodothyronine may involve 
splitting o f the diphenyl ether leading to formation o f a hydroxyl group in  the 4- position.
I
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Compound n K
Mean ± SD
mol. organic 
compound*
IBHR 8 33.7 ± 3.7 2.9
di -IB  HR 5 25.5 ± 3.1 2.0
t 3 6 37.0 ± 3.7 0.9
t 4 4 47.0 ± 6.0 0.5
2-iodophenol 3 13.0 ± 0.5 7.7
3-iodophenol 3 1.3 ± 0 .2 76.9
4-iodophenol 3 50.0 ± 6.2 2.0
SIAB 4 7.5 ± 1.0 13.3
*mol. organic com pound is the num ber o f  m oles o f  organic com pound that have 
the sam e catalytic activity as one m ole o f  iodide.
Table 3.7 Catalytic activ ity o f some iodine-containing organic compounds in the 
cerium (IV) - antim ony(III) spectrophotometric microassay.
1 *
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Figure 3.8 The structures o f some iodine-containing organic compounds, 
(a) IBHR  (b) 3 ’ ,5’ ,3,5-tetraiodothyronine (T4) (c) 3-iodotyrosine
(d) 3,5-di-iodothyronine (e) 3’ ,3,5-tri-iodothyronine (T3).
Figure 3.9 The structures o f some iodine-containing organic compounds, 
(a) 2-iodophenol (b) 3-iodophenol (c) 4-iodophenol (d) 2-iodoaniline
(e) N-succinim idyl (4-iodoacetyl) aminobenzoate (SIAB).
r*-CT>
COja
<
Iodine conc. (mg)
Figure 3.10 Graph o f absorbance at 497nm plotted against iodine concentration, follow ing  
treatment o f potassium iodide standards w ith cerium (IV) and extraction o f the liberated 
iodine into toluene.
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Compound Iodine liberated 
(mg/10mg compound)
% of total iodine
IBHR 0.51 15.5
t 3 1.92 32.8
t4 1.52 23.2
SIAB 0.01 0.2
Table 3.8 Iodine liberated by iodine-containing organic compounds, fo llow ing treatment 
with cerium(IV) and extraction o f die liberated iodine into toluene (n=2).
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Figure 3.11 Graph o f absorbance at 380nm plotted against concentration fo r IBHR and 
di-IBHR  standards assayed in  the cerium (IV) - antimony(m) spectrophotometric 
microassay.
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3.2.4 Optimisation of reaction variables for the cerium(IH) fluori metric microassay.
The cerium (IV) - antimony(III) microassay can be monitored by measuring the 
fluorescence o f the cerium (III) formed during the reaction. The excitation and emission 
spectra o f cerium (m ) are shown in Fig 3.12; excitation and emission wavelengths o f 
260nm and 360nm, respectively, were used in  the experimental work. The microassay was 
optimised w ith respect to incubation period and reagent concentration, using the same 
procedure as fo r the spectrophotometric microassay (Section 3.2.1), except that potassium 
iodide standards in the range 2 to 8ng/ml were used as the reaction became non-linear 
above a concentration o f 8ng/ml. The optimum conditions chosen were those that yielded 
good linearity (correlation coefficient, r) and a large difference in  absorbance values over 
the range o f standards tested (slope) for graphs o f absorbance plotted against potassium 
iodide concentration.
The fluorescence intensity was measured every 10min, from 10 to 60min (Fig 3.13). 
Incubation periods o f 10min and 20min resulted in graphs w ith correlation coefficients o f 
less than 0.94. Increasing the incubation period resulted in better correlation coefficients 
(r=0.985 fo r 30min, r=0.993 fo r 60min). The slope increased as the incubation period was 
increased; a value o f 0.693(±0.102) was obtained using a 10min incubation, while a value 
o f 22.495(±0.522) was obtained using a 60min incubation. An incubation period o f 60min 
was chosen as optimum.
The effect o f increasing eerie ammonium sulphate concentration is shown in Fig 3.14. 
Increasing the concentration from 0.01M to 0.03M did not cause any significant change 
in the slope. A  value o f 15.495(10.509) was obtained using 0.01M cerium(IV) and a value 
o f 15.810(±1.200) was obtained using 0.03M cerium(TV). Correlation coefficients o f 0.98 
were obtained using 0.01M, 0.015M and 0.02M cerium(TV), which were better than those 
obtained using 0.025M and 0.03M cerium(IV) (r=0.951 and 0.889, respectively). A  eerie 
ammonium sulphate concentration o f 0.02M was chosen as optimum. K irkbright et al. 
(1966) studied the variation in fluorescence intensity produced by increasing the 
cerium (IV) concentration, while keeping the arsenic(III) concentration constant. The 
fluorescence intensity increased up to a 2:1 molar ratio o f cerium(IV):arsenic(III), and then 
decreased fo r higher ratios. I t was suggested that the decrease was due to an inner- filte r 
effect caused by absorption o f the emission radiation by the excess cerium(IV).
The sulphuric acid concentration was increased from 5M to 8M  (Fig 3.15). The use o f 6M
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H2S04 resulted in the highest slope value (13.900±0.183). All H2S04 concentrations tested 
gave similar correlation coefficients (r=0.98). A concentration of 6M HjSO,, was chosen 
as optimum. The use of H2S04 was reported by Kirkbright et al. (1966), and by Tanaka 
et al. (1986) who used flow injection analysis for fluorimetric determination of the 
Sandell-Kolthoff reaction. Toledano et al. (1989) used a medium of HC1 for the 
fluorimetric stopped flow determination of the Sandell-Kolthoff reaction. They studied the 
use of H2S04, HC104 and HC1, and found that the catalytic action of iodide was greatest 
in HC1. H N03 could not be used, as nitrate ions had an inhibitory effect on the 
fluorescence of cerium(III).
Antimony potassium tartrate concentrations in the range 0.02M to 0.05M were tested in 
the microassay (Fig 3.16). Concentrations of 0.02M and 0.03M antimony(III) gave lower 
slope values, of 9.305(±0.938) and 15.950(11.145), respectively, than 0.04M antimony(III) 
which gave a slope value of 24.455(11.049). A concentration of 0.05M antimony(HI) gave 
a slope value of 21.085(11.876). Similar correlation coefficients (r=0.98) were obtained 
for all the concentrations tested. An antimony(m) concentration of 0.04M was chosen as 
optimum.
The conditions for the optimised cerium(III) fluorimetric microassay were similar to those 
for the spectrophotometric microassay, except that a higher concentration of antimony 
potassium tartrate was used for the fluorimetric assay. Potassium iodide standards were 
assayed in the optimised fluorimetric microassay; an example of a graph of fluorescence 
intensity plotted against concentration is shown in Fig 3.17. The linear range for the graph 
is 2 to 8ng/ml potassium iodide (r=0.991). The intra-assay accuracy and precision (Table 
3.9) and inter-assay accuracy and precision (Table 3.10) were calculated The intra- and 
inter-assay mean values obtained for the standards were within 93-107% of the true values, 
but the %CV for some of the standards was greater than 10%.
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Figure 3.12 Fluorescence spectra for cerium(III): A, excitation and B, emission.
1 and 3: 10ng/ml potassium iodide, 0.03M antimony potassium tartrate, 0.02M eerie 
ammonium sulphate in 6M H2S04.
2 and 4: 10ng/ml potassium iodide, 0.03M antimony potassium tartrate.
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Figure 3.13 Effect of incubation period on the slope and correlation coefficient (r) of the
graph of fluorescence intensity plotted against concentration for potassium iodide standards
assayed in the cerium(III) fluorimetric microassay.
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Figure 3.14 Effect of cerium(IV) concentration on the slope and correlation coefficient (r)
of the graph of fluorescence intensity plotted against concentration for potassium iodide
standards assayed in the cerium(III) fluorimetric microassay.
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Figure 3.15 Effect of sulphuric acid concentration on the slope and correlation coefficient
(r) of the graph of fluorescence intensity plotted against concentration for potassium iodide
standards assayed in the cerium(III) fluorimetric microassay.
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Figure 3.16 Effect of antimony(III) concentration on the slope and correlation coefficient
(r) of the graph of fluorescence intensity plotted against concentration for potassium iodide
standards assayed in the cerium(III) fluorimetric microassay.
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Figure 3.17 Graph of fluorescence intensity plotted against concentration of potassium 
iodide standards assayed in the optimised cerium(III) fluorimetric microassay.
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KI conc. (ng/ml) Mean ± SD %CV
2 1.87 ± 0.31 16.7
4 4.12 ± 0.32 7.7
6 5.69 ± 0.66 11.7
8 8.50 ± 0.43 5.0
Table 3.9 Intra-assay accuracy and precision results for potassium iodide standards 
assayed in the cerium(III) fluorimetric microassay (n=8).
KI conc. (ng/ml) Mean ± SD %CV
2 1.85 ± 0.24 13.2
4 4.01 ± 0.53 13.3
6 6.39 ± 0.52 8.1
8 7.88 ± 0.69 8.8
Table 3.10 Inter-assay accuracy and precision results for potassium iodide standards 
assayed in the cerium (III) fluorimetric microassay (n=7).
9 6
3.2.5 Optimisation of reaction variables fo r the cerium (TV) - 8-hydroxyquinoIine-5- 
sul phonic acid fluorim etric m icroassay.
Cerium(IV) can oxidise 8-hydroxyquinoline-5-sulphonic acid to give a fluorescent species. 
The cerium(TV) - antimony(III) reaction is allowed to proceed as usual, and after a fixed 
time 8-hydroxyquinoline-5-sulphonic acid is added and the fluorescence produced is 
measured. The excitation and emission spectra of the fluorescent species are shown in Fig 
3.18; excitation and emission wavelengths of 370nm and 480nm, respectively, were used 
in the experimental work. The microassay was optimised with respect to incubation period 
before addition of 8-hydroxyquinoline-5-sulphonic acid, time of reading the fluorescence 
intensity and volume of 8-hydroxyquinoline-5-sulphonic acid.
Incubation periods of 45min, 60min, 75min and 90min were tested (Fig 3.19). Incubation 
periods of 60min and 75min gave slope values of 7.330(±0.823) and 7.555(±0.776), 
respectively, and correlation coefficients of 0.995 and 0.993, respectively. These values 
were better than those obtained for 45min or 90min, which gave slope values of 
4.195(±0.376) and 2.847(±0.455), respectively, and correlation coefficients of 0.957 and 
0.856, respectively. An incubation period of 60min was chosen as optimum.
The fluorescence intensity produced was monitored from lmin to 25min after the addition 
of 8-hydroxyquinoline-5-sulphonic acid (Fig 3.20). The fluorescence reached a maximum 
after 5min, after which there was a slight decrease from a fluorescence intensity of 125 
at 5min to 119 at 25min. All fluorescence readings were taken within 5 to 15min after 
the addition of 8-hydroxyquinoline-5-sulphonic acid. Pal et al. (1977) studied the reaction 
between cerium(IV) and 8-hydroxyquinoline-5-sulphonic acid, and reported that the 
fluorescence intensity of the oxidation product reached a maximum after 30 seconds and 
remained constant for 35 to 40min.
The effect of increasing the volume of 8-hydroxyquinoline-5-sulphonic acid is shown in 
Fig 3.21. (Due to the poor solubility of 8-hydroxyquinoline-5-sulphonic acid, the highest 
concentration that could be prepared was 1.5mM, therefore the concentration in the 
reaction was increased by increasing the volume added to the reaction.) Increasing the 
volume from 30pl to 50pl caused an increase in the slope from a value of 4.450(±0.059) 
to 6.495(±0.581). Further increases in the volume to 60pl or 70pl caused a decrease in the 
slope; a value of 5.880(±0.350) was obtained using 60pl and a value of 5.335(±0.451) was 
obtained using 70pl. Correlation coefficients of 0.99 were obtained for all volumes tested.
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A volume of 50jal was chosen as optimum.
A graph of fluorescence intensity plotted against concentration for potassium iodide 
standards assayed in the optimised microassay is shown in Fig 3.22. The linear range for 
the assay is 2 to 8ng/ml potassium iodide (r=0.990). The intra-assay accuracy and 
precision (Table 3.11) and inter-assay accuracy and precision (Table 3.12) were calculated. 
The mean values for the standards were within 95 to 107% of the true values, except for 
the inter-assay result for 2ng/ml potassium iodide which gave a mean value that was 112% 
of the true value. The %CV for some of the standards was greater than 10%.
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Figure 3.18 Fluorescence spectra for cerium(IV) - 8-hydroxyquinoline-5-sulphonic acid 
(80HQ): A, excitation and B, emission.
1 and 3: 10ng/ml potassium iodide, 0.03M antimony potassium tartrate, 0.02M eerie 
ammonium sulphate in 6M H2S04, 1.5mM 80HQ.
2 and 4: 10ng/ml potassium iodide, 0.03M antimony potassium tartrate, 1.5mM 80HQ.
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Figure 3.19 Effect of incubation period on the slope and correlation coefficient (r) of the
graph of fluorescence intensity plotted against concentration for potassium iodide standards
assayed in the cerium(IV) - 8-hydroxyquinoline-5-sulphonic acid fluorimetric microassay.
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Figure 3.20 The fluorescence intensity of the cerium(IV) - 8-hydroxyquinoline-5-sulphonic 
acid fluorimetrie microassay, read at various time points after the addition of 8- 
hydroxyquinoline-5-sulphonic acid.
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Figure 3.21 Effect of 8-hydroxyquinoline-5-sulphonic acid volume on the slope and 
correlation coefficient (r) of the graph of fluorescence intensity plotted against 
concentration for potassium iodide standards assayed in the cerium(IV) - 8-hydroxy- 
quinoline-5-sulphonic acid fluorimetric microassay.
102
Kl c o n c .  (ng/ml)
Figure 3.22 Graph of fluorescence intensity plotted against concentration of potassium 
iodide standards assayed in the optimised cerium(IV) - 8-hydroxy-quinoline-5-sulphonic 
acid fluorimetric microassay.
KI conc. (ng/ml) Mean ± SD %CV
2 2.14 ± 0.31 14.5
4 3.80 ± 0.45 11.9
6 6.30 ± 0.44 7.0
8 7.73 ± 0.66 8.6
Table 3.11 Intra-assay accuracy and precision results for potassium iodide standards 
assayed in the cerium(IV) - 8-hydroxyquinoline-5-sulphonic acid fluorimetric microassay 
(n=8).
KI conc. (ng/ml) Mean ± SD %CV
2 2.25 ± 0.20 9.0
4 3.94 ± 0.52 13.2
6 6.30 ±0.10 1.5
8 7.72 ± 0.23 3.0
Table 3.12 Inter-assay accuracy and precision results for potassium iodide standards 
assayed in the cerium(IV) - 8-hydroxyquinoline-5-sulphonic acid fluorimetric assay (n=5).
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3.2.6 Com parison o f the spectrophotom etric m icroassay with the fluorim etric 
m icroassays.
The cerium(IV) - antimony(III) microassay has been monitored by both spectrophotometric 
and fluorimetric methods. In the cerium(III) fluorimetric method the increase in 
fluorescence intensity was measured against a low blank value, while in both the spectro­
photometric and the cerium(IV) - 8-hydroxyquinoline-5-sulphonic acid methods the 
decrease in absorbance or fluorescence intensity was measured against a high blank value. 
The linear range for the fluorimetric microassays for potassium iodide standards was 2 to 
8ng/ml; the spectrophotometric microassay had a wider linear range of 2 to lOng/ml for 
potassium iodide standards. The relationship between fluorescence intensity and 
fluorophore concentration is non-linear at higher fluorophore concentrations (Ingle and 
Ryan, 1981). This is not a problem in trace analysis where the concentration of the 
monitored species is less than IpM, but for these experiments the concentration of 
cerium(IV) is in the millimolar range.
Tanaka et al. (1985) reported a detection limit of 0.8pM iodide using spectrophotometric 
monitoring of the Sandell-Kolthoff reaction. The detection limit was improved by the use 
of fluorimetric monitoring (Tanaka et al., 1986). A detection limit of 50nM iodide was 
obtained using fluorimetric monitoring of the fluorescent species produced by cerium(IV) 
oxidation of 8-hydroxyquinoline-5-sulphonic acid, and a detection limit of 3nM iodide was 
obtained using fluorimetric monitoring of cerium(III). In the work carried out here, no 
improvement in sensitivity was obtained using fluorimetric monitoring of the cerium(IV) - 
antimony(III) microassay. Fluorimetric monitoring is, in principle, more sensitive than 
spectrophotometric monitoring, but in practice the sensitivity is restricted by several factors 
(Hemmila, 1985). Background fluorescence from, for example, plastics or impurities in 
the reagents and quenching of the fluorescence intensity due to the sensitivity of 
fluorescent compounds to their environment can limit the sensitivity of fluorescent 
techniques. The instrumentation is also expensive and complex, as excitation and emission 
optics must be incorporated, and low light levels are measured by the detector. The Perkin 
Elmer Luminescence Spectrophotometer used to monitor fluorescence intensity for these 
experiments is capable of reading both cuvettes and 96 well plates. However, there is a 
40-fold reduction in fluorescence intensity when reading from plates compared to cuvettes. 
Also, in order to read plates the optics had to be altered manually. Alignment of the
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optics is critical, and manual alteration introduces the potential for errors in the alignment 
and damage of the optical fibres over time.
The intra- and inter-assay accuracy and precision values obtained for the spectro- 
photometric assay were better than those obtained for the fluorimetric assays. The mean 
values for potassium iodide standards were within 96 to 107% of the true values when 
assayed in the spectrophotometric assay; the mean values were within 93 to 107% and 95 
to 112% of the true values when assayed in the cerium(III) fluorimetric assay and the 
cerium(IV) - 8-hydroxyquinoline-5-sulphonic acid fluorimetric assay, respectively. The 
%CV values for all standards were less than 10% when assayed in the spectrophotometric 
assay, but values of greater than 10% were obtained for some standards in both of the 
fluorimetric assays. Since assay parameters such as linear range, accuracy and precision 
were better for the spectrophotometric microassay compared with the fluorimetric 
microassays, it was decided to use only the spectrophotometric microassay for future work.
3.3 Summary.
The reaction between cerium(IV) and antimony (III), reported by Bognar and Sarosi (1965), 
has been successfully adapted for use in a microassay format, and used to determine iodide 
and iodine-containing compounds. The microassay can be used as a replacement for the 
Sandell-Kolthoff microassay developed by O’Kennedy et al. (1989). The 
spectrophotometric cerium(IV) - antimony(III) microassay has a linear range of 2 to 
lOng/ml for potassium iodide standards, and 0.02 to O.lpg/ml for IBHR standards. It was 
not possible to achieve the same sensitivity using IBHR standards as with potassium iodide 
standards. The sensitivity of the microassay for IBHR is limited by the fact that only a 
percentage of the iodine in IBHR is liberated to catalyse the reaction, thus the catalytic 
activity is inferior to that of potassium iodide. The use of di-IBHR did not lead to any 
improvement in the sensitivity.
Fluorimetric monitoring of the reaction was investigated in an attempt to improve the 
sensitivity. Two fluorimetric methods were investigated. One was based on the direct 
measurement of cerium(III), and the other was based on the measurement of the 
fluorescence produced by the cerium(IY) oxidation of 8-hydroxyquinoline-5-sulphonic acid. 
The linear range for the fluorimetric microassays was 2 to 8ng/ml for potassium iodide 
standards; the spectrophotometric microassay can be used for measurement of a wider
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range o f potassium iodide standards and no improvement in sensitivity was obtained using 
fluorimetrie monitoring o f the microassay. The intra- and inter-assay accuracy and 
precision values obtained for potassium iodide standards measured in the 
spectrophotometric assay were better than the values obtained in the fluorimetrie assays.
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4. USE OF IBHR - LABELLED ANTIBODIES.
4.1 Introduction.
The use of the Sandell-Kolthoff microassay for the detection of IBHR-labelled 
antibodies in immunoassays has been described. O’Kennedy and Keating determined 
mouse IgG levels (O’Kennedy and Keating, 1991) and human IgG levels (O’Kennedy 
and Keating, 1993) using a two-site immunoassay and the Sandell-Kolthoff reaction for 
detection of the IBHR label. This system was compared with the use of HRP-labelled 
antibodies in an ELISA. In this chapter, the use of IBHR-labelled antibodies in an 
immunoassay for human IgG levels and their detection using the cerium(IV) - 
antimony(III) microassay is described. The results were compared with those obtained 
using the Sandell-Kolthoff microassay, and with an ELISA.
The level of iodination of antibodies was studied by labelling with different amounts 
of IBHR. The immunoreactivity of the iodinated antibodies was assessed in the two- 
site immunoassay. The relative binding pattern of native and iodinated antibodies was 
studied using real-time biospecific interaction analysis (BIAcore).
The principle of BIAcore is described in detail by Jonsson and Malmquist (1992). 
BIAcore uses surface plasmon resonance (SPR) to investigate biospecific interactions 
at the surface of a sensor chip. The SPR response is correlated to changes in the 
refractive index at the chip surface, which are caused by mass changes on the surface 
due to components binding to the chip, for example, on immobilisation of ligand onto 
the chip or on binding of analyte to the immobilised ligand. The sensor chip is held 
in place in the instrument with a microfluidic cartridge which controls delivery of 
samples into a buffer that passes continuously over the chip surface. The chip consists 
of a glass slide with a gold film, to which is linked a carboxymethylated dextran. The 
dextran is activated by derivatisation with N-hydroxysuccinimide (NHS) and N-ethyl- 
N’-(dimethylamino-propyl)carbodiimide (EDC), forming reactive NHS-esters. The 
ligand of interest is immobilised by formation of a covalent bond between amino 
groups on the ligand and the NHS-esters. Unreacted NHS-esters remaining on the chip 
are deactivated by reaction with ethanolamine. The ligand bound to the chip surface 
is freely accessible to three-dimensional antibody-antigen interactions. Interactions 
between the ligand and the analyte are directly detected by measuring changes in the 
SPR response, which is presented through the BIAcore software as resonance units 
(RU). A sensorgram (a plot of RU versus time) is obtained for each interaction. The 
ligand matrix on the chip is regenerated after each interaction using either acidic or
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basic solution, which removes the non-covalently bound analyte but not covalently 
attached ligand. In this way, multiple antibody-antigen interactions can be studied 
using the same ligand matrix.
4.2 Results and discussion.
4.2.1 Two-site immunoassays for human IgG.
Antibodies were labelled with IBHR, and free and conjugated IBHR were separated by 
dialysis. The cerium(IV) - antimony(III) microassay was used to measure the amount 
of IBHR in the conjugate, assuming that the catalytic activity of IBHR is not altered 
on conjugation. Since the catalytic activity of the iodine atom in IBHR is dependent 
on the presence of the hydroxyl group ortho to it (Section 3.2.3), and this group is not 
involved in the conjugation reaction, the catalytic activity of free and conjugated IBHR 
should be similar. The BioRad assay was used to determine the amount of protein in 
the conjugate. IBHR can introduce groups into a protein that interfere in the 
measurement of its concentration. The methods frequently used for measurement of 
protein concentration are absorbance at 280nm, the BCA assay and the BioRad assay. 
The structure of IBHR is similar to tyrosine, thus conjugation of IBHR to a protein 
introduces groups which absorb at 280nm (O’Kennedy et al., 1989), and the use of 
absorbance at 280nm is no longer an accurate measure of protein concentration. 
Knight and Welch (1978) reported that the main sites of labelling on conjugation of 
IBHR to a protein are lysine residues, with small amounts of tyrosine and histidine 
residues being labelled. The BCA assay is based on the use of Biuret reagent, which 
interacts mainly with cysteine, cystine, tryptophan and tyrosine, and the peptide bond 
(Wiechelman et al., 1988). Increasing IBHR concentration was found to be linearily 
related to increasing colour intensity in the BCA assay (O’Kennedy and Keating, 
1993). This interference may be due to the structural similarity of IBHR to tyrosine. 
The BioRad assay is based on the use of the Bradford reagent, Coomassie brilliant blue 
G-250, which interacts mainly with arginine residues, while other basic resides (lysine 
and histidine) and aromatic residues (tyrosine, tryptophan and phenylalanine) give a 
slight response (Compton and Jones, 1985). Thus, IBHR may interfere in the BioRad 
assay due to modification of lysine residues, or IBHR itself may interfere in the assay 
(O’Kennedy et al., 1989). To test for interference in the assay, a set of IBHR 
standards was assayed using the BioRad reagent. The absorbance values obtained were 
compared to those obtained for IgG standards in the same range (Fig 4.1); the 
absorbance due to IBHR was negligible. Therefore, it was decided to use the BioRad
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assay for the determination of protein concentration of IBHR-labelled proteins. On 
average, 19 moles of IBHR were conjugated per mole of antibody. Conjugation levels 
of 17 moles of IBHR (O’Kennedy and Keating, 1991) and up to 23 moles of IBHR 
(O’Kennedy and Keating, 1993) per mole of antibody have been reported.
Antibodies were labelled with HRP also. The enzyme-antibody absorbance ratio was 
determined by measuring the absorbance of the conjugate at 403nm and 280nm. This 
ratio provides a guide to the amount of HRP conjugated, which influences conjugate 
performance. A ratio in the range 0.3 to 0.5 indicates a conjugate with high enzyme 
activity without adverse effect on the antibody titre, and low background readings 
(Catty and Raykundalia, 1989). On average, a ratio of 0.36 was obtained for the 
conjugates prepared for these experiments. The enzyme activity of the conjugate was 
measured by addition of substrate to the conjugate, diluted to lpg/ml IgG, and 
measurement of the absorbance at intervals. A graph of absorbance plotted against 
time is shown in Fig 4.2. Conjugates that have an absorbance of 1.0 in 10 to 15min, 
and an absorbance of 1.5 or greater in 25 to 30min have suitable enzyme activity for 
ELISA (Catty and Raykundalia, 1989); these criteria were met by the conjugate 
prepared for these experiments.
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Figure 4.1 Graph of absorbance at 595nm plotted against concentration of IBHR 
standards and IgG standards assayed in the BioRad protein assay.
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Figure 4.2 Graph of absorbance at 492nm plotted against time, for measurement of the 
enzyme activity of HRP-labelled antibodies.
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Human IgG levels in standards and human serum samples were determined in a two- 
site immunoassay using IBHR-labelled antibodies, with detection of the IBHR label by 
either the cerium(IV) - antimony(III) microassay or the Sandell-Kolthoff microassay, 
and using HRP-labelled antibodies. The protocol for the immunoassay is outlined in 
a flow diagram in Fig 4.3. In order to ensure the reliability of the comparison between 
the three assay systems, the same batch of anti-human IgG antibodies were used in 
each system.
The optimum dilution of the conjugated antibodies was determined in the 
immunoassay. IBHR-labelled antibodies were diluted in the range 1/10 to 1/80; the 
results are shown in Table 4.1. Dilutions of 1/10 and 1/20 gave the largest change in 
absorbance over the range of IgG standards tested; a dilution of 1/20 was chosen as 
optimum, since this was less wasteful of antibody. On average, this corresponded to 
an antibody concentration of 22pg/ml. HRP-labelled antibodies were diluted in the 
range 1/80 to 1/640; the results are shown in Table 4.2. A dilution of 1/160 was 
chosen as optimum. On average, this corresponded to an antibody concentration of 
6pg/ml.
The linear range of the immunoassays was determined from standard curves of 
absorbance plotted against human IgG concentration, on a log scale. The standard 
curves obtained using IBHR-labelled antibodies, with detection by the cerium(IV) - 
antimony(III) microassay and the Sandell-Kolthoff microassay are shown in Fig 4.4 and 
Fig 4.5, respectively. The standard curve obtained using HRP-labelled antibodies is 
shown in Fig 4.6. Human IgG standards, in the range 0.05 to 2pg/ml, could be 
determined using IBHR-labelled antibodies with detection by the cerium(IV) - 
antimony(III) microassay (r=0.994) or the Sandell-Kolthoff microassay (r=0.973). 
Standards in the range 0.0064 to 0.25pg/ml could be determined using HRP-labelled 
antibodies (r=0.998); the use of an HRP label allowed measurement of lower 
concentrations of human IgG. The use of an HRP label also resulted in a greater 
difference in absorbance values over the range of standards tested. The difference in 
absorbance values between the zero standard and the highest standard was 0.666 using 
IBHR-labelled antibodies, with detection by the cerium(IV) - antimony(III) reaction, 
while it was 1.163 using HRP-labelled antibodies.
O’Kennedy and Keating (1993) measured 5 to 40ng/well (which corresponds to 0.05 
to 0.4pg/ml) of human IgG using IBHR-labelled antibodies with detection by the 
Sandell-Kolthoff microassay, and HRP-labelled antibodies. They measured the 
absorbance for both systems after lhr, and the absorbance using HRP-labelled
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antibodies became non-linear above 25ng/well. For the experiments reported here, the 
absorbance of each system was measured at different times in order to determine the 
linear range of each system. The absorbance for the cerium(IV) - antimony(III) 
microassay was measured after 2hr, for the Sandell-Kolthoff microassay the absorbance 
was measured after lhr, and for HRP-labelled antibodies the absorbance was measured 
after 15min.
The intra- and inter-assay accuracy and precision were calculated for the standards. 
The results obtained using IBHR-labelled antibodies, with detection by the cerium(IV) - 
antimony(ni) microassay are shown in Table 4.3 and Table 4.4. The results obtained 
using the Sandell-Kolthoff microassay are shown in Table 4.5 and Table 4.6. The 
results obtained using HRP-labelled antibodies are shown in Table 4.7 and Table 4.8. 
The intra-assay mean values for all standards were within 90 to 110% of the true 
values, with the exception of the O.Olpg/ml standard for the immunoassay using the 
Sandell-Kolthoff reaction for detection of antibodies which had a mean value 115% of 
the true value. The inter-assay mean values were within 83 to 115% of the true values; 
each system had standards that fell outside the acceptable range of 90-110%. Each of 
the systems had intra- and inter-assay %CV values greater than 10% for some 
standards.
The IgG concentration in five human serum samples was measured in each of the assay 
systems; the results are shown in Table 4.9. The concentration of IgG in serum from 
healthy individuals varies over a wide range, falling between 7 and 14 mg/ml. The 
results obtained for the samples using the cerium (TV) - antimonyCLH) microassay 
differed from the results using the Sandell-Kolthoff microassay by 19% (range 3 to 
51%), and from the results using HRP-labelled antibodies by 15% (range 1 to 42%). 
The results for the Sandell-Kolthoff microassay differed from the results obtained using 
HRP-labelled antibodies by 24% (range 1 to 50%). The standard error obtained using 
IBHR-labelled antibodies was lower than that obtained using HRP-labelled antibodies, 
an observation that was also reported by O’Kennedy and Keating (1993).
The possibility of using IBHR-labelled antibodies in an immunoassay, and the 
favourable comparison of this to an ELISA, was previously reported by O’Kennedy and 
Keating (1991 and 1993). The results reported here indicate that the Sandell-Kolthoff 
reaction can be successfully replaced by the cerium(IV) - antimony(m) reaction for 
detection of the IBHR label. The use of IBHR-labelled antibodies to measure human 
IgG concentration shows good agreement with the use of HRP-labelled antibodies, with 
respect to accuracy and precision of the standards, and with respect to the results
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obtained for serum samples. However, the use of HRP-labelled antibodies does offer 
the advantage that lower concentrations of human IgG can be measured. The detection 
limit of immunoassays is determined by several factors (Tijssen, 1985). The adsorption 
of ligand to the solid phase, the stability of this interaction, the ratio of the surface of 
the solid phase to the volume of the sample, the avidity of the antibody - antigen 
reaction, the quality of the conjugate and the detection system for the label are all 
factors which determine the detection limit. The systems compared here are identical 
with respect to the first three factors, but differ with respect to the last three factors. 
For example, the colorimetric reaction used for detection of the HRP label gives an 
increase in absorbance against a low blank value, while the microassays used for 
detection of the IBHR label give a decrease in absorbance against a high blank value. 
The sensitivity of the cerium(IV) - antimony(III) detection system is limited by the fact 
that only a percentage of the iodine in IBHR is liberated to catalyse the reaction 
(Section 3.2.3). The use of fluorimetric monitoring, instead of spectrophotometric 
monitoring, did not improve the sensitivity (Section 3.2.6). The same batch of anti­
human IgG antibodies were used in all systems, but the antibodies were labelled with 
either IBHR or HRP producing conjugates with very different characteristics. This is 
illustrated, for example, by the optimum dilution of the conjugates since a higher 
dilution of the HRP-labelled antibodies could be used compared with the IBHR-labelled 
antibodies. The HRP conjugation procedure was carried out according to the periodate 
method, which was investigated and optimised by Tijssen and Kurstack (1984). The 
conjugates produced by this optimised method gave higher titre in an ELISA compared 
with conjugates produced using a previous periodate method (Nakane and Kawaoi, 
1974). Iodination procedures using radioactive iodine have been widely used, and are 
thus well investigated and optimised. However, iodination using non-radioactive iodine 
has not been widely used. Therefore, the iodination of antibodies with various levels 
of non-radioactive IBHR was investigated.
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Coat plates: lOug/ml anti-human IgG antibodies (lOOul/well)
I 2hr 37° C 
Wash
I
Block: 0.5%(w/v) gelatin (200ul/well)
I lhr 37° C
Wash
1
Human IgG standards (lOOul/well)
1 lhr 37° CWash
I
Labelled anti-human IgG antibodies (lOOul/well)
* 30min 37° CWash
I
Add appropriate substrates 
and read absorbance using Titertek plate reader
Figure 4.3 Flow diagram of the two-site immunoassay using IBHR- or HRP-Iabelled 
antibodies. (A detailed description of the protocol is given in Section 2.6.1)
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Hum an Ig G  conc. (jig/m l) D ilution o f conjugated antibody
1/10 1/20 1/40 1/80
0 1.343 1.345 1.366 1.364
0.05 1.296 1.285 1.298 1.316
0.1 1.257 1.266 1.248 1.298
0.25 1.118 1.186 1.210 1.254
0.5 1.089 1.143 1.175 1.221
1 0.960 1.067 1.112 1.224
Table 4.1 Determination of the optimum dilution of IBHR-labelled antibodies to use 
in the two-site immunoassay. The results shown are absorbance values at 380nm.
H um an Ig G  conc. (fig/m l) D ilution of conjugated antibody
1/80 1/160 1/320 1/640
0 0.199 0.174 0.139 0.126
0.05 0.720 0.642 0.523 0.358
0.1 0.837 0.760 0.596 0.438
0.25 1.020 0.906 0.743 0.542
0.5 1.096 1.012 0.819 0.610
1 1.153 1.042 0.907 0.698
Table 4.2 Determination of the optimum dilution of HRP-labelled antibodies to use in 
the two-site immunoassay. The results shown are absorbance values at 405nm.
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Figure 4.4 Graph of absorbance at 380nm plotted against concentration of human IgG 
standards assayed in a two-site immunoassay, using IBHR-labelled antibodies detected 
by the cerium(TV) - antimony(III) reaction.
The absorbance value for the zero standard was 1.294.
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Figure 4.5 Graph of absorbance at 414nm plotted against concentration of human IgG 
standards assayed in a two-site immunoassay, using IBHR-labelled antibodies detected 
by the Sandell-Kolthoff reaction.
The absorbance value for the zero standard was 0.620.
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Figure 4.6 Graph of absorbance at 405nm plotted against concentration of human IgG 
standards assayed in a two-site immunoassay, using HRP-labelled antibodies.
The absorbance value for the zero standard was 0.114.
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Human IgG conc. (ug/ml) Mean ± SD % c v
0.05 0.05 ± 0.01 9.4
0.1 0.10 ± 0.02 17.9
0.25 0.23 ± 0.04 16.9
0.5 0.53 ± 0.07 12.5
1 1.06 ± 0.12 11.2
2 1.99 ± 0.13 6.4
Table 4.3 Intra-assay accuracy and precision results for human IgG standards assayed 
in a two-site immunoassay using IBHR-labelled antibodies detected by the cerium(IV) - 
antimony(III) microassay (n=8).
Human IgG conc. (|ug/ml) Mean ± SD % c v
0.05 0.06 ± 0.004 7.2
0.1 0.09 ± 0.01 9.8
0.25 0.23 ± 0.03 12.5
0.5 0.50 ± 0.05 9.5
1 1.06 ± 0.10 9.5
2 2.29 ± 0.34 15.0
Table 4.4 Inter-assay accuracy and precision results for human IgG standards assayed 
in a two-site immunoassay using IBHR-labelled antibodies detected by the cerium(IV) - 
antimony(III) microassay (n=6).
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Human IgG conc. (ug/ml) Mean ± SD % c v
0.05 0.05 ± 0.01 14.6
0.1 0.12 ± 0.02 17.3
0.25 0.22 ± 0.04 17.6
0.5 0.47 ± 0.09 20.0
1 1.08 ± 0.15 14.4
2 1.94 ± 0.27 14.0
Table 4.5 Intra-assay accuracy and precision results for human IgG standards assayed 
in a two-site immunoassay using IBHR-labelled antibodies detected by the Sandell- 
Kolthoff microassay (n=8).
Human IgG conc. (ug/ml) Mean ± SD % c v
0.05 0.05 ± 0.004 6.9
0.1 0.11 ± 0.002 1.8
0.25 0.25 ± 0.05 19.4
0.5 0.42 ± 0.06 14.3
1 1.08 ± 0.18 16.6
2 1.84 ± 0.27 14.6
Table 4.6 Inter-assay accuracy and precision results for human IgG standards assayed 
in a two-site immunoassay using IBHR-labelled antibodies detected by the Sandell- 
Kolthoff microassay (n=3).
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Human IgG conc. (|ng/ml) Mean ± SD % c v
0.0064 0.007 ± 0.001 9.2
0.0125 0.012 ± 0.001 9.1
0.025 0.023 ± 0.003 11.3
0.05 0.050 ± 0.005 9.6
0.1 0.110 ±0.013 11.4
0.25 0.238 ± 0.031 12.9
Table 4.7 Intra-assay accuracy and precision results for human IgG standards assayed 
in a two-site immunoassay using HRP-labelled antibodies (n=8).
Human IgG conc. (ug/ml) Mean ± SD % c v
0.0064 0.006 ± 0.001 11.4
0.0125 0.011 ±0.001 9.6
0.025 0.026 ± 0.005 17.7
0.05 0.057 ± 0.008 13.5
0.1 0.113 ± 0.008 7.4
0.25 0.233 ± 0.022 9.6
Table 4.8 Inter-assay accuracy and precision results for human IgG standards assayed 
in a two-site immunoassay using HRP-labelled antibodies (n=5).
Sample A (n=5) 
Mean ± SD
B (n=3) 
Mean ± SD
C (n=5) 
Mean ± SD
1 5.5 ±2 .0 4.5 ±0.6 4.9 ±0.7
2 8.3 ± 1.9 7.7 ±2.3 7.6 ±2.4
3 13.9 ± 4.7 13.5 ± 2.9 9.8 ±2.8
4 15.4 ± 0.8 23.3 ± 0.6 15.5 ± 4.3
5 24.0 ± 2.3 26.6 ± 0.9 21.9 ± 10.2
SE 2.3 1.5 4.1
SE is standard error.
Table 4.9 IgG concentration (mg/ml) in human serum samples assayed in a two-site 
immunoassay using:
(A) IBHR-labelled antibodies detected by the cerium(IV) - antimony(III) microassay
(B) IBHR-labelled antibodies detected by the Sandell-Kolthoff microassay
(C) HRP-labelled antibodies.
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4.2.2 Iodination of antibodies with various levels of IBHR.
Anti-human IgG antibodies (lmg) were reacted with 0.1, 0.25, 0.5, 1, 1.5 and 2mg of 
IBHR. The molar ratio of IBHR reacted to free amino groups was calculated using an 
estimate of 90 free amino groups per goat IgG (Kendall et al., 1983). This is shown 
in Table 4.10. In Table 4.10 the moles of IBHR conjugated to antibody for each 
conjugate are also shown.
4.2.2.1 Assessment of the relative binding pattern using the BIAcore.
The relative binding pattern of the conjugates was assessed using the BIAcore, i.e. how 
do antibodies labelled with increasing amounts of IBHR bind relative to each other and 
relative to native antibodies. Human IgG was immobilised onto a sensor chip. An 
example of a sensorgram obtained for the immobilisation of human IgG onto a sensor 
chip is shown in Fig 4.7. Native anti-human IgG antibodies were passed over the 
surface of the chip, and the response obtained was taken to represent maximum binding 
(i.e. 100%). An example of a sensorgram obtained for the interaction between the 
immobilised human IgG and native anti-human IgG antibodies is shown in Fig 4.8. 
The IBHR-labelled anti-human IgG antibodies were passed over the surface of the chip; 
the response obtained was expressed as a percentage of the maximum binding. A 
control, which consisted of antibodies that were taken through the iodination reaction 
in the absence of IBHR, was included. The BIAcore results are shown in Table 4.11. 
The binding of IBHR-labelled antibodies to immobilised antigen was decreased relative 
to the binding of native antibodies; the decrease in binding was directly related to the 
amount of IBHR conjugated to the antibodies. For example, antibodies labelled with 
21 moles of IBHR per mole of antibody gave only 14% of the maximum binding 
obtained for native antibodies, while antibodies labelled with 6 moles of IBHR per 
mole of antibody gave 68% of the maximum binding.
This decrease in binding upon iodination may be due to several factors. The mere 
manipulation of antibodies in dilute solutions during the iodination reaction and 
purification can cause denaturation (Parker, 1976), as can exposure to chemicals used 
in the iodination reaction. This is illustrated by the control antibodies which were 
taken through the iodination process in the absence of IBHR, and gave only 84% of 
the maximum binding. The introduction of IBHR into antibodies can cause 
conformational and charge changes. Use of the chloramine T method, with 
introduction of an iodine atom into tyrosine residues, causes conformational changes 
as iodine is a large atom, similar in size to a benzene ring, and causes a reduction of
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the pK of the tyrosine residues (Bolton and Hunter, 1973). IBHR is larger than iodine, 
and conjugation of IBHR to a protein is by substitution of an amino group with an 
iodophenol group. Introduction of IBHR molecules may, therefore, cause greater 
alteration in conformation and charge of a protein than observed with introduction of 
iodine atoms (Bolton and Hunter, 1973). The number of IBHR molecules conjugated 
to the antibodies is also a factor. Heavy iodination may be detrimental. Introduction 
of iodine into a protein depends on the distribution, reactivity and accessibility of the 
target amino acids to iodination. As the level of iodination is increased, the likelihood 
of introduction of iodine into a critical amino acid is increased, and this can lead to 
losses in reactivity (Parker, 1976). Iodination with chloramine T to produce heavily 
iodinated proteins is reported to decrease the specific binding activity, and increase the 
tendency of the protein to aggregate and bind non-specifically, although these effects 
may be due to the direct reaction of chloramine T with the protein, in addition to the 
introduction of iodine atoms (Parker, 1976). It is difficult to compare the levels of 
incorporation of IBHR into antibodies reported in these experiments, with the levels 
of incorporation of radioactive iodine reported in the literature. With radioiodination, 
the incorporation of iodine is usually kept to one atom of 125I per IgG, as incorporation 
of levels higher than this may lead to "decay catastrophe" (Hales and Woodhead, 
1980), where reduction in protein reactivity occurs during iodination and storage due 
to damage caused by exposure to high levels of radioactivity.
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Mg of IBHR# Molar ratio 
IBHR:amino 
group*
moles of IBHR 
conjugated per 
mole of Ab
Control - -
0.1 0.5 : 1 6
0.25 1.1 : 1 10
0.5 2.3 : 1 18
1 4.6 : 1 21
1.5 6.9 : 1 26
2 9.1 : 1 30
# Milligrammes o f IBHR reacted with lm g o f goat anti-human IgG antibodies.
* The molar ratio o f IBHR reacted to free amino groups, using an estimate of 90 free amino groups per goat 
IgG molecule (Kendall et al., 1983).
Table 4.10 Conjugates prepared by reaction of anti-human IgG antibodies with 
increasing amounts of IBHR.
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Figure 4.7 An example of a sensorgram showing the immobilisation of human IgG 
onto the activated surface of a sensor chip.
(1) Baseline for the unmodified sensor chip surface
(2) Activation of the chip surface causes an increase in the SPR signal due to changes 
in the refractive index
(3) Baseline after activation
(4) Immobilised human IgG before deactivation
(5) Deactivation of unreacted NHS-esters
(6) Immobilised human IgG after deactivation
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Figure 4.8 An example of a sensorgram showing the interaction between human IgG 
immobilised on the surface of a sensor chip, and native anti-human IgG antibodies.
(1) Baseline for the human IgG matrix on the chip surface
(2) Anti-human IgG antibodies bound to the human IgG matrix
(3,4,5) Regeneration of the human IgG matrix with pulses of lOmM HC1
(6) Regenerated human IgG matrix
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Molar ratio IBHRramino group* % of maximum binding
Control 84
0.5 : 1 68
1.1 : 1 44
2.3 : 1 22
4.6 : 1 14
6.9 : 1 10
*The molar ratio of IBHR reacted to free amino groups, using an estimate of 90 free amino groups per goat 
IgG molecule (Kendall et al., 1983).
Table 4.11 BIAcore results (n=2) for the binding of anti-human IgG antibodies, 
labelled with increasing amounts of IBHR, to human IgG. The results are expressed 
as a percentage of the maximum binding, where the binding of native anti-human IgG 
antibodies is taken as 100%. The control is anti-human IgG antibodies that have been 
through the iodination process in the absence of IBHR.
4.2.2.2 Assessment of im m unoreactivity in an immunoassay.
The immunoreactivity of the conjugates was assessed in the two-site immunoassay for 
human IgG (Section 4.2.1). Human IgG standards were measured using each of the 
conjugates; the graphs of absorbance plotted against IgG concentration, on a log scale, 
are shown in Fig 4.9. A decrease in the amount of IBHR conjugated to the antibodies 
did not lead to any improvement in the immunoassay results.
The results for each conjugate can be compared to the results for the conjugate 
obtained using a 4.6:1 molar ratio, as this is the conjugation ratio used for the 
experiments in Section 4.2.1. The graph obtained using this conjugate was linear in 
the range 0.05 to 2pg/ml human IgG (r=0.994), as were the graphs for the conjugates 
produced using a 1.1:1 molar ratio (r=0.988) and a 2.3:1 molar ratio (r=0.989). The 
conjugate produced using a 0.5:1 molar ratio resulted in a loss of sensitivity; standards 
in the range 0.1 to 2pg/ml human IgG were measured (r=0.965). Hie slope of the 
graphs decreased as the level of iodination was decreased A slope of 0.349 was 
obtained using the conjugate produced at a 4.6:1 molar ratio, while a slope of 0.116 
was obtained using the conjugate produced at a 0.5:1 molar ratio. The BIAcore results 
indicated that an increase in the binding of antibody to antigen is obtained when the 
amount of IBHR conjugated to the antibody is decreased No benefit due to increased 
binding was observed in these immunoassays using conjugates labelled with decreasing 
amounts of IBHR. Immunoassay performance is based not just on the antibody - 
antigen reaction, but on several parameters including the detection reaction. The 
sensitivity of the cerium(IV) - antimony(IH) reaction for IBHR is limited as only a 
percentage of the iodine in IBHR is liberated to catalyse the reaction (Section 3.2.3), 
thus for conjugates containing low levels of IBHR the reaction may not be sensitive 
enough to detect the small amount of label present in the immunoassay.
Increasing the level of iodination did not adversely affect the immunoassay results. 
Human IgG standards in the range 0.05 to 2pg/ml could be measured using conjugates 
produced using a 6.9:1 molar ratio (r=0.993) and a 9.1:1 molar ratio (r=0.988). The 
disadvantage of the use of higher levels of iodination was that the non-specific binding 
increased. For example, the absorbance for wells containing iodinated antibody, but 
no antigen, was 1.499 using a 0.5:1 molar ratio, 1.423 using a 4.6:1 molar ratio and 
1.319 using a 9.1:1 molar ratio.
It is difficult to compare the immunoreactivity of these conjugates with conjugates 
prepared using radioactive iodine because, as previously discussed the level of 
conjugation with radioactive iodine is considerably lower. Bolton and Hunter (1973)
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reported that conjugation levels of up to 3 moles of radioactive IBHR per mole of 
insulin, 1.5 moles of IBHR per mole of human growth hormone, and 0.8 moles of 
IBHR per mole of human thyroid stimulating hormone did not adversely affect the 
immunoreactivity of the tracers; but these levels of conjugation are considerably lower 
than those used for non-radioactive IBHR. Alfthan (1986) labelled monoclonal anti­
human chorionic gonadotropin antibodies with two moles of 125I per mole of IgG. 
Preparation of labelled antibodies with higher specific activities resulted in a tracer with 
lower immunoreactivity and lower sensitivity. For comparison purposes, labelling of 
antibodies with NHS-biotin could be considered. NHS-biotin is similar in size to 
IBHR, and the same chemistry is used for the labelling reaction for both molecules. 
Guesdon et al. (1979) prepared biotinylated sheep anti-rabbit IgG antibodies by reaction 
of various molar ratios of NHS-biotin to free amino groups of the antibody. NHS- 
biotin was dissolved in DMF, and reacted with a lOmg/ml solution of antibody in 0.1 M 
NaHC03. Conjugates were prepared using NHS-biotin : amino group ratios of 0.1:1, 
1:1,4:1 and 10:1. The binding capacity of these biotinylated antibodies was not altered 
compared with native antibodies. Kendall etal. (1983) prepared biotinylated goat anti­
mouse IgG antibodies using the same procedure as Guesdon et al. (1979). They 
assessed the immunoreactivity of the conjugates in an ELISA. Conjugation at NHS- 
biotin : amino group ratios of 0.25:1 and 0.5:1 resulted in a loss of sensitivity; ratios 
of 1:1, 2:1, and 4:1 produced usable reagents, with the 1:1 reagent being the most 
sensitive; a ratio of 8:1 produced an undesirable product.
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Figure 4.9 Graph of absorbance at 380nm plotted against concentration of human IgG 
standards assayed in a two-site immunoassay, using antibodies labelled with various 
amounts of EBHR.
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4.3 Summary.
The feasibility of the use of the cerium(IV) - antimony(III) reaction for the detection 
of IBHR-labelled antibodies in an immunoassay for human IgG has been illustrated, 
and the results obtained have been shown to be comparable to those obtained using the 
Sandell-Kolthoff reaction for detection of the IBHR label, or using HRP-labelled 
antibodies. The three assay systems show good agreement with respect to accuracy and 
precision of the standards, and with respect to the results obtained for serum samples 
measured in each assay. The use of HRP-labelled antibodies does, however, enable the 
use of a higher working dilution of the conjugated antibody and measurement of lower 
concentrations of human IgG.
Antibodies were labelled with various levels of IBHR. The relative binding pattern of 
the labelled antibodies was assessed using the BIAcore. The results indicated that 
reduction of the amount of IBHR conjugated to the antibodies led to an increase in the 
binding to antigen, relative to the binding of native antibodies. The immunoreactivity 
of the labelled antibodies was assessed in an immunoassay. Standard curves of 
absorbance plotted against human IgG concentration were prepared for each conjugate. 
Using antibodies labelled with high levels of IBHR (10 to 30 moles of IBHR per mole 
of antibody) human IgG in the range 0.05 to 2pg/ml could be measured. Using 
antibodies labelled with low levels of IBHR (6 moles of IBHR per mole of antibody) 
resulted in a loss of sensitivity, as standards in the range 0.1 to 2pg/ml could be 
measured. The slope of the standard curves increased as the level of iodination was 
increased, but so also did the non-specific binding. A molar ratio of IBHR to free 
amino groups of the antibody of 2.3:1 or 4.6:1 produced conjugates which contained 
18 and 21 moles of IBHR per mole of antibody, respectively, and which could be used 
to measure human IgG in the range 0.05 to 2pg/ml producing standard curves with 
good slope values and low non-specific binding.
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5. USE OF THE AVIDIN-BIOTIN SYSTEM AND OF BISPECIFIC F(ab’)2 
ANTIBODIES.
5.1 Introduction.
In an immunoassay for human IgG, the linear range using IBHR-labelled antibodies 
was 0.05 to 2pg/ml, while using HRP-labelled antibodies the linear range was 0.0064 
to 0.25pg/ml. The HRP-labelled antibodies could be used to measure lower 
concentrations of human IgG. The detection limit of immunoassays is determined by 
several factors, including the quality of the conjugate and the detection system for the 
label (Tijssen, 1985). > The preparation of IBHR-antibody conjugates was previously 
optimised (Section 4.2.2), and so also was the detection system for the IBHR label 
(Section 3.2). Therefore, improvement of the detection limit by modification of the 
design of the immunoassay was investigated. The immunoassay was modified using 
procedures that lead to a high accumulation of label per antigen molecule (Tijssen, 
1985). This chapter describes the use of two such procedures: the avidin-biotin system 
and bispecific F(ab’)2 antibodies.
Avidin is a glycoprotein found in the egg white and tissues of birds, reptiles and 
amphibia. Avidin is a tetramer, consisting of four identical subunits, each of which has 
a binding site for biotin. Biotin, one of the B complex vitamins found in tissue and 
blood, is a co-enzyme for enzymes involved in carboxylation reactions. Avidin binds 
non-covalently to biotin with high affinity (1015 M'1), and the resulting complex is 
extremely stable (Tijssen, 1985). Due to the high affinity and stability, the use of 
avidin-biotin technology has been exploited for many applications, such as affinity 
chromatography, affinity cytochemistry, immunoassays and gene probes (Wilchek and 
Bayer, 1988). The avidin-biotin system can be applied in several ways to 
immunoassays (Avrameas, 1992). In the labelled avidin-biotin (LAB) system, antigen 
is detected by addition of biotinylated antibody, followed by addition of labelled avidin. 
In the bridged avidin-biotin (BRAB) system, antigen is detected by addition of 
biotinylated antibody, followed by addition of native avidin and, finally, addition of 
labelled biotin. This system is based on the fact that due to steric hindrance all four 
binding sites on the avidin are not involved in the interaction with the biotinylated 
antibody. Thus, the remaining sites are free to bind the labelled biotin. The BRAB 
system can be simplified by formation of soluble avidin-labelled biotin complexes, by 
preincubation of labelled biotin with avidin. These complexes are subsequently used 
to analyse biotinylated antibody.
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Immunoassays based on the avidin-biotin system are reported to be in the order of 2 
to 100 fold more sensitive than conventional immunoassays (Avrameas, 1992). This 
is due to several factors. The high affinity of the avidin-biotin binding means that the 
avidin-biotin complex is stable in washing and incubation steps. Biotinylation of 
antibodies, and of some enzymes, has no effect on the biological activity (Guesdon, 
1979). The avidin-biotin system is very versatile. One biotinylated antibody can be 
used as a second antibody in many different immunoassays, and detected using LAB 
or BRAB systems. The high isoelectric point of avidin (pi 10.5) can contribute to non­
specific binding and high background (Avrameas, 1992). This can be overcome by the 
use of streptavidin, a biotin binding protein isolated from Streptomyces avidinii which 
has an isoelectric point of 5.
The use of LAB and BRAB immunoassays for the measurement of human IgG was 
investigated. IBHR-labelled avidin and IBHR-labelled biotin were prepared, and used 
in the LAB and BRAB immunoassays, respectively.
Bispecific F(ab)2 antibodies were also used in an immunoassay to measure human IgG. 
Bispecific antibodies are hybrid antibodies that possess two different Fab’ fragments, 
which are each specific for a different antigen. They may be produced by biological 
or chemical means, and have a variety of potential uses. Bispecific antibodies binding 
to both a target cell and a therapeutic drug can be used in chemotherapy to localise 
large quantities of the drug at the target site, while bispecific antibodies binding to, for 
example, an enzyme and an antigen can be used for enzyme immobilisation in 
immunocytochemistry and EIA (Nolan and O’Kennedy, 1990).
Biological production involves the use of cell fusion techniques. Two hybridomas, 
producing monoclonal antibodies to different antigens, can be fused producing a 
quadroma, or, a hybridoma, producing antibodies to one antigen, can be fused with a 
spleen cell from an animal immunised with the second antigen, producing a trioma 
(Nolan and O’Kennedy, 1990). Both of these methods produce cell lines which secrete 
a mixed population of parental and bispecific antibodies, from which the bispecific 
antibodies can be purified. Milstein and Cuello (1984) reported the use of cell fusion 
techniques to produce hybrid hybridomas secreting bispecific antibodies that could be 
used in immunoassays and immunohistochemistry.
Chemical production of bispecific antibodies involves separation of parental antibodies 
into fragments, and reconstitution of the fragments to produce the bispecific antibody. 
Nisonoff and Mandy (1962) prepared bispecific F(ab’)2 antibodies by chemical means. 
Parental antibodies were treated with pepsin to yield F(ab’)2 fragments, which were
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reduced to Fab’ fragments by the addition of mercaptoethylamine hydrochloride. Fab’ 
fragments from the two parental antibodies were mixed in equal quantities, and random 
reoxidation of the disulphide bonds was achieved in the presence of oxygen. The 
product contained both homodimers and heterodimers of F(ab’)2, although heterodimers 
of dual specificity made up a large proportion of the product.
Other chemical methods have been reported. Brennan et al. (1985) subjected 
antibodies to digestion with pepsin, followed by reduction with 2-mercaptoethylamine, 
in the presence of the dithiol complexing agent sodium arsenite, to yield Fab’ 
fragments. Free thiols on the Fab’ fragments were activated using 5,5’-di-thiobis(2- 
nitrobenzoic acid) to yield Fab’- thionitrobenzoate (TNB) derivatives. One of the Fab’- 
TNB derivatives was reconverted to Fab’-thiol by reduction with 2-mercaptoethylamine, 
and mixed with the other Fab’-TNB derivative to form the bispecific F(ab’)2 antibody. 
To determine whether the chemical manipulations caused alterations in the antigen 
binding site, anti-p-galactosidase F(ab’)2 was prepared, and was carried through the 
procedure. The original and reconstituted F(ab’)2 were tested by ELISA, and no 
significant difference in the performance was observed.
Glennie et al. (1987) also produced F(ab’)2 fragments by digestion with pepsin. These 
were reduced with 2-mercaptoethanol (2-ME) to produce Fab’ fragments (Fab’SH). One 
of the Fab’SH fragments was reacted with o-phenylenedimaleimide, producing 
maleimidated Fab’ (Fab’^ ^ .  The two Fab’ species were mixed at a molar ratio of 
Fab’MAL : Fab’SH of 1:1.3, using low pH and the presence of EDTA, which favours thiol 
and maleimide reaction and minimises the reoxidation of thiol groups. The product 
was reduced with 2-ME and alkylated with iodoacetamide to remove unwanted 
products, such as F(ab’)2 homodimers. The bispecific F(ab’)2 antibodies formed were 
linked by thioether bonds; the proposed structure is shown in Fig 5.1. The bispecific 
F(ab’)2 antibodies were tested in three systems to confirm that the antigen binding sites 
were not altered by the chemical manipulations: they were used to stain cells with the 
fluorescent compound, phycoerythrin; to deliver the plant ribosome inactivating protein, 
saporin, to cells; and to target cells for lysis by cellular effectors.
The work reported in this chapter describes the preparation of bispecific F(ab’)2 
antibodies from goat anti-human IgG antibodies and rabbit anti-BSA antibodies using 
the method of Glennie et al. (1987), and their use as bridging agents between human 
IgG and iodinated BSA in an immunoassay for human IgG.
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Figure 5.1 The proposed structure of the bispecific F(ab’)2 antibody produced by the 
method of Glennie et al. (1987). The structure shown is for a bispecific F(ab’)2 
antibody produced by recombination of Fab’ fragments from mouse antibodies.
The cysteinyl sulphurs of one fragment are joined to carboxyamidomethyl (Q), while 
the cysteinyl sulphurs of the other fragment are joined to o-phenylenedisuccinimide (R) 
which also links the two Fc’ fragments.
5.2 Results and discussion.
5.2.1 The avidin - biotin system.
5.2.1.1 Preparation of IBHR-labelled avidin.
IBHR-labelled avidin was prepared using reaction ratios of 0.15, 0.25, 0.35, 0.45 and 
lmg of IBHR to lmg of avidin. The conjugates were purified and characterised using 
the same procedure as for IBHR-labelled antibodies (Section 4.2.1). The use of lmg 
of IBHR produced an unsuitable conjugate, as the conjugate precipitated on storage 
overnight at 4°C. The amount of IBHR conjugated at each reaction ratio is shown in 
Table 5.1.
The conjugates were tested in a LAB immunoassay for human IgG to determine the 
reaction ratio which would yield a conjugate with suitable activity. The protocol for 
the immunoassay is outlined in a flow diagram in Fig 5.2. BSA was used as the 
blocking protein for this immunoassay, as non-specific binding of avidin to gelatin was 
observed. On addition of IBHR-labelled avidin to wells precoated with 0.5%(w/v) 
gelatin or 1.5%(w/v) BSA, washing, followed by addition of the reagents for the 
cerium(IV) - antimony(III) reaction, average absorbance values of 0.258 and 1.506 
were obtained for the wells precoated with gelatin and BSA, respectively. An 
absorbance value of 1.496 was obtained for control wells.
Biotinylated anti-human IgG antibodies were prepared by reaction of N-hydroxy- 
succinimidobiotin (NHS-biotin) with antibodies at a 2:1 molar ratio, using an estimate 
of 90 free amino groups per goat IgG (Kendall et al., 1983). The free and conjugated 
NHS-biotin were separated by dialysis.
The standard curves of absorbance plotted against human IgG concentration, on a log 
scale, obtained for the conjugates are shown in Fig 5.3. Each of the conjugates could 
be used to measure human IgG in the range 0.05 to 0.5pg/ml. The slope of the graph 
increased as the level of iodination was decreased, from a value of 0.238 using avidin 
labelled with 21 moles of IBHR, to a value of 0.470 using avidin labelled with 12 
moles of IBHR. Since a low amount of IBHR conjugated to avidin led to improved 
performance in the immunoassay, a reaction ratio of 0.15mg IBHR reacted with lmg 
avidin was chosen for use in further work.
The binding of IBHR-labelled avidin to biotinylated antibodies was compared to the 
binding of native avidin, using the BIAcore. Biotinylated antibodies were immobilised 
onto the surface of a sensor chip, and native avidin was passed over the surface. The 
response obtained was taken to represent maximum binding (i.e. 100%). IBHR-labelled 
avidin was passed over the surface; the response was 54% of the maximum binding.
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The reduction in binding activity of labelled avidin may be due to the conjugation of 
IBHR to lysine residues. Gitlin et al. (1987) reported that the lysine residues of avidin 
are involved in the biotin binding site. They modified lysine residues with 1-fluoro- 
2,4-dinitrobenzene, and the biotin binding activity decreased with increasing 
modification. Modification of just one lysine residue per subunit was sufficient to 
destroy biotin binding. Nevertheless, iodination of avidin does not preclude its use in 
assay systems. Cuatrecasas and Hollenberg (1976) prepared radiolabelled avidin using 
IBHR, and reported that the biotin binding activity of the labelled avidin was not 
impaired compared with native avidin. Kulomaa et al. (1979) used avidin iodinated 
by the chloramine T method as a tracer in a radioimmunoassay for chicken avidin and 
Mock and DuBois (1986) used IBHR-labelled avidin to measure biotin concentration 
in plasma and urine samples.
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mg IBHR * moles of IBHR conjugated per 
mole of avidin
0.15 12 (n=3)
0.25 14 (n=3)
0.35 18 (n=l)
0.45 21 (n=l)
* Milligrammes of IBHR reacted with lmg of avidin.
Table 5.1 Conjugates prepared by reaction of avidin with increasing amounts of IBHR.
Coat plates: 10ug/ml anti-human IgG antibodies (100ul/well)
|  2hr 37° C 
Wash
IBlock: 1.5%(w/v) BSA (200ul/well)
 ^ lhr 37° CWash
I
Human IgG standards (100ul/well)
1 lhr 37° CWash
l
Biotinylated anti-human IgG antibodies (100ul/well)
 ^ lhr 37° CWash
IIBHR-labelled avidin (100ul/well)
I 20min RT
Wash
I
Add appropriate substrates 
and read absorbance using Titertek plate reader
Figure 5.2 Flow diagram of the immunoassay using IBHR-labelled avidin. (A detailed 
protocol is given in Section 2.7.3).
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IgG c o n c .  (ug/ml) ® 0 . 1 5 mg 
■ 0 . 2 5 mg 
o 0 .3 5 mg 
♦ 0 .4 5 mg
Figure 5.3 Graph of absorbance at 380nm plotted against concentration of human IgG
standards assayed in an immunoassay using avidin labelled with various amounts of 
IBHR.
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5.2.1.2 Labelled avidin-biotin (L A B ) imm unoassay for human IgG .
Human IgG levels in standards and human serum samples were measured in a LAB 
immunoassay using biotinylated anti-human IgG antibodies and IBHR-labelled avidin. 
The same batch of anti-human IgG antibodies was used for these experiments as for 
the immunoassays using labelled antibodies (Section 4.2.1). The optimum dilution of 
biotinylated anti-human IgG antibodies and IBHR-labelled avidin was determined in 
the immunoassay. Biotinylated antibodies were diluted in the range 1/50 to 1/400. 
The results are shown in Table 5.2. A dilution of 1/200 was chosen as optimum, as 
this gave a large change in absorbance values over the range of IgG standards tested. 
IBHR-labelled avidin was diluted in the range 1/8 to 1/64. The results are shown in 
Table 5.3. A dilution of 1/16 was chosen as optimum.
The standard curve of absorbance plotted against human IgG concentration, on a log 
scale, is shown in Fig 5.4. The linear range of the immunoassay was 0.025 to 0.5jig/ml 
human IgG (r=0.993). The intra- and inter-assay accuracy and precision were 
calculated for the standards. The results are shown in Table 5.4 and Table 5.5. The 
intra-assay mean values were within 91 to 112% of the true values. The inter-assay 
mean values were within 84 to 118% of the true values. The %CV values for all 
standards were less than 10%, with the exception of the intra-assay %CV for the 
O.lpg/ml standard, and the inter-assay %CV for the 0.025pg/ml and 0.05pg/ml 
standards.
The results for the LAB immunoassay can be compared with the results obtained for 
the immunoassays using labelled antibodies (Section 4.2.1). Human IgG standards in 
the range 0.05 to 2pg/ml could be measured using IBHR-labelled antibodies. Thus, the 
assay was improved by the use of IBHR-labelled avidin as lower concentrations of 
human IgG could be measured. However, standards in the range 0.0064 to 0.25pg/ml 
could be measured using HRP-labelled antibodies, and the difference in absorbance 
values between the zero standard and the highest standard was 1.163, which is greater 
than the difference in absorbance values using either IBHR-labelled antibodies (0.666) 
or IBHR-labelled avidin (0.597). The intra- and inter-assay accuracy results were 
better using labelled antibodies than with labelled avidin.
The IgG concentration in five human serum samples was measured in the LAB 
immunoassay, and in immunoassays using IBHR-labelled antibodies and HRP-labelled 
antibodies. The results are shown in Table 5.6. There is good agreement between the 
results obtained in the different immunoassay systems. The results for the samples 
using IBHR-labelled avidin differed from the results using IBHR-labelled antibodies
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by 12% (range 2 to 22%), and from the results using HRP-labelled antibodies by 8% 
(range 1 to 29%). The results obtained using IBHR-labelled antibodies differed from 
the results using HRP-labelled antibodies by 18% (range 6 to 27%). The standard error 
obtained using an HRP label was lower than that obtained using an IBHR label, in 
contrast to the results reported previously for labelled antibodies (Section 4.2.1). 
Different preparations of HRP and IBHR conjugates were used for the previous 
experiments and these experiments, which may account for the difference in the 
standard error.
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H um an Ig G  conc. (jig/m l) D ilution of antibody
1/50 1/100 1/200 1/400
0 1.448 1.495 1.505 1.492
0.05 1.286 1.353 1.336 1.335
0.1 1.194 1.278 1.257 1.248
0.25 1.093 1.186 1.146 1.214
0.5 1.039 1.104 1.110 1.129
Table 5.2 Determination of the optimum dilution of biotinylated antibody. The results 
shown are absorbance values at 380nm.
H um an Ig G  conc. (jig/m l) D ilution of avidin
1/8 1/16 1/32 1/64
0 1.490 1.517 1.501 1.509
0.05 1.359 1.372 1.351 1.362
0.1 1.268 1.243 1.248 1.283
0.25 1.136 1.128 1.186 1.196
0.5 1.006 0.985 1.043 1.099
Table 5.3 Determination of the optimum dilution of IBHR-labelled avidin. The results 
shown are absorbance values at 380nm.
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Figure 5.4 Graph of absorbance at 380nm plotted against concentration of human IgG 
standards assayed in an immunoassay using IBHR-labelled avidin.
The absorbance value for the zero standard was 1.551.
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Human IgG conc. (pg/ml) Mean ± SD % c v
0.025 0.028 ± 0.003 9.1
0.05 0.046 ± 0.004 9.5
0.1 0.091 ± 0.013 14.3
0.25 0.240 ± 0.009 3.9
0.5 0.533 ± 0.035 6.6
Table 5.4 Intra-assay accuracy and precision results for human IgG standards assayed 
in an immunoassay using IBHR-labelled avidin (n=6).
Human IgG conc. (pg/ml) Mean ± SD % c v
0.025 0.029 ± 0.003 10.6
0.05 0.044 ± 0.005 12.0
0.1 0.080 ± 0.014 6.1
0.25 0.245 ± 0.013 8.1
0.5 0.591 ± 0.030 4.9
Table 5.5 Inter-assay accuracy and precision results for human IgG standards assayed 
in an immunoassay using IBHR-labelled avidin (n=7).
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Sam ple A (n = 6 )  
M ean ± SD
B (n =5)  
M ean ±  SD
C (n =5)  
M ean ±  SD
6 11.5 ± 2.5 9.4 ± 1.8 11.3 ± 1.1
7 13.3 ± 1.9 12.6 ± 3.3 13.4 ± 0.7
8 13.7 ± 2.3 13.5 ± 2.3 10.6 ± 1.4
9 15.1 ±4.8 13.1 ± 2.8 15.7 ± 1.7
10 16.3 ± 1.9 12.8 ± 1.0 16.6 ± 1.9
SE 2.7 2.2 1.4
SE is standard error.
Table 5.6 IgG concentration (mg/ml) in human serum samples assayed 
immunoassays using:
(A) IBHR-labelled avidin
(B) IBHR-labelled antibodies
(C) HRP-labelled antibodies.
5.2.1.3 Preparation of IB H R -labelled biotin.
The LAB immunoassay, using IBHR-labelled avidin, can be directly compared with a 
BRAB immunoassay, using IBHR-labelled biotin. IBHR-labelled biotin was prepared 
using two biotin compounds: biotin hydrazide and biotin-LC-hydrazide. The structures 
of some biotin compounds are shown in Fig 5.5. Initially, the reaction of biotin 
hydrazide with IBHR was carried out using a reaction ratio of lmg of IBHR to either 
lmg or 0.75mg of biotin hydrazide, but using these ratios a large amount of precipitate 
was obtained soon after the addition of biotin hydrazide to IBHR. A reaction ratio of 
lmg of IBHR to 0.38mg of biotin hydrazide was therefore used; this corresponds to 
a molar ratio of 1.7:1. The conjugate was purified by TLC. Two TLC methods, 
reported by Horsburgh and Gompertz (1978) and by Evangelatos et al. (1991) for the 
purification of iodinated biotin, were examined to see if they were suitable to use for 
the purification of the IBHR-biotin conjugates prepared for these experiments. 
Horsburgh and Gompertz (1978) prepared N-(6-aminohexyl)-biotinamide, and 
radioiodinated this using IBHR. The iodinated biotin conjugate (IBC) was purified 
using two TLC systems. In the first system a mobile phase of ethyl acetate:glacial 
acetic acid (100:3, v/v) was used; N-(6-aminohexyl)-biotinamide and IBC remained at 
the origin, while IBHR migrated. The biotin compounds were eluted using 50%(v/v) 
ethanol, and applied to the second TLC system in order to separate them. A mobile 
phase of butanol:glacial acetic acid:water (93:5:5, v/v/v) was used. IBC migrated with 
an Rf of 0.38. The area of the chromatogram corresponding to this was removed, and 
the conjugate eluted as before. The conjugate prepared using biotin hydrazide and 
IBHR was applied to these TLC systems. In the first system, IBHR migrated with an 
Rf of 0.21, while biotin hydrazide and the conjugate remained at the origin. In the 
second system, IBHR remained at the origin, while biotin hydrazide and the conjugate 
migrated with Rf’s of 0.11 and 0.16, respectively. This purification procedure was 
considered inconvenient as two TLC systems were required, and poor separation of 
biotin hydrazide and the conjugate was obtained.
Evangelatos et al. (1991) prepared iodinated biotinamide, by reaction of radioiodinated 
tyramine with NHS-biotin, and purified the conjugate by TLC using a mobile phase of 
butanol:2M ammonia:ethanol (3:1:1, v/v/v). Iodinated biotinamide migrated with an 
Rf of 0.67. The area of the chromatogram corresponding to this was scraped off, and 
the conjugate eluted with 50%(v/v) ethanol. The conjugate prepared using biotin 
hydrazide and IBHR was applied to this TLC system. IBHR migrated with an Rf of 
0.24, biotin hydrazide migrated with an Rf of 0.46 and the conjugate migrated with an
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Rf of 0.81. The use of this purification method was preferred as only one TLC 
procedure had to be carried out, and good separation of the conjugate from the 
reactants was obtained.
A conjugate was also prepared by reaction of biotin-LC-hydrazide with IBHR. Biotin- 
LC-hydrazide has a "spacer arm" between the bicyclic ring system and the amino group 
of the side chain. The biotin binding site is deep in avidin, and suboptimal results can 
be obtained in immunoassays if this is not taken into account (Tijssen, 1985). The 
IBHR label is introduced into biotin hydrazide via the amino group, thus any reduction 
in sensitivity due to steric hinderance or engulfment of the iodine label in the binding 
site will be eliminated using biotin-LC-hydrazide. O’Shannessy et al. (1987) used 
biotin-LC-hydrazide for quantification of glycoproteins on electroblots. Glycoproteins 
were labelled with biotin-LC-hydrazide, and after PAGE were transferred onto 
nitrocellulose membranes and detected using HRP-labelled streptavidin. The use of 
biotin-LC-hydrazide proved twice as sensitive as the use of biotin hydrazide for the 
detection of a r acid glycoprotein.
The reaction of IBHR and biotin-LC-hydrazide was carried out using a reaction ratio 
of lmg of IBHR to 0.55mg of biotin-LC-hydrazide, which corresponds to a molar ratio 
of 1.7:1. The conjugate was purified by TLC; IBHR migrated with an Rf of 0.24, 
biotin-LC-hydrazide migrated with an Rf of 0.50 and the conjugate migrated with an 
Rf of 0.84.
The area of the TLC corresponding to the appropriate compounds was scraped off, and 
eluted with 50%(v/v) ethanol. The solutions were evaporated to lOOjil, and made up 
to 1ml with 0.03M phosphate buffer, pH 7.3. Appropriate dilutions were prepared and
added to plates that had been precoated with avidin. After washing, the presence of 
IBHR was detected using the cerium(IV) - antimony(III) reaction. The results for 
biotin hydrazide and biotin-LC-hydrazide are shown in Table 5.7 and Table 5.8, 
respectively. In both cases, only the area corresponding to the conjugate displayed 
catalytic activity, confirming that it is IBHR-labelled biotin as it contains biotin that 
can bind to avidin and IBHR that can catalyse the cerium(IV) - antimony(III) reaction. 
The concentration of the purified conjugates was measured in the cerium(IV) - 
antimony(III) microassay and the colorimetric assay for biotin, and the percentage yield 
of conjugate was calculated. Low yields were obtained: the average yield of conjugate 
was 15% using biotin hydrazide and 11% using biotin-LC-hydrazide. The solubility 
of the biotin compounds in borate buffer was poor; the highest concentration that 
would stay in solution was 1.5mg/ml. This limited the amount of biotin that could be
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reacted with IBHR, and therefore the amount of conjugate produced. The volume of 
the two reactants for the conjugation reaction had to be low, as the purification by TLC 
could be cumbersome if carried out on large volumes.
(b)
H
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Figure 5.5 The structures o f some biotin compounds (a) biotin (b) biotin hydrazide 
(c) biotin-LC-hydrazide (biotin aminocaproyl hydrazide) (d) NHS-biotin.
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Sample Dilution Abs. (380nm)
Control - 1.258
IBHR 1/10 1.246
Biotin hydrazide 1/10 1.236
Conjugate 1/10 0.852
1/20 0.986
1/40 1.202
Table 5.7 Spots from a TLC plate, corresponding to IBHR, biotin hydrazide and 
IBHR-labelled biotin, were added to an avidin coated plate. After incubation and 
washing, the cerium(IV) - antimony (IE) microassay was used to detect the presence of 
IBHR.
The control is wells to which 0.03M phosphate buffer, pH 7.3, was added.
Sample Dilution Abs. (380nm)
Control - 1.254
IBHR 1/10 1.249
B iotin-LC-hydrazide 1/10 1.255
Conjugate 1/10 1.039
1/20 1.172
1/40 1.244
Table 5.8 Spots from a TLC plate, corresponding to IBHR, biotin-LC-hydrazide and 
IBHR-labelled biotin, were added to an avidin coated plate. After incubation and 
washing, the cerium(IV) - antimony(III) microassay was used to detect the presence of 
IBHR.
The control is wells to which 0.03M phosphate buffer, pH 7.3, was added.
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5.2.1.4 Bridged avidin-biotin (BRAB) immunoassay for human IgG.
Human IgG levels were measured in a BRAB immunoassay, using biotinylated anti­
human IgG antibodies, avidin and IBHR-labelled or HRP-labelled biotin. A flow 
diagram of the protocol is shown in Fig 5.6. The optimum dilution of biotinylated 
antibodies was determined previously (Section 5.2.1.2). The optimum dilution of 
avidin was determined using avidin diluted in the range 1/50 to 1/400, and biotinylated 
HRP. The results are shown in Table 5.9. A dilution of 1/50 was chosen as optimum. 
The standard curves of absorbance plotted against human IgG concentration, on a log 
scale, obtained for IBHR-biotin conjugates prepared using biotin hydrazide and biotin- 
LC-hydrazide are shown in Fig 5.7. The graphs were linear in the range 0.05 to 
2pg/ml for both conjugates (r=0.993 for the conjugate prepared using biotin hydrazide, 
r=0.995 for the conjugate prepared using biotin-LC-hydrazide). However, the 
difference in absorbance values between the zero standard and the 2jjg/ml standard was 
only 0.096 for the conjugate prepared using biotin hydrazide, and 0.101 for the 
conjugate prepared using biotin-LC-hydrazide. Lower concentrations of human IgG 
could be measured using the LAB immunoassay (0.025 to 0.5jag/ml), and the difference 
in absorbance values between the zero standard and the 0.5pg/ml standard was 0.597. 
The immunoassay using IBHR-labelled antibodies had the same linear range as the 
BRAB immunoassay, but the difference in absorbance values between the zero standard 
and the 2pg/ml standard was 0.666.
As a check on the BRAB immunoassay procedure, the immunoassay was carried out 
using biotinylated HRP. A standard curve of absorbance plotted against human IgG 
concentration, on a log scale, is shown in Fig 5.8. The graph was linear in the range 
0.05 to 2jag/ml (r=0.989), thus the measuring range of the immunoassay was the same 
using either an HRP or an IBHR label. The difference in absorbance values between 
the zero standard and the 2pg/ml standard was 1.030. The intra-assay and inter-assay 
accuracy and precision results for the standards are shown in Table 5.10 and Table 
5.11, respectively. The intra-assay mean values were within 81 to 114% of the true 
values; the inter-assay mean values were within 88 to 128% of the true values. The 
intra-assay %CV values for all standards were less than 10%, while the inter-assay 
%CV values were greater than 10% for the 0.25pg/ml, lpg/ml and 2pg/ml standards. 
The intra-assay and inter-assay accuracy results obtained using IBHR-labelled avidin 
in the LAB immunoassay were better than those obtained using biotinylated HRP in 
the BRAB immunoassay.
The poor results obtained using IBHR-labelled biotin may be improved by increasing 
the amount of label present. A biotin-thyroxine conjugate could be used, which would 
contain four times the amount of iodine compared with IBHR-labelled biotin. Smith- 
Palmer et al. (1993), reported the preparation of a biotin-thyroxine conjugate by 
reaction of NHS-biotin with thyroxine methyl ester. Purification of IBHR-labelled 
biotin by TLC meant that only small reaction volumes could be used, resulting in low 
yields of conjugate from any single conjugation reaction. Alternative purification 
methods could be used. For example, Wai Chan and Bartlett (1986) used gel filtration 
to purify a conjugate prepared by reaction of N-(6-aminohexyl)-biotinamide and IBHR, 
and Smith etal. (1987) used HPLC to purify iodinated biotinylglycyltyrosine, prepared 
by reaction of NHS-biotin with glycyltyrosine which had been radioiodinated using 
iodobeads.
5.2.1.5 Comparison of LAB and BRAB immunoassays.
LAB and BRAB immunoassays are reported to be in the order of 2 to 100 fold more 
sensitive than conventional immunoassays (Avrameas, 1992). For these experiments, 
the use of IBHR-labelled avidin in the LAB immunoassay enabled measurement of 
lower concentrations of human IgG than the use of IBHR-labelled antibodies in a two- 
site immunoassay, but the use of IBHR-labelled biotin in the BRAB immunoassay did 
not. The use of biotinylated HRP did not improve the measuring range of the BRAB 
immunoassay, but did give a greater difference in absorbance values between the zero 
standard and the highest standard than any of the immunoassays using an IBHR label. 
Reports in the literature of the sensitivity of LAB systems compared to BRAB systems 
differ. Kendall et al. (1983) compared a standard ELISA using alkaline phosphatase 
(AP) labelled antibodies for detection of mouse antibody to hepatitis B surface antigen, 
with a LAB ELISA using AP-labelled avidin and a BRAB ELISA using biotinylated 
AP. The LAB ELISA was 82 times more sensitive than the standard ELISA, while the 
BRAB ELISA was 23 times more sensitive than the standard ELISA. Vilja et al.
(1985) used the avidin-biotin system in an ELISA for lactoferrin. The use of HRP- 
labelled avidin in the LAB ELISA enabled measurement of O.lng/ml lactoferrin. The 
use of biotinylated HRP in the BRAB ELISA enabled measurement of 0.2ng/ml 
lactoferrin. Both the LAB and BRAB systems were more sensitive than RIA. 
However, Yolken et al. (1983) found that the BRAB system was more sensitive than 
the LAB system, when used for the detection of bacterial antigens. For example, a 
LAB ELISA using AP-labelled avidin for measurement of antigen derived from
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Haemophilus influenzae had a detection limit of 0.64ng/ml, while a BRAB ELISA 
using biotinylated HRP had a detection limit of 0.16ng/ml.
The BRAB system has greater potential for increased sensitivity than the LAB system. 
Biotinylation of many proteins has no effect on the activity of the protein (Guesdon et 
al., 1979), and a second amplification step is included in the BRAB assay. 
Nevertheless, there are several factors which may have led to increased sensitivity in 
LAB immunoassays compared with BRAB immunoassays. The high affinity of the 
avidin-biotin binding means that the complex is stable in the extra wash and incubation 
steps required in BRAB immunoassays, but some reversal of antibody-antigen binding 
may occur (Kendall et al., 1983). The formation of large lattices in BRAB 
immunoassays on the binding of avidin-labelled biotin complexes to biotinylated 
antibody may cause steric hindrance (Vilja et al., 1985). Also, the biotinylation of AP 
adversely affects the enzyme activity (Guesdon et al., 1979).
For the experiments reported here, iodination of avidin was shown to decrease the 
biotin binding activity, therefore, it would be expected that the results for the BRAB 
immunoassay would be better than the LAB immunoassay. However, in the BRAB 
immunoassay only one IBHR molecule would be bound per avidin molecule, while in 
the LAB immunoassay more than this would be bound as, on average, 12 moles of 
IBHR were conjugated per mole of avidin.
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Coat plates: 10ug/ml anti-human IgG antibodies (100ul/well)
i 2hr 37° C 
Wash
i
Block: 1.5%(w/v) BSA (200ul/well)
J' lhr 3 7 °C Wash
I
Human IgG standards (100ul/well)
I lhr 37° C 
Wash
I
Biotinylated anti-human IgG antibodies (100ul/well)
I lhr 37° C 
Wash
IAvidin (100ul/well)
 ^ 20min RT Wash
I
Labelled biotin (lOOul/well)
1 20min RT 
Wash
i
Add appropriate substrates 
and read absorbance using Titertek plate reader
Figure 5.6 Flow diagram of the immunoassay using IBHR-labelled biotin and
biotinylated HRP. (A detailed protocol is given in Section 2.8.4).
158
Human IgG conc. (Mg/ml) Dilution of avidin
1/50 1/100 1/200 1/400
0 0.108 0.078 0.079 0.073
0.05 0.154 0.130 0.125 0.125
0.1 0.186 0.166 0.160 0.155
0.25 0.404 0.314 0.270 0.263
0.5 0.665 0.566 0.477 0.388
1 0.994 0.827 0.683 0.491
2 1.108 0.956 0.794 0.521
Table 5.9 Determination of the optimum dilution of avidin. The results shown are 
absorbance values at 405nm.
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Figure 5.7 Graph of absorbance at 380nm plotted against concentration of human IgG 
standards assayed in an immunoassay using IBHR-biotin conjugate.
(A) Conjugate prepared using biotin hydrazide.
(B) Conjugate prepared using biotin-LC-hydrazide.
The absorbance values for the zero standards were 1.464 using the conjugate prepared 
using biotin hydrazide and 1.460 using the conjugate prepared using biotin-LC- 
hydrazide.
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Figure 5.8 Graph of absorbance at 405nm plotted against concentration of human IgG 
standards assayed in an immunoassay using biotinylated HRP.
The absorbance value for the zero standard was 0.017.
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Human IgG conc. (pg/ml) Mean ± SD % c \
0.05 0.06 ± 0.004 6.4
0.1 0.11 ± 0.01 7.1
0.25 0.20 ± 0.01 5.6
0.5 0.50 ± 0.04 8.3
1 1.14 ± 0.08 7.4
2 1.90 ± 0.07 3.5
Table 5.10 Intra-assay accuracy and precision results for human IgG standards 
assayed in an immunoassay using biotinylated HRP (n=8).
Human IgG conc. fag/ml) Mean ± SD % c v
0.05 0.05 ± 0.01 9.3
0.1 0.11 ±0 .01 8.4
0.25 0.22 ± 0.02 10.2
0.5 0.51 ± 0.04 7.5
1 1.28 ± 0.15 12.0
2 1.85 ± 0.20 10.6
Table 5.11 Inter-assay accuracy and precision results for human IgG standards assayed 
in an immunoassay using biotinylated HRP (n=5).
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5.2.2 Bispecific F(ab’)2 antibodies.
5.2.2.1 Preparation of bispecific F(ab’)2 antibodies.
Bispecific F(ab’)2 antibodies, with the capability to bind to human IgG and iodinated 
BSA, were produced using goat anti-human IgG and rabbit anti-BSA antibodies. Goat 
anti-human IgG antibodies were purchased as affinity isolated antibodies. Rabbit anti- 
BSA antibodies were purified from rabbit antiserum by ammonium sulphate 
precipitation, followed by affinity chromatography using CNBr-activated Sepharose to 
which BSA had been coupled. The purity of goat and rabbit antibodies was assessed 
using SDS-PAGE (Fig 5.9a). A single band was obtained for both antibodies, with an 
apparent molecular weight of 195kDa.
Bispecific F(ab’)2 antibodies were prepared by the method of Glennie et al. (1987), and 
were purified by affinity chromatography. The final performance of bispecific 
antibodies in an immunoassay depends on the absence of parental antibodies, as these 
may interfere in the binding of the bispecific antibodies to die antigen by displacement 
of the bispecific antibodies (Bugari et al., 1990). Takahashi et al. (1991) used 
bispecific antibodies, produced from hybridomas secreting antibodies to hCG and 
urease, in a two-site immunoassay for hCG. Using unpurified bispecific antibodies (i.e. 
parental antibodies were still present) the sensitivity was equivalent to that obtained in 
an immunoassay using anti-hCG antibodies conjugated to urease; the sensitivity was 
enhanced using bispecific antibodies purified by HPLC.
The yield o f bispecific F(ab’)2 antibodies was low. The procedure was initially carried 
out using 1.5mg of parental antibodies, resulting in a yield of only 1.2%. The 
procedure was repeated using 5mg of parental antibodies, resulting in a yield of 11.1%. 
Glennie et al. (1987) used 10 to 15mg of parental antibodies, and obtained bispecific 
F(ab’)2 of between 50 to 70% of the final product. However, Cook and Wood (1994) 
used the method of Glennie et al. (1987) and reported a yield of only 7%. The low 
yield could be due to the different susceptibilities of antibodies to digestion by pepsin. 
Glennie et al. (1987) carried out pepsin digestion on two different mouse monoclonal 
antibodies; one antibody yielded greater than 70% of F(ab’)2> while the other yielded 
50%. Cook and Wood (1994) carried out pepsin digestion on four mouse monoclonal 
antibodies; only two of these produced sufficient F(ab’)2 for production of bispecific 
F(ab’)2. The number of purification steps required during the production of the 
bispecific antibodies may also contribute to the low yield, as protein will be lost during 
dialysis and chromatography steps.
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The purity and molecular weight of the bispecific F(ab’)2 antibodies were checked by 
SDS-PAGE (Fig 5.9b). A single band was obtained, with an apparent molecular 
weight of 84kDa. The approximate molecular weight of F(ab’)2 would be lOOkDa. 
The bispecific F(ab’)2 may have a lower molecular weight than expected due to 
dissociation of the goat light chain, yielding a bispecific F(ab’)2 antibody composed of 
rabbit light chain - rabbit heavy chain - goat heavy chain. Dissociation of the rabbit 
light chain is unlikely to occur, as the maleimidation reaction may lead to intra­
molecular cross-linking of the light chain to the heavy chain by a thioether bond 
(Glennie et a i ,  1987).
The presence of goat Fab’ fragments and rabbit Fab’ fragments of the bispecific F(ab’)2 
was checked by ELISA (Table 5.12). The ELISA confirms the presence of goat Fab’ 
and rabbit Fab’ fragments, and demonstrates that both Fab’ fragments have retained 
antigen binding capacity.
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(a) Lane 1 Lane 2  Lane 3
195kDa
112kDa
84kDa
63kDa
52.5kDa ->
35kDa
32kDa
(b ) Lane 1 Lane 2
195kDa
112kDa
84kDa
63kDa
52.5kDa
35kDa
32kDa
*
Figure 5.9 SDS-PAGE gels obtained for:
(a) molecular weight marker (lane 1), affinity purified goat anti-human IgG antibodies 
(lane 2), and affinity purified rabbit anti-BSA antibodies (lane 3).
(b) molecular weight marker (lane 1), and bispecific F(ab’)2 antibodies (lane 2).
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Sample Abs. (405nm)
(a) (b)
Control 0.154 0.184
Bispecific F(ab’)2 antibodies 1.185 1.056
Goat anti-human IgG antibodies 0.217 0.089
Rabbit anti-BSA antibodies 0.208 0.197
Table 5.12 ELISA to detect the presence of goat Fab’ and rabbit Fab’ fragments of 
the bispecific F(ab’)2 antibodies.
(a) Microtitre plates were coated with human IgG. After washing and blocking, 
antibody samples were added. After washing, HRP-labelled anti-rabbit IgG antibodies 
were added.
(b) Microtitre plates were coated with BSA. After washing and blocking, antibody 
samples were added. After washing, HRP-labelled anti-goat IgG antibodies were 
added.
The control is wells to which 0.03M phosphate buffer, pH 7.3, was added.
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5.2.2.2 Immunoassay for human IgG using bispecific F(ab’)2 antibodies.
Bispecific F(ab’)2 antibodies were used in an immunoassay for the measurement of 
human IgG concentration. The protocol for the immunoassay is outlined in a flow 
diagram in Fig 5.10. The immunoassay was initially performed using IBHR-labelled 
BSA; the standard curve of absorbance plotted against human IgG concentration, on 
a log scale, is shown in Fig 5.11. The graph was linear in the range 0.25 to 2pg/ml 
human IgG (r=0.990), but the difference in absorbance values between the zero 
standard and the 2pg/ml standard was only 0.059. This may be due to the low amount 
of IBHR label present, as on average just 15 moles of IB HR were conjugated per mole 
of BSA. BSA contains 19 free amino groups (Schipper et al., 1991) to which IBHR 
can be conjugated, which is low compared with goat antibodies which have 90 free 
amino groups. In order to introduce more iodine label into BSA, IBHR-labelled BSA 
was subjected to iodination by the chloramine T method to introduce iodine into the 
tyrosine residues. Iodinated BSA prepared in this way had, on average, 40 moles of 
iodine conjugated per mole of BSA.
The binding of rabbit anti-BSA antibodies to iodinated BSA was assessed using the 
BIAcore. Anti-BSA antibodies were immobilised onto a sensor chip. Native BSA was 
passed over the surface of the chip, and the response obtained was taken to represent 
maximum binding (i.e. 100%). IBHR-labelled BSA and BSA, iodinated by the IBHR 
and chloramine T iodination methods, were passed over the surface of the chip, and the 
response obtained was expressed as a percentage of the maximum binding. IBHR- 
labelled BSA gave 104% of the maximum binding; BSA, iodinated by the IBHR and 
chloramine T iodination methods, gave 112% of the maximum binding. Native BSA 
was reapplied at the end of the experiment; 97% of the maximum binding was 
obtained. Iodination of BSA does not have an adverse effect on the binding to anti- 
BSA antibodies.
BSA, iodinated by the IBHR and chloramine T iodination methods, was used in the 
immunoassay for measurement of human IgG. The standard curve of absorbance 
plotted against human IgG concentration, on a log scale, is shown in Fig 5.11. The 
graph was linear in the range 0.1 to 2pg/ml human IgG (r=0.997), thus the use of BSA, 
iodinated by the IBHR and chloramine T iodination methods, enabled measurement of 
slightly lower concentrations of human IgG compared with the use of IBHR-labelled 
BSA. However, the use of IBHR-labelled antibodies (linear range 0.05 to 2pg/ml) and 
IBHR-labelled avidin (linear range 0.025 to 0.5pg/ml) enabled measurement of lower 
concentrations of human IgG. Also, using BSA, iodinated by the IBHR and
167
chloramine T iodination methods, the difference in absorbance values between the zero 
standard and the 2jig/ml standard was only 0.123.
In order to check the performance of the bispecific F(ab’)2 antibodies, the immunoassay 
was carried out using HRP-labelled BSA. The standard curve of absorbance plotted 
against concentration, on a log scale, is shown in Fig 5.12. The graph was linear in 
the range 0.0125 to lpg/ml (r=0.995), thus enabling measurement of lower 
concentrations of human IgG compared with the use of IBHR-labelled antibodies and 
IBHR-labelled avidin. The intra-assay and inter-assay accuracy and precision results 
for the standards are shown in Table 5.13 and Table 5.14. The intra-assay mean values 
were within 92 to 110% of the true values, while the inter-assay mean values were 
within 82 to 110% of the true values. The intra- assay %CV values were greater than 
10% for the 0.05pg/ml and the 0.25pg/ml standards, while the inter-assay %CV values 
were greater than 10% for the 0.0125jig/ml and the O.lpg/ml standards. Overall, the 
intra- and inter-assay accuracy results were better than those obtained using labelled 
antibodies or labelled avidin. The linear range obtained for the bispecific F(ab’)2 
antibodies using HRP-labelled BSA shows good comparison with that obtained using 
HRP-labelled antibodies (linear range 0.0064 to 0.25pg/ml). This illustrates that the 
bispecific F(ab’)2 antibodies can be successfully applied to the immunoassay, and 
indicates that the poor results obtained using iodinated BSA are possibly due to the 
iodine label. The cerium(IV) - antimony(III) reaction can only detect a percentage of 
the iodine present in iodinated compounds (Section 3.2.3), which limits the sensitivity 
of the immunoassay using iodinated BSA. Better results may be obtained using a 
protein which could be more heavily iodinated than BSA. For example, thyroglobulin 
which has 90 free amino groups (Schipper et al., 1991) could be heavily labelled with 
IBHR, and used in the immunoassay with bispecific F(ab’)2 antibodies produced from 
anti-human IgG and anti-thyroglobulin antibodies.
There are several advantages to the use, in immunoassays, of bispecific F(ab’)2 
antibodies with one binding site for the antigen and one binding site for the label. 
Immobilisation of the label is achieved without the need for chemical modification of 
the antibody by covalent attachment of the label. Labelling antibodies with enzymes 
can alter the activity of both the antibody and the enzyme, and antibody-enzyme 
conjugates are often less stable than the unconjugated species (Takahashi et al., 1991). 
Iodination of antibodies has been shown to alter the antigen binding activity, and the 
performance in an immunoassay (Section 4.2.2). Production of bispecific F(ab’)2 
antibodies requires chemical modification of antibodies, but these modifications are site
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specific. Using the method of Glennie et al. (1987) modification is carried out at the 
hinge region of the antibodies away from the antigen binding sites. Therefore, the 
antigen binding capacity should be unaffected.
There are several examples in the literature of the successful use of bispecific 
antibodies for immobilisation of the label in immunoassays. Bispecific antibodies were 
produced by fusion of hybridomas and by chemical means, by Gorog et al. (1989). 
The bispecific antibodies reacted with carcinoembryonic antigens (CEA) and with P- 
galactosidase, and were used in a homogeneous immunoassay for measurement of 
CEA. Bispecific antibodies produced by fusion of hybridomas have been used by 
several workers. Bugari et al. (1990) used bispecific antibodies to human lutropin and 
(3-galactosidase in a two-site immunoassay for the measurement of lutropin, which had 
a sensitivity comparable to commercial RIA and IRMA kits. Takahashi et al. (1991) 
detected 15mIU/ml of hCG using bispecific antibodies reacting with hCG and urease. 
The detection limit was 25mIU/ml using urease-labelled anti-hCG antibodies. 
Bispecific antibodies reacting with human interferon-a-2 and HRP were used by 
Kontsekova et al. (1992) in a two-site ELISA to measure interferon-a-2 levels of 
O.lng/ml, which was almost the same sensitivity as an ELISA using HRP-labelled 
antibodies. Stratieva-Taneeva et al. (1993) used bispecific antibodies binding both 
interleukin-2 (IL2) and HRP for the analysis of recombinant IL2 in both direct and 
competitive EIAs. The experiments reported in this chapter illustrated that bispecific 
F(ab’)2 antibodies, with one binding site for the analyte and one binding site for a 
protein conjugated to the label, could be successfully used to measure human IgG. The 
use of HRP-labelled BSA illustrated that the bispecific antibodies could produce 
comparable results to a conventional immunoassay using HRP-labelled antibodies, and 
could improve the results using IBHR-labelled antibodies. The poor results obtained 
using IBHR-labelled BSA were possibly due to problems with detection of the IB HR 
label.
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Coat plates: lOug/ml anti-human IgG antibodies (lOOul/well)
I 2hr 37° C 
Wash
I
Block: 0.5%(w/v) gelatin (200ul/well)
I lhr 37° CWash
1Human IgG standards (lOOu 1/well)
i  lhr 37° C
Wash
I
Bispedfic F(ab02 antibodies (lOOul/well)
I lhr 37° CWash
1Labelled BSA (lOOul/well)
J' 30min 37° CWash
I
Add appropriate substrates 
and read absorbance using Titertek plate reader
F ig u re  5 .10  Flow diagram of the immunoassay using bispecific F(ab’)2 antibodies. (A 
detailed protocol is given in Section 2.9.3).
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Figure 5.11 Graph of absorbance at 380nm plotted against concentration of human IgG 
standards assayed in an immunoassay using bispecific F(ab’>2 antibodies. The 
antibodies were detected using:
(A) IBHR-labelled BSA
(B) BSA, iodinated using the IBHR and chloramine T methods of iodination.
The absorbance values for the zero standards were 1.500 using IBHR-labelled BSA and 
1.502 using BSA, iodinated using the IBHR and chloramine T methods of iodination.
171
u>©
»■O<
IgG c o n e ,  (ug/ml)
Figure 5.12 Graph of absorbance at 405nm plotted against concentration of human IgG 
standards assayed in an immunoassay using bispecific F(ab’)2 antibodies and 
HRP-Iabelled BSA.
The absorbance value for the zero standard was 0.165.
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Human IgG conc. (pg/ml) Mean ± SD % c v
0.0125 0.014 ± 0.001 7.3
0.025 0.023 ± 0.001 5.7
0.05 0.047 ± 0.008 17.0
0.1 0.095 ± 0.003 3.4
0.25 0.243 ± 0.038 15.5
0.5 0.535 ± 0.002 0.4
1 1.014 ± 0.081 8.0
Table 5.13 Intra-assay accuracy and precision results for human IgG standards 
assayed in an immunoassay using bispecific F(ab’)2 antibodies and HRP-labelled BSA 
(n=8).
Human IgG conc. (jig/ml) Mean ± SD % c v
0.0125 0.013 ± 0.002 11.3
0.025 0.021 ± 0.001 2.9
0.05 0.049 ± 0.005 10.0
0.1 0.110 ± 0.013 12.0
0.25 0.262 ± 0.018 6.8
0.5 0.528 ± 0.036 6.9
1 0.986 ± 0.028 2.8
Table 5.14 Inter-assay accuracy and precision results for human IgG standards assayed 
in an immunoassay using bispecific F(ab’)2 antibodies and HRP-labelled BSA (n=4).
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5.3 Summary.
The avidin-biotin system and bispecific F(ab’)2 antibodies were used in immunoassays 
for the measurement of human IgG. A LAB immunoassay, using biotinylated anti­
human IgG antibodies and IBHR-labelled avidin, was set up. Avidin was labelled with 
various levels of IBHR; a reduction in the amount of IBHR conjugated to avidin led 
to improved performance of the labelled avidin in the immunoassay. Human IgG 
standards in the range 0.025 to 0.5pg/ml were measured using this immunoassay, which 
is an improvement to the measuring range for the immunoassay using IBHR-labelled 
antibodies (0.05 to 2pg/ml). A BRAB immunoassay, using biotinylated anti-human 
IgG antibodies, avidin and IBHR-labelled biotin, was also set up. IBHR was 
conjugated to two biotin compounds; biotin hydrazide and biotin-LC-hydrazide. The 
conjugates were used in the BRAB immunoassay to measure human IgG standards in 
the range 0.05 to 2pg/ml, but a very small difference in absorbance values between the 
zero standard and the 2pg/ml standard was obtained. The performance of the BRAB 
immunoassay was checked using biotinylated HRP. The same range of human IgG 
standards could be measured using biotinylated HRP as could be measured using 
IBHR-labelled biotin, but a greater difference in absorbance values between the zero 
standard and the 2pg/ml standard was obtained with biotinylated HRP. The use of the 
LAB immunoassay enabled measurement of lower concentrations of human IgG than 
was possible using either IBHR-labelled antibodies in a conventional immunoassay or 
using the BRAB immunoassay.
Bispecific F(ab’)2 antibodies, reacting with human IgG and BSA, were prepared by a 
chemical method. These antibodies were used as bridging agents between human IgG 
and iodinated BSA, in an immunoassay for human IgG. Using IBHR-labelled BSA, 
human IgG standards in the range 0.25 to 2pg/ml were measured. In order to increase 
the amount of label, the tyrosine residues on IBHR-labelled BSA were iodinated by the 
chloramine T method. Iodinated BSA prepared in this way could be used to measure 
standards in the range 0.1 to 2pg/ml. In both cases, a very small difference in 
absorbance values was obtained between the zero standard and the 2pg/ml standard. 
The performance of the bispecific F(ab’)2 antibodies was checked using HRP-labelled 
BSA; human IgG standards in the range 0.0125 to lpg/ml could be measured, which 
is lower than the measuring range of the immunoassay using IBHR-labelled antibodies. 
This indicates that the bispecific F(ab’)2 antibodies functioned effectively as bridging 
agents between human IgG and BSA. The poor results obtained using iodinated BSA 
were possibly due to the detection of the iodine label. The cerium(IV) - antimony(III)
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reaction can only detect a percentage of the iodine present in iodinated compounds, 
which limits the sensitivity of the detection of iodinated BSA. The use of a protein 
that could be more heavily iodinated than BSA could possibly lead to an improvement 
in the immunoassay results.
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6. MEASUREMENT OF THYROXINE.
6.1 Introduction.
The thyroid gland secretes the hormones thyroxine (T4) and 3 ’,3,5-tri-iodothyronine 
(T3). (The structures of the hormones are shown in Fig 3.8) The hormones are 
synthesised by iodination of tyrosine residues of thyroglobulin, a glycoprotein in the 
follicles of the thyroid gland. Thyroglobulin is not biologically active, but on 
proteolysis releases the hormones into the blood. T4 is produced in much larger 
quantities than T3. The mean T4 concentration in normal human serum is llln M , 
while the mean T3 concentration is just 1.82nM (Wiersinga and Chopra, 1982). 
However, T3 is the more potent hormone and is five to ten times more active than T4. 
The primary function of the hormones is to increase the basal metabolic rate and 
oxygen consumption in many tissues, and they play an important role in the maturation 
of brain and bone. Hypothyroidism, a deficiency in T4, is characteristic of the disease 
myxedema. A deficiency of T4 during development results in retarded mental 
development and bone growth. Hyperthyroidism, excessive secretion of T4, is 
responsible for Graves’ disease or exophthalmic goitre. In hypothyroidism, serum T3 
levels are decreased to a lesser extent relative to the decrease in T4 levels, while in 
hyperthyroidism, T3 levels are increased to a greater extent relative to the increase in 
T4 (Wiersinga and Chopra, 1982).
A large proportion of the T4 in the blood circulates tightly bound to the serum proteins 
thyroxine-binding globulin (TBG), thyroxine-binding pre-albumin (TBPA) and albumin. 
The unbound T4 (free T4) represents only a small amount (<0.03%) of the total T4. 
Free T4 is the physiologically active component, whereas the protein bound fraction 
represents a reservoir of the hormone with which the free fraction is in dynamic 
equilibrium (Liewendahl, 1990). In order to measure the total T4 concentration in 
serum the binding of T4 to serum proteins can be blocked using several agents, for 
example, 8-anilino-l-naphthalenesulphonic acid, thiomerosal or sodium salicylate 
(Wiersinga and Chopra, 1982). Mean free T4 concentrations in the region of 25pM 
have been reported (Liewendahl et al., 1990). Total T4 concentration falls within the 
range 50 to 150nM in euthyroid patients; T4 serum concentrations are lower than 50nM 
in hypothyroid patients and higher than 150nM in hyperthyroid patients.
Historically, T4 concentration was estimated by measurement of the iodine content in 
a protein precipitate of serum (serum protein bound iodine) and by in vivo radioiodine 
tracer tests, but these methods were subject to interference from iodine-containing
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drugs and non-hormonal iodine (Liewendahl, 1990). In the 1960s competitive 
saturation analysis, based on the use of TBG, was introduced for measurement of T4. 
The assay was based on competition between labelled and unlabelled T4 for binding 
to TBG, similar to RIA, but as the separation of bound and free fractions was by 
electrophoresis the method was unsuitable for routine use (Liewendahl, 1990). It was 
not until the 1970s that RIAs for T4 were developed, because of the problems in raising 
polyclonal antibodies to small haptens. Since then, RIA has been widely used for the 
measurement of T4. 125I can be used as an internal label in the T4 molecule, providing 
a tracer with high specific activity. In the 1980s nonisotopic T4 immunoassays using 
labels such as enzymes, fluorescent compounds and chemiluminescent compounds, 
were introduced. As non-isotopic methods can be automated, their use for 
measurement of T4 will probably become widespread in the future.
This chapter describes an immunoassay for T4 which uses the four iodine atoms present 
in T4 as the label. Anti-T4 antibodies immobilised onto microtitre plates are used to 
capture T4, and the iodine is detected using the cerium(IV) - antimony(HI) reaction.
6.2 Results and discussion.
6.2.1 Determination of T4 using the cerium(IV) - antimony (HI) microassay.
T4 standards were measured using the cerium(IV) - antimony(III) microassay. A graph 
of absorbance plotted against concentration of T4 is shown in Fig 6.1. The graph was 
linear in the range 20 to lOOnM T4 (r=0.995). The intra-assay accuracy and precision 
(Table 6.1) and inter-assay accuracy and precision (Table 6.2) were calculated for the 
T4 standards. The intra- and inter-assay mean values were within 94 to 108% of the 
true values, with the exception of the 40nM standard which had an inter-assay mean 
value of 114% of the true value. The %CV values for all standards were less than 
10%. Clarke (1991) measured T4 in the range 32 to lOOOnM in the Sandell-Kolthoff 
reaction, using 0.075M arsenious acid and 0.02M eerie ammonium sulphate diluted in 
10% (v/v) H N03 with measurement of the absorbance at 405nm. The detection of 
lower concentrations of T4 using the cerium(IV) - antimony(III) reaction may be due 
to the measurement of the absorbance at 380nm, a wavelength closer to the absorbance 
maximum for cerium(IV) than 405nm (Section 3.2.1).
The catalytic activity of iodine in organic compounds is complex, and is inferior to the 
catalytic activity of inorganic iodide. The catalytic activity of iodine in T4 was directly 
compared to that of potassium iodide, and the K value (the catalytic activity per iodine 
atom of the compound) was calculated (Section 3.2.3). The K value for T4 was
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calculated as 47.0%; 0.5 moles of T4 have the same catalytic activity as one mole of 
iodide. K values of 57% and 62% were obtained for T4 by Timotheou-Potamia (1988) 
and O’Kennedy et al. (1989), using the Sandell-Kolthoff reaction. The sensitivity of 
the cerium(IV) - antimony(III) reaction for measurement of T4 is limited by the fact 
that only a percentage of the iodine in T4 is liberated by cerium(IV) to catalyse the 
reaction. Following treatment with cerium(IV), just 23.2% of the total iodine in T4 was 
liberated.
(luuo8G) 
'sqv
T4 c o n c .  (nM)
Figure 6.1 Graph of absorbance at 380nm plotted against concentration of T4 standards 
assayed in the cerium(IV) - antimony(III) microassay.
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T4 conc. (nM) Mean ± SD %CV
20 20.9 ± 1.5 7.3
40 43.2 ± 2.5 5.9
60 57.4 ± 1.6 2.8
80 79.6 ± 7.9 9.9
100 104.0 ± 8.6 8.3
Table 6.1 Intra-assay accuracy and precision results for T4 standards assayed in the 
cerium(IV) - antimony(III) microassay (n=8).
T4 conc. (nM) Mean ± SD %CV
20 18.7 ± 1.8 9.8
40 45.5 ± 2.2 4.8
60 62.2 ± 6.1 9.9
80 80.2 ± 4.7 5.8
100 98.1 ± 2.0 2.0
Table 6.2 Inter-assay accuracy and precision results for T4 standards assayed in the 
cerium(IV) - antimony(III) microassay (n=6).
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6.2.2 Immunoassay for T4.
T4 standards were measured in an immunoassay using anti-T4 antibodies to capture the 
T4, and the four iodine atoms in T4 as the label. The protocol for the immunoassay is 
outlined in a flow diagram in Fig 6.2. Three anti-T4 antibodies were available: Dako 
rabbit anti-T4 antibodies which were purchased as the purified immunoglobulin fraction 
of rabbit anti serum, Sigma rabbit anti-T4 anti serum and S APU sheep anti-T4 antiserum. 
The IgG fraction was purified from rabbit and sheep antiserum by ammonium sulphate 
precipitation. The binding of the antibodies to T4 was studied using the BIAcore. T4 
was immobilised onto the surface of a sensor chip, and anti-T4 antibodies were passed 
over the surface. The response obtained for SAPU sheep anti-T4 antibodies was taken 
to represent maximum binding (i.e. 100%). The response for the other antibodies was 
expressed as a percentage of the maximum binding. Dako rabbit anti-T4 antibodies 
gave 20% of the maximum binding, and Sigma rabbit anti-T4 antibodies gave 37% of 
the maximum binding. The anti-T4 antibodies obtained from SAPU were, therefore, 
most suitable for use in the T4 immunoassay. The SAPU antiserum to X* is produced 
using a T4 - human serum albumin conjugate, which is prepared using a water soluble 
carbodiimide to form a peptide bond between T4 and albumin. In this way, T4 is 
oriented such that the outer ring, which is the portion of the molecule required to 
produce the most specific antibodies, projects outwards from the framework of the 
carrier protein (Munro et al., 1983).
The ammonium sulphate-purified SAPU anti-T4 antibodies were used in an 
immunoassay to measure T4 standards. A graph of absorbance plotted against 
concentration of T4 is shown in Fig 6.3. The graph was linear in the range 75 to 
300nM (r=0.990); but a difference of only 0.163 was obtained between the absorbance 
values for the zero standard and the 300nM standard. Clarke (1991), using the same 
batch of sheep anti-T4 antibodies and the same immunoassay format, but with the 
Sandell-Kolthoff reaction for detection of the iodine, achieved a detection limit of 
125nM. The lower detection limit using the cerium(IV) - antimony(III) reaction may 
be due to measurement of the absorbance at a wavelength closer to the absorbance 
maximum for cerium(IV) (Section 6.2.1).
The normal range for T4 in human serum is 50 to 150nM; samples from hypothyroid 
patients have T4 concentrations lower than 50nM. Immunoassays for the measurement 
of T4 must, therefore, be able to measure lower than 50nM. This has been achieved 
using radioactive iodine and non-isotopic labels. A competitive RIA for total T4, using 
anti-T4 antibodies and 125I-T4, was reported by Wiersinga and Chopra (1982). The
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detection limit was 6nM, and the measuring range was 15 to 515nM. Immunoassays 
using T4 conjugated to enzymes such as HRP, AP or P-galactosidase have been 
reported. For example, Gonzalez et al. (1991) developed a competitive immunoassay 
using a T4 -[J-galactosidase conjugate and anti-T4 antibodies immobilised onto 
microtitre plates. The label was detected using 4-methyl-umbelliferyl-fS-D- 
galactopyranoside as substrate. The sensitivity was 2.5nM, and the measuring range 
was 24 to 386nM. A chemiluminescent immunoassay which does not require the 
addition of substrate or secondary signal substances was developed by Sturgess et al.
(1986). Anti-T4 antibodies labelled with a chemiluminescent acridinium ester were 
incubated with T4 and T4-rabbit IgG conjugate. Separation of bound and free fractions 
was achieved using anti-rabbit IgG antibodies bound to magnetic particles. The 
sensitivity was InM, and the measuring range was 20 to 190nM. Other methods 
include the use of europium chelators for a time-resolved fluorimetric immunoassay 
(Diamandis, 1992), and a homogeneous assay based on phase-modulation fluorescence 
spectroscopy (Ozinskas et al., 1993). These assays are suitable for measurement of 
total T4 concentration in serum from hypothyroid, euthyroid and hyperthyroid patients. 
Immunoassays for measurement of free T4 require greater sensitivity. For example, 
Christofides et al. (1992) developed a one-step EIA for free T4 using 125I-labelled anti- 
T4 antibodies. The measuring range of the assay was 2 to 130pM.
The immunoassay for T4 described in this chapter has the advantage that there is no 
necessity to prepare labelled derivatives of either T4 or antibodies, as the iodine atoms 
present in T4 serve as the label In one step free T4 analogue methods, labelled 
derivatives of T4 compete with T4 for binding to immobilised anti-T4 antibodies. The 
methods are based on the assumption that T4 analogues will bind to antibodies but not 
to serum proteins. However, several reports have demonstrated that albumin does bind 
to T4 analogues, leading to inaccurate measurements of free T4 in serum containing 
abnormal concentrations of albumin (Liewendahl, 1990). The immunoassay described 
here would eliminate this problem if it was sufficiently sensitive for measurement of 
free T4. The assay format is simple; all that is required is the incubation of T4 with 
anti-T4 antibodies immobilised onto a microtitre plate, and detection of the iodine using 
the cerium(IV) - antimony(III) reaction. T4 concentrations in the range 75 to 300nM 
can be measured in this assay. However, human serum samples were not assayed as 
the assay was not sufficiently sensitive to measure euthyroid and hypothyroid samples. 
Alterations to the assay design could extend the measuring range to lower 
concentrations of T4. Antibodies could be immobilised onto a particulate solid phase,
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such as agarose, cellulose, Sephadex or dextran. Particulate solid phases are more 
efficient as the ratio of the surface of the solid phase to the volume of the sample is 
high, the solid phase can be dispersed throughout the reaction mixture and the rate of 
antibody-antigen reactions is faster than with antibodies immobilised onto microtitre 
plates (Tijssen, 1985). The orientation o f solid phase binding of the antibody via the 
Fc portion could also be used to improve the antigen binding capacity and, therefore, 
the measuring range of the assay (Porstmann and Kiessig, 1992). This can be achieved 
in two ways. The solid phase can be precoated with protein A, a protein isolated from 
the cell wall of Staphylococcus aureus which has the ability to bind the Fc portion of 
IgG, or antibodies can be immobilised, after periodate oxidation, to amino groups on 
the solid phase via the carbohydrate moiety of the Fc portion. Alternatively, T4 could 
be isolated from samples using organic extraction or chromatography, and the isolated 
T4 measured directly in the cerium(IV) - antimony(III) microassay. Knapp et al. (1974) 
separated T4 and T3 on ion-exchange columns, and measured the concentrations of the 
hormones using the Sandell-Kolthoff reaction. The measuring range for T4 was 2.6 to 
386nM, while for T3 the measuring range was 0.3 to 46nM.
6.3 Summary.
The cerium(IV) - antimony(III) microassay can be used to measure T4 standards in the 
range 20 to lOOnM. The catalytic activity of the iodine atoms in T4 is inferior to that 
of inorganic iodide, which limits the sensitivity of the assay for measurement of T4. 
An immunoassay for measurement of T4 was developed. Anti-T4 antibodies were 
immobilised onto microtitre plates, and T4 standards were added. The iodine atoms in 
T4 served as the label, and were detected using the cerium(IV) - antimony(III) reaction. 
T4 standards in the range 75 to 300nM could be measured in the immunoassay.
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Coat plates: 10ug/ml anti-T^ antibodies (100ul/well)
|  2hr 37° C
Wash
iBlock: 0.5 %(w/v) gelatin (200ul/well)
lhr 37° CWash
IT 4 standards (100ul/well)
i  lhr 37° CWash
i
Add appropriate substrates 
and read absorbance using Titertek plate reader
Figure 6.2 Flow diagram of the immunoassay for measurement of T4. (A detailed 
description of the protocol is given in Section 2.10).
(tuuo8
0) 
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T4 c o n c .  (nM)
Figure 6.3 Graph of absorbance at 380nm plotted against concentration for T4 
standards assayed in the T4 immunoassay.
185
7. CONCLUSION.
Historically, radioactive iodine has been used as a label for the development of 
sensitive immunoassays, but there are hazards associated with the use of radioisotopes. 
Non-radioactive iodine can be used as an alternative label in immunoassays. Iodination 
techniques are widely used and well characterised, and these can be applied to the 
labelling of proteins with non-radioactive iodine for use as a tracer in immunoassays. 
The iodine label can be detected using a chemical method.
The reaction between cerium(IV) and arsenic(III), the Sandell-Kolthoff reaction, has 
been used for the detection of iodine. O’Kennedy et al. (1989) developed a microassay 
for iodine based on the Sandell-Kolthoff reaction. This was later used to detect IBHR- 
labelled antibodies in immunoassays for mouse IgG (O’Kennedy and Keating, 1991) 
and human IgG (O’Kennedy and Keating, 1993).
A microassay to measure iodine, based on the reaction between cerium(IV) and 
antimony (HI), was developed. This assay was optimised, and was proved to be an 
alternative to the Sandell-Kolthoff microassay. The microassay was monitored both 
spectrophotometrically, by measuring the absorbance of the cerium(IV), and 
fluorimetrically, by measuring the fluorescence of cerium(III) or measuring the 
fluorescence produced by the oxidation of 8-hydroxyquinoline-5-sulphonic acid by 
cerium(IV). Potassium iodide standards in the range 2 to lOng/ml were measured in 
the spectrophotometric microassay; standards in the range 2 to 8ng/ml were measured 
in the fluorimetric microassays. The spectrophotometric assay had a wider linear 
range, and better accuracy and precision.
The microassay was used to measure IBHR standards in the range 0.02 to O.lpg/ml. 
The catalytic activity of iodine in iodo-compounds depends on the liberation of the 
iodine by cerium(IV), and is inferior to that of inorganic iodide (Bowden et al., 1955). 
On treatment with cerium(IV), 15.5% of the iodine in IBHR was liberated. The 
catalytic activity o f IBHR on the cerium(IV) - antimony(III) reaction is limited by the 
fact that only a percentage of the iodine is liberated to catalyse the reaction. Thus, it 
was not possible to achieve the same sensitivity using IBHR standards as with 
potassium iodide standards.
IBHR-labelled antibodies were prepared, and were used in an immunoassay for human 
IgG, with detection of the IBHR label by the cerium(IV) - antimony(IH) reaction or the 
Sandell-Kolthoff reaction. Both of these systems could be used to measure human IgG 
standards in the range 0.05 to 2pg/ml. The results obtained illustrated that the
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cerium(IV) - antimony(III) reaction could be successfully used as a replacement to the 
Sandell-Kolthoff reaction, for the detection of the IBHR label in immunoassays. The 
immunoassay was also carried out using HRP-labelled antibodies. Human IgG 
standards in the range 0.0064 to 0.25pg/ml were measured using HRP-labelled 
antibodies. The systems using the IBHR label and the HRP label were comparable 
with respect to accuracy and precision of the standards, and with respect to the results 
obtained for serum samples. However, lower concentrations of human IgG could be 
measured using the HRP label, and the difference in absorbance values between the 
zero standard and the highest standard was greater using the HRP label (1.163) 
compared with the IBHR label (0.666).
The iodination of antibodies with non-radioactive IBHR was examined. Iodination 
techniques using radioactive iodine are well characterised, but the use of non­
radioactive iodine is not. The iodination of antibodies with various levels of IBHR was 
investigated, using molar ratios of IBHR to free amino groups of the antibody of 0.5:1, 
1.1:1,2.3:1,4.6:1, 6.9:1 and 9.1:1. (A molar ratio of 4.6:1 was used for the production 
of IBHR-labelled antibodies for use in the immunoassay for human IgG). Greater 
conjugation of IBHR was achieved using higher molar ratios. The relative binding 
pattern of the iodinated antibodies was assessed using the BIAcore. The binding to 
antigen decreased, relative to the binding of native antibodies, as the level of 
conjugation of IBHR increased. In an immunoassay for human IgG, the use of the 
conjugate prepared using a 0.5:1 ratio resulted in a loss of sensitivity, as the cerium(IV) 
- antimony(III) reaction could not detect the low concentrations of label present in the 
immunoassay, and the resulting standard curve had a low slope value. Using 
conjugates prepared at higher molar ratios resulted in greater sensitivity. The slopes 
of the standard curves increased with increasing conjugation of IBHR, but so too did 
non-specific binding. Conjugates produced using 2.3:1 and 4.6:1 ratios gave the best 
performance in the immunoassay.
A 4.6:1 molar ratio was the ratio already in use. Thus, changing the level of iodination 
of the antibody would not result in any significant improvement to the immunoassay 
performance. Therefore, procedures that lead to a high accumulation of label per 
antigen molecule were examined in an effort to improve the immunoassay. Two 
methods were investigated: the avidin-biotin system and bispecific F(ab’)2 antibodies. 
A LAB immunoassay, using biotinylated anti-human IgG antibodies and IBHR-labelled 
avidin, was used to measure human IgG standards in the range 0.025 to 0.5pg/ml. A 
BRAB immunoassay, using biotinylated anti-human IgG antibodies, avidin and labelled
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biotin, was used to measure standards in the range 0.05 to 2pg/ml. The measuring 
range of the BRAB immunoassay was the same using IBHR-labelled biotin or 
biotinylated HRP, but the use of the HRP label produced a difference in absorbance 
values between the zero standard and the 2pg/ml standard of 1.030, while the 
difference was, on average, only 0.099 using the IBHR label. The LAB immunoassay 
could be used to measure lower concentrations of human IgG than the BRAB 
immunoassay and was an improvement on the conventional immunoassay using IBHR- 
labelled antibodies.
Bispecific F(ab’)2 antibodies, reacting with human IgG and BSA, were used in an 
immunoassay as bridging agents between human IgG and labelled BSA. Using BSA, 
iodinated by the IBHR and chloramine T methods of iodination, human IgG standards 
in the range 0.1 to 2pg/ml could be measured, while using HRP-labelled BSA standards 
in the range 0.0125 to ljig/ml could be measured. As before, the use of the HRP label 
produced a greater difference in absorbance values between the zero standard and the 
highest standard; the difference was 0.123 using iodinated BSA, and 0.854 using HRP- 
labelled BSA.
An immunoassay for T4, which used the four iodine atoms on T4 as the label, was 
developed. Anti-T4 antibodies, immobilised onto microtitre plates, were used to capture 
the T4, and the iodine was detected by the cerium(IV) - antimony(III) reaction. The 
assay could be used to measure T4 standards in the range 75 to 300nM. The format 
of this immunoassay is simple and there is no requirement to prepare labelled 
derivatives of either antigen or antibody. However, in order to be used to measure T4 
in patient samples a detection limit of less than 50nM would be required.
The detection limit in immunoassays is determined by several factors, including the 
detection system for the label. In all the immunoassay systems tested here, the use of 
HRP-labelled reagents resulted in detection of lower concentrations of analytes and a 
greater difference in absorbance values over the range of the standard curves than the 
use of IBHR-labelled reagents. Since only a percentage of the iodine in IBHR is 
catalytically active, only a percentage of the iodine label present can be detected by the 
cerium(IY) - antimony(III) reaction. An improvement in the detection of the iodine 
label would lead to an improvement in the performance of immunoassays using IBHR- 
labelled reagents.
Fluorimetric monitoring of reactions is, in general, more sensitive than 
spectrophotometric monitoring. However, for the cerium(IV) - antimony(III) 
microassay the detection limit was not improved by the use of fluorimetric monitoring.
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This may have been due to the spectrophotometer used to measure the fluorescence 
intensity. This was capable of reading cuvettes and plates, but with a 40 fold reduction 
in fluorescence intensity when reading from plates. Manual alteration of the optics had 
to be carried out in order to read from plates, which was not ideal as the alignment of 
the optics is critical and manual alteration could lead to damage of the optics. The 
detection limit of the microassay may, therefore, have been improved if a dedicated 
fluorimetric plate reader had been used to measure the fluorescence intensity. The 
cerium(IV) - antimony(m) reaction is just one of many kinetic reactions which are 
catalysed by iodide. One of these reactions could be used as an alternative detection 
system for the IBHR label. Since cerium(IV) is a one electron oxidising agent that 
oxidises organic compounds, an alternative reaction would only be suitable if it 
involved a reactant that could also oxidise iodine-containing organic compounds with 
subsequent liberation of the iodine. Alternatives to IBHR could be used as labelling 
reagents. The use o f di-IB HR was considered as an alternative label which would 
increase the amount o f iodine present per label molecule. However, the use of di- 
IBHR did not improve the detection limit of the cerium (TV) - antimony(III) reaction, 
as the same range o f standards could be measured for IBHR and di-IBHR.
The use of non-radioactive iodine, and of the cerium (TV) - antimony(III) reaction for 
detection of the iodine, has several advantages. The Sandell-Kolthoff reaction has been 
used to measure iodine in samples such as milk, urine, salt and pharmaceutical 
samples. The cerium(IV) - antimony(HI) reaction could be used as a replacement for 
the Sandell-Kolthoff reaction, as it has a comparable measuring range, and the 
requirement to use arsenious acid, a carcinogen, would be eliminated. Non-radioactive 
iodine can be used as a replacement for 125I as a label in assays where an iodine label 
is required, but sensitivity is not critical. There are several examples of this. The 
immunoassays described here for human IgG illustrate that non-radioactive iodine and 
the cerium(IV) - antimony(III) reaction are suitable for measurement of analytes which 
are present in milligramme amounts in serum. Keating et al. (1991) used non- 
radioactive iodine-labelled BSA, with the Sandell-Kolthoff reaction for detection, for 
the determination of proteolytic activity. Microtitre plates were coated with IBHR- 
labelled BSA, protease was added, and after washing the amount of iodinated substrate 
remaining was determined and used to calculate the proteolytic activity. The enzymes 
trypsin, pepsin, papain and collagenase were tested. Nolan (1994) used non-radioactive 
iodine-labelled IgG, F(ab’)2, Fab’ and bispecific F(ab’)2 antibodies to determine relative 
affinity values. Microtitre plates were coated with the appropriate antigen, and the
189
iodinated antibodies were added. After washing the iodine label was measured using 
the Sandell-Kolthoff reaction, and used to calculate the relative binding of the antibody 
fragments. A laboratory that does not have facilities fra- using radioactive compounds 
but needs to use a protein purification protocol that requires the use of 125I to "track" 
the protein during the purification steps could use the non-radioactive iodine label 
instead of 125I.
The major drawback to the use of the non-radioactive iodine label in immunoassays is 
the poor sensitivity compared to an enzyme label. The sensitivity is limited by several 
factors. Iodine must be liberated from iodine-containing organic compounds in order 
to be catalytically active, but only a percentage of the total iodine is liberated by 
cerium(IV). Detection o f the cerium(IV) - antimony(III) reaction is not performed at 
the absorbance maximum for cerium (TV), the dynamic range of the spectrophotometric 
measurement of this reaction is narrower than that of the reaction for detection of the 
HRP label, and the decrease in absorbance is measured against a high blank value. 
Due to the poor sensitivity the non-radioactive iodine label would not be suitable for 
detection of analytes where sensitivity is critical.
The work reported in this thesis illustrates the effectiveness of the cerium(TV) - 
antimony(III) microassay as a replacement for the Sandell-Kolthoff reaction for 
detection of iodide and iodine-containing organic compounds. It also illustrates the 
effectiveness of non-radioactive iodine as a label in immunoassay systems using 
iodinated antibodies, the avidin-biotin system and bispecific F(ab’)2 antibodies.
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